65th ASH® Annual Meeting and Exposition

December 9-12, 2023
San Diego, CA

PROGRAM-AT-A-GLANCE
Review the data at the 2023 ASH Annual Meeting & Exposition.

THERE’S SO MUCH TO DISCOVER

Come visit us December 9-12 at booth #1033 or visit DARZALEXHCP.com
Call for Editor Nominations

ASH Seeks Inaugural Editor-in-Chief for a New Journal

ASH has begun the process of selecting an inaugural editor to lead a new open access journal focused on global hematology, recently approved for addition to the Society's peer-reviewed *Blood* journals portfolio beginning in 2024.

*Blood Global Hematology* is a new open access, peer-reviewed journal which aims to publish high-quality research, local adaptations of clinical guidelines, and opinion articles that improve the lives of patients in low- and middle-income countries. It will offer an online, rapid publishing venue for research focused on hematology-specific healthcare delivery in local or regional settings conducted in or focused on low- and middle-income countries and/or with a global reach and applicability. As part of the *Blood* journals portfolio, *Blood Global Hematology* will connect to the ASH mission of educating hematologists worldwide to improve patient care.

The inaugural editor-in-chief will begin work in the Spring of 2024 and will help establish the initial editorial team and peer review procedures. Candidates must have significant editorial experience, preferably as an editor of a peer-reviewed journal; a distinguished research record; broad and comprehensive knowledge of basic, translational, and clinical research; and a record of leadership in the community. Successful candidates should have an interest in developing innovative new content, knowledge of ASH programs and initiatives, experience coordinating international collaborations, and familiarity with international experts in the field to solicit relevant, high-quality articles.

Candidates must be ASH members in good standing with an MD, MD/PhD, or equivalent degree. The term is five years with the potential for one five-year extension. An honorarium will be provided.

ASH members may self-nominate for this position by submitting a cover letter, a CV, a brief description of previous editorial experience, and a vision statement for the journal. Nominations from international members are encouraged. Members are also welcome to nominate a colleague by submitting a brief informal endorsement. ASH will confirm the nominee's membership status and request submission of additional materials to complete the nomination. ASH prohibits members employed by a pharmaceutical or biomedical company from serving in an editorial position.

All submissions should be sent to EditorSearch@hematology.org by the deadline of 11:59 P.M. EST on December 20, 2023.
# Table of Contents

## About ASH
- ASH Executive and Program Committees 5
- Reviewers of Abstracts and *Hematology* 2023 8
- Corporate Acknowledgements 11
- Recipients of Awards 15

## Guide to Navigating the Meeting
- General Information 23
- Diversity, Equity, and Inclusion at ASH 35
- Non-CME Sessions 37

## Meeting Schedule
- Day-At-A-Glance 41

## Invited Speaker Sessions
- General Sessions 65
- Special Interest Sessions 67
- Trainee Activities (Open to Trainees Only) 75

*continued on next page*
# Education Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education Sessions</td>
<td>83</td>
</tr>
<tr>
<td>Education Spotlight Sessions</td>
<td>93</td>
</tr>
<tr>
<td>How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)</td>
<td>95</td>
</tr>
</tbody>
</table>

# Scientific Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Sessions</td>
<td>101</td>
</tr>
<tr>
<td>Scientific Symposia</td>
<td>107</td>
</tr>
<tr>
<td>Scientific Spotlight Sessions</td>
<td>109</td>
</tr>
<tr>
<td>Scientific Workshops</td>
<td>113</td>
</tr>
<tr>
<td>ASH Poster Walks</td>
<td>117</td>
</tr>
<tr>
<td>Meet the Scientist (Ticketed Sessions)</td>
<td>119</td>
</tr>
</tbody>
</table>

# Abstract Sessions

<table>
<thead>
<tr>
<th>Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Categories</td>
<td>121</td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td>125</td>
</tr>
<tr>
<td>Poster Presentations</td>
<td>133</td>
</tr>
</tbody>
</table>

# Exhibitors

<table>
<thead>
<tr>
<th>Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satellite Symposia</td>
<td>139</td>
</tr>
<tr>
<td>Product Theaters</td>
<td>151</td>
</tr>
<tr>
<td>Industry Theaters</td>
<td>157</td>
</tr>
<tr>
<td>Company Showcases</td>
<td>159</td>
</tr>
<tr>
<td>Exhibitor Directory</td>
<td>161</td>
</tr>
</tbody>
</table>
AMERICAN SOCIETY OF HEMATOLOGY
EXECUTIVE COMMITTEE

STAFF LIAISONS:
Martha Liggett, Esq., mliggett@hematology.org
Matthew Gertzog, MBA, CAE, mgertzog@hematology.org
LaFaundra Neville Ingram, CAP, lneville@hematology.org

OFFICERS:
President: Robert A. Brodsky, MD
President-Elect: Mohandas Narla, DSc
Vice President: Belinda Avalos, MD
Secretary: Cynthia E. Dunbar, MD
Treasurer: Joseph Mikhael, MD, FRCP, MEd

COUNCILLORS:
Christopher R. Flowers, MD, MSc ('26)
  Alison Loren, MD ('23)
  Bob Löwenberg, MD, PhD ('23)
  Charlotte Marie Niemeyer, MD ('26)
  Sarah H. O'Brien, MD ('25)
  Betty Pace, MD ('24)
  Jamile M. Shammo, MD ('24)
  Wendy Stock, MD ('25)
PROGRAM COMMITTEE

STAFF LIAISON:
Ana Velarde
E-mail: avelarde@hematology.org

Robert A. Brodsky, MD ('23) - Chairperson, President
Mohandas Narla, DSc ('23) - Ex-Officio: President-Elect
Joseph Mikhail, MD, FRCPC, MEd ('23) - Ex-Officio: Treasurer
Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary
Belinda Avalos ('25) - Ex-Officio: Vice President
Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, Blood
Catherine M. Bollard, MD ('26) - Liaison, Blood Advances Editor-in-Chief
Jennifer R. Brown, MD, PhD ('23) - Liaison, Chair, Committee on Educational Affairs
Hetty Carraway, MD ('24) - Liaison, Chair, Committee on Training
Adam Cuker, MD ('23) - Liaison, Chair, Committee on Quality
Chancellor E. Donald, MD ('23) - Liaison, Chair, Committee on Practice
Aaron T. Gerds, MD, MS ('23) - Liaison, Editor-in-Chief, ASH Clinical News
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
Shaji Kunnathu Kumar, MD ('25) - Liaison, Editor-in-Chief, The Hematologist
Eduardo Magalhães Rego, MD, PhD ('23) - Liaison, Chair, International Members Committee
Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, Blood
Mikkael A. Sekeres, MD ('22) - Liaison, Chair, Committee on Communications
Andrew S. Weyrich, PhD ('26) - Liaison, Blood Advances Deputy Editor
Allison Walker, MD, MPH, MBA – Liaison, Chair, Committee on Diversity, Equity and Inclusion
Alisa Wolberg, PhD ('24) - Liaison, Chair, Committee on Scientific Affairs
ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

STAFF LIAISON:
Ana Velarde
E-mail: avelarde@hematology.org

Jean M. Connors, MD ('23) - 2023 Education Program Co-Chair
Amy E. DeZern, MD ('23) - 2023 Education Program Co-Chair
Kojo Elenitoba-Johnson, MD ('23) - 2023 Scientific Program Co-Chair
Elizabeta Nemeth, PhD ('23) - 2023 Scientific Program Co-Chair

John Koreth, MD, PhD ('24) - 2024 Education Program Co-Chair
Rakhi Naik, MD, MHS ('24) - 2024 Education Program Co-Chair
Sant Rayn Pasricha, MBBS, MPH, PhD ('24) – 2024 Scientific Program Co-Chair
Jennifer Trowbridge, PhD ('24) – 2024 Scientific Program Co-Chair
Hanny Al-Samkari, MD ('24) - Editor, Hematology
Suneet Agarwal, MD, PhD ('23) - Appointed Member
Alice Bertaina, MD, PhD ('24) – Appointed Member
Steven Fein, MD ('23) – Appointed Member
Francesca Gay, MD, PhD ('23) – Appointed Member
Andreas Greinacher, MD ('23) – Appointed Member
Betty Hamilton, MD ('23) – Appointed Member
Manali Kamdar, MD ('23) – Appointed Member
Richard M. Kaufman, MD ('23) - Appointed Member
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
Dipti Patel Donnelly, MD ('23) – Appointed Member
Kristen Pettit, MD ('23) - Appointed Member
David Sallman, MD ('23) - Appointed Member
Sharon Savage, MD ('23) – Appointed Member
Clifford Takemoto, MD ('23) - Appointed Member
Justin Taylor, MD ('23) - Appointed Member
2023 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of Hematology 2023, the ASH Education Program.

ASH ABSTRACTS COORDINATING REVIEWERS

Maureen Okam Achebe
Diego Adriamnen Herrera
Josefin Ahnstrom
Juan Alderuccio
Immacolata Andolfo
Anthony Audino
Karen Ballen
Joao Barata
Roger Belzair
Adam Binder
Robert Bowman
Hetty Carraway
Namrata Chandhok
Shanmugananthan Chandrasakan
Shruti Chaturvedi
David Coffey
Rachel Cook
Raul Cordoba
Emily Curran
Susan DeWolf
Meghan Drayton Jackson
Martin Dreyling
Delfim Duarte
Barbara Elchhorst
Tarec Christoffer El-Galaly
Carmen Fava
Jonathan Flanagan
Lucy Fox
Miguel Ganuza Fernandez
Ulrich Gering
Mark Geyer
Arnab Ghosh
James Godfrey
Kandace Gollomp
Damian Green
Emma Groarke
Boglarka Gyurkocza
Tanja Hartmann
Rong He
Alex Herrera
Michael Heuser
Kyle Hewitt
Matthew Hsieh
Andrew Intlekofer
Singmoo Jeong
Courtney Jones
Swetha Kambhampati
Shaji Kumar
Catherine Lai
Catherine Lee
Jessica Leonard
Sheng Li
Richard Little
Rui Lu
Nadim Mahmud
Enrica Marchi
Kathy McGraw
Maximilian Merz
Lekha Mikkilineni
Ghulam Rehman Mohyuddin
Florence Nguyen-Khac
Grzegorz Nowakowski
Oluibusola Oluwole
Sung-Yun Pai
Freda Passam
Fabiana Perna
Bethan Psaila
Muna Qayed
Patrick Reagan
Andreas Reiter
Kerry Rogers
Jacob Rowe
Elna Saah
Bethany Samuelson Bannew
Jordan Schaefer
David Scott
Urvi Shah
Kenneth Shain
Kristin Shimano
Melody Smith
Anna Maria Sureda Balari
Natasha Szuber
Ali Taher
Douglas Tremblay
Cindy Varga

ASH ABSTRACTS REVIEWERS

Yasmin Abaza
Oussama Abla
Jeremy Abramson
Melissa Acquazzino
Lionel Ades
Catherine Aftandilian
Imo Akpan
Ibrahim Aldoss
Alvaro Alencar
Lapo Alinari
Jeanne Boudreaux
Andrew Brunner
Jennifer Brudno
Annamaria Brioli
Marc Braunstein
Thorsten Braun
Jenifer Carew
Nabanita Bhunia
Giada Bianchi
James Biek
Melinda Ann Biernacki
Andrea Biondi
Lionel Blanc
Judith Boer
Kelly Bolton
Claire Booth
Mercedes Borge
Prithviraj Bose
Marita Bosticardo
Alexander Boucher
Jeanne Boudreaux
Andrew Branagan
Thorsten Braun
Marc Braunstein
Annamaria Brioli
Jennifer Brudno
Andrew Brunnner
Emily Bryer
Barbara Buldini
Lambert Busque
Craig Byersdorfer
Anna Candoni
Antonino Carbone
Jennifer Carew
Shannon Carpenter
Luciano Costa
Francesca Cottini
Angelo D’Alessandro
Alexey Danilov
Faith Davies
Blachy Davila Saldana
Kara Davis
Lucia De Franceschi
Maria Eugenia de la Morena-Barrio
Laurence de Leval
Erich De Paula
Thomas Deloughery
Karl Desch
Ani Deshpande
Robert Di Blasi
Anita D’Souza
Sarah Ducamp
Jarrod Dudakov
Amy Duffield
Carlo Dufour
Remy Dulery
Amy Dunn
Walter Dzik
Karen Effinger
Firas El Chaer
Najia El Jundi
Shannon Elf
Patrick Ellsworth
Miriam Erlacher
Jason Farrar
Jonathan Feld
Francisca Ferrer Marin
Simone Ferrero
Lynda Foltz
Lisa Forbes Satter
Henrik Frederiksen
Sylvia Freeman
Matthew Frigault
Hideaki Fujiwara
David Gailani
Radhika Gangaraju
Harsh Bhat
Domenico Gurnari
Fabio Gueli
Nicolai Giulani
Benjamin Goldenspan
Andres Gomez-De Leon
Michael Gre"n
Philipp Greif
Hildegard Greinix
Nicole Grieselhuber
Kira Gritsch
Tanja Gruber
Sonia Guedan
Fabio Guolo
Carmelo Gurnari

8
2023 REVIEWERS

Alejandro Gutierrez
Fernanda Gutierrez-Rodrigues
Monica Guzman
Claudia Haferlach
Roman Hajek
Stephanie Halene
Mehdi Hamadani
Betty Hamilton
Doris Hansen
Eliza Hawkes
Caroline Heckman
Ute Hegenbart
Florian Heidel
Olaf Heidenreich
Jens Hillengass
Devendra Hiwase
Gabriela Hobbs
Toril Holien
Junshik Hong
Alessandro Isidori
Raphael Itzykson
Shai Izraei
Elias Jabbour
Salvia Jain
Sakshi Jasra
Reena Jayani
Mats Jerkeman
Patrick Connor Johnson
Wojciech Jurczak
Jonas Jutzi
Martin Kaiser
Matko Kalac
Maggie Kalev-Zylinska
Christopher Kanakry
Reem Karmali
Adetola Kassim
Vanessa Kennedy
Jennifer Kesselheim
Nigel Key
Nandita Khera
Matthew Kim
Jean-Jacques Kiladjian
Katherine King
Frederikus Klokk
Vidyasagar Koduri
Christian Koenecxe
Steffen Koschmieder
Stavroula Kousteni
Arushi Khurana
Anita Krishnan
Andrea Kuhnl
Kevin H.M. Kuo
David Kuter
Marco Ladetto
Rahul Lakhotia
Nicole Lamanna
Daniel Landsburg
Hans Lee
Eva Leinoe
Georg Lenz
Huihui Li
John Ligdone
Ming Y Yeong Lim
Emily Limerick
Luca Lo Nigro
Cheryl Lobo
Camille Lobry
Richard Lock
Alison Loren
Izidore Losso
Daniel Lucas-Alcaraz
Stefano Luminari
Maria Teresa Lupo Stanghellini
Meng Lv
Joseph Maakaron
Kylee Maclachlan
Yazan Madanat
Kami Maddocks
Kris Michael Mahadeo
Johnny Mahlangu
Francis Mahon
Ajay Major
Florent Malard
Luca Malcovati
Ariela Marshall
Sven Maschek
Matthew Maurer
Hind Medyoun
Reid Merriman
Laura Michaelis
Kenichi Mihara
Courtney Nicole Miller-Chism
Coraline Mlynarczyk
Mohamed Mohty
John Molina
Francesca Montanari
Jerome Moreaux
Kerry Morrone
Moath Mustafa Ali
Satu Mustioki
Niroshan Nadarajah
Bertrand Nadel
Swati Naik
Ranjit Nair
Cindy Neunert
Peter Newburger
Laura Newell
Diu T.T. Nguyen
Ruben Nieszvizky
Robin Norris
Sarah O'Brien
Alexander Oesper
Yihai Ofra
Hiroti Ohguchi
Bilal Omer
Oluwatoyosi Onwuemene
Jad Othman
Neil Palmisano
Helen Papadaki
Erin Parry
Anand Ashwin Patel
Minral Patnaik
Robert Paulson
Katerina Pavenski
Miguel Arturo Pavlovsky
Tea Pemovska
Guilherme Fleurie Perini
Caroline Philpott
Georgios Pongas
Maurilio Ponzi
Jerlym Porter
Nicola Pozzi
Pedro Prata
Anca Prica
Barbara Pro
John Anto Pulikkan
Hang Quach
Anne Quinquel
Brittany Knick Ragon
Ramy Rahmé
Ron Ram
Muthalagu Ramanathan
Pavan Reddy
Christopher Reilly
Linda Resar
Rebecca Richards
Ingo Ringshausen
Antonio Ristiano
Jason Romanick
Rizwan Romee
Marlies Rossmann
Harvey Roweth
Sergio Rutella
Russell Ryan
Zohar Sachs
Neeraj Saini
R. Leo Sakemura
Ben Samelson-Jones
Jose Sandoval-Sus
Kristen Sanfilippo
Jolanda Sarno
Prakash Satwani
Tim Sauer
Caner Saygin
Alexandra Schifferli
Fredrik Schjesvold
Sol Schulman
Liora Michel Schultz
Eduard Schulz
Jan Jacob Schuringa
Juliana Schwaab
Juerg Schwaller
Marie Scully
Mikkael Sekeres
Valentina Serafin
Brian Shaffer
Nishi Shah
Jamile Shamo
Naranje Shaminuganathan
Noha Sharafeldin
Joseph Shaw
Geoffrey Shouse
Elizabeth Shpall
Tanya Siddiqi
David Siegel
Robert Singer
Wellington Silva
Laura Silvestri
Sharon Singh
Pratibha Singh
Ankur Singh
Shireen Sirhan
Julia Skokowa
Luke Smart
Andrew Snow
Brian Shaffer
Valentina Serafin
Simona Soverini
Andrew Stahl
Adam Sperling
Simona Soverini
Andrew Stahl
Laura Silvestri
Sharon Singh
Pratibha Singh
Ankur Singh
Shireen Sirhan
Julia Skokowa
Luke Smart
Andrew Snow
Simona Soverini
Adam Sperling
Maximilian Stahl
Joseph Staneck
Kimberly Stegmaier
Laurie Steiner
Paolo Strati
Jonathan Strreford
Christopher Su
Senthil Sukumar
Prithu Sundd
Agoston Gyula Szabo
Owen Tamplin
Yvette Tanheco
Benoit Tessoulin
Suzanne Thibodeaux
Meghan Thompson
Courtney Thornburg
Sigrun Thorsteinsson
Swapna Thota
Brian Till
Zuzana Tothova
Jan Trka
Steven Tsai
Mazie Tsang
Venee Tubman
Lucie Turcotte
Dimitrios Tzachanis
Masumi Ueda Oshima
Bert Van der Reijden
Antoni Varelias
Anant Vatsayan
Leandro Venturutti
Sangeetha Venugopal
Amit Verma
Vip Virpakasit
Linus Voelker
Bastian von Tresckow
Ajay Vora
Radovan Vrhovac
Vladan Vucinic
Franziska Wachtler
Aman Wadhwa
Nina Wagner-Johnston
Johannes Waldschmidt
Alison Walker
Roland Walter
Anthony Washington
Jonathan Webster
Lachelle Weeks
Andrew Wei
Jeffrey Weitz
Jason Westin
Joseph Wiemels
Adrian Wistern
Lindsay Wilde
Jennifer Wilkes
Eric Winer
Eric Wong
Chuanfeng Wu
Ana Xavier
Stephanie Xie
Victor Zavbeck
Andrew Yee
Jonathan Yen
Guy Young
Neil Zakai
Emanuele Zucca
Jeffrey Zwicker
HEMATOLOGY 2023 REVIEWERS

Jeremy S. Abramson
Catherine Aftandilian
Suneet Agarwal
Haris Ali
Pamela Blair Allen
Andrew S. Artz
Michael Auerbach
Nizar J. Bahlis
Brian J. Ball
Kenneth A. Bauer
Pavan K. Bendapudi
Alice Bertain
Bhavana Bhatnagar
Neel S. Bhatt
Javier Bolaños-Meade
Prithviraj Bose
Robert A. Brodsky
Jennifer N. Brudno
Patricia A.R. Brunker
Andrew M. Brunner
John M. Burke
James B. Bussel
Scott Canna
Maria Dominica Cappellini
Hetty E. Carraway
Marc Carrier
Shruti Chaturvedi
Luke Y.C. Chen
Yi-Bin Chen
Jacques Chioroni
Satheesh Chonat
Douglas B. Cines
Nathan T. Connell
Mhairi Copland
Jorge Cortes
Luciano J. Costa
Anita D’Souza
Alexey V. Danilov
Thomas G. DeLoughery
Amy E. DeZern
Yvonne A. Efebera
Hesham Eissa
Andrew M. Evens
Lorenzo Falchi
Steven Fein
Courtney Fitzhugh
Courtney D. Fitzhugh
Radhika Ganagaraju
David A. Garcia
Valentin Garcia-Gutierrez
Francesca Gay
Nilanjan Ghosh
Andreas Glenthoj
Ajay K. Gopal
Jed B. Gorlin
Rachael F. Grace
Tara Graff
Elizabeth A. Griffiths
Emma M. Groarke
Monique Hartley-Brown
David Henry
Gabriela Hobbs
Christopher S. Hourigan
Amanda Jacobson-Kelly
Nitin Jain
Siddhartha Jaiswal
Murali Janakiram
Martin F. Kaiser
Theodosia A. Kalfa
Manali Kamdar
Julie Kanter
Richard M Kaufman
Sioban B. Keel
Steve Kitchen
Adam S. Kittai
Jan-Henning Klusmann
Paul Knoebel
Peter Koudes
Taxiarchis V. Kourelis
Nicolaus Kröger
Amrita Y. Krishnan
Rebecca Kruse-Jarres
Nicole Kucine
Stephan Ladiach
Michele P. Lambert
Rebecca Karp Leaf
Jerrold H. Levy
Howard Allen Liebman
Tara L. Lin
Ton Lisman
Frederick L. Locke
Sagar Lonial
Tiffany L. Lucas
Marlise R. Lukin
Leo Luznik
Ryan C. Lynch
Stephen MacDonald
Katerina Machova Polakova
John P. Manis
Deepa Manwani
Camila Masias
Jennifer McNeer
Robert T. Means
Matthew G. Mei
Reid W. Merryman
Saskia Middeldorp
Tamara P. Miller
Alice S. Mims
Alison J. Moskowitz
Fionnuala B. Ni Áinle
Swati Naik
Eneida R. Nemeczek
Cindy E. Neunert
Marena Rebekka Niewisch
Sven R. Olson
Timothy S. Olson
Giovanna Palladini
Jeanne M. Palmer
Anand A. Patel
Dipti Patel-Donnelly
Steven Z. Pavletic
Françoise Pirenne
Allyson Pishko
Daniel A. Polleya
Keith W. Pratz
Muna Qayed
Christian Rêcher
Jean-Antoine Ribel
Lara N. Roberts
David A. Sallman
Bethany T. Samuelson Bannow
Sharon A. Savage
Bipin N. Savani
Jordan K. Schaefer
Zbigniew Macdonald
Szczepiorkowski
Gary J. Schiller
Jecko Thachil
Alvin H. Schmaier
Alexis A. Thompson
Kirk R. Schultz
Andreas Tiede
Roger E.G. Schutgens
Chaitra Ujiani
Mikaela A. Sekeres
Rolf T. Urbanus
Nirali N. Shah
Celalettin Ustun
Urvi A. Shah
Jurjen Versluis
Naranie Shanmuganathan
Jeff P. Sharan
Joseph J. Shatziel
Akiko Shimamura
Michelle Sholzberg
Roni Shouval
Deborah M. Siegel
Leslie Skeith
Heather J. Symons
Zbigniew Macdonald
Szczepiorkowski
Jecko Thachil
Alexis A. Thompson
Andreas Tiede
Chaitra Ujiani
Rolf T. Urbanus
Celalettin Ustun
Jurjen Versluis
Adrianna Vlachos
Alison R. Walker
Jason R. Westin
Joshua F. Zeidner
Jeffrey A. Zonder
2023 ASH Annual Meeting Foundation Run/Walk Supporters

PREMIER
Acrotech Biopharma, Inc.
AstraZeneca
Biomea Fusion, Inc.
Editas Medicine
Gilead and Kite Oncology
GSK
Regeneron
Syndax Pharmaceuticals

LEAD
AbbVie
Blueprint Medicines
Seagen Inc.

SUPPORTING
Freeman
Novartis
Ono Pharmaceuticals

2023 ASH Annual Meeting Education Supporters

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2023 ASH Annual Meeting:

Hematology 2023: The Education Program
AstraZeneca
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

General Education Grant
AbbVie
AstraZeneca
GlaxoSmithKline
Incyte Corporation
Lilly USA, LLC
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Seagen
Syndax Pharmaceuticals Inc.
These acknowledgments reflect contributions made prior to October 13, 2023.

2023 ASH Independent Medical Education Supporters
ASH would like to acknowledge the following companies for their support:

- Agios Pharmaceuticals Inc.
- Astellas Pharma US, Inc.
- Bristol Myers Squibb
- CRISPR Therapeutics, Inc.
- Daiichi Sankyo, Inc.
- GlaxoSmithKline
- Johnson & Johnson Innovative Medicine
- Kite Pharma Inc.
- Novartis Pharmaceuticals
- Pfizer Inc.
- Syneos Health
- Vertex Pharmaceuticals

2023 ASH Award Supporters
ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Minority Recruitment Initiative and Scholar Award programs:

- AstraZeneca
- Novartis Pharmaceuticals

2023 Annual Meeting Corporate Supporters
ASH would like to acknowledge the following companies for their support of the 2023 Annual Meeting:

- AbbVie
- ASH Red
- AstraZeneca
  - Exhibit Hall Aisle Signs
- Daiichi Sankyo, Inc.
  - PosterCast
- Gilead and Kite Oncology
  - Internet Stations and Wi-Fi
- GSK
  - ASH Hotel Door Drop Bag
  - Mobile Device Charging Stations
- Incyte
  - Hydration Stations
- Johnson & Johnson
  - Hand Sanitizing Stations
  - Headshot Alley
  - Mobile Device Charging Stations
- Loxo@Lilly
  - Photo Zone and Social Media Wall
- NMDP
  - ASH-a-Palooza – Gold Level Supporter
- Sanofi
  - ASH Park @ the Plaza
  - Hand Sanitizing Stations
  - Mobile Device Charging Stations
  - (Marriott Marquis San Diego Marina)
- Spark Therapeutics
  - ASH-a-Palooza – Silver Level Supporter
- Syndax Pharmaceuticals
  - Mobile App
2023 ASH Global Initiatives

ASH would like to acknowledge and thank the following companies and foundation for supporting ASH’s international consortia:

Consortium on Newborn Screening in Africa
Bristol-Myers Squibb
Novartis
Revvity

International Consortium on Acute Leukemia
Torsten Haferlach Leukemia Diagnostics Foundation
Illumina

2023 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:

Premier Circle
GSK
Pfizer
Regeneron

Partner Circle
AstraZeneca
Bristol-Myers-Squibb
Kite
Lilly
Novartis
Vertex

Advocate Circle
Agios
Amgen
Astellas
Beigene
Genentech
Genmab
Johnson & Johnson Innovative Medicine
Merck
Novo Nordisk
Sanofi

Insider Circle
Bluebird Bio
Kura Oncology
Orca Bio
Rigel
Syndax

2023 ASH Health Equity Collective

The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH’s work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:

Bristol-Myers Squibb
Genentech
GSK
Johnson & Johnson Innovative Medicine
Lilly
Merck
Novartis
Pfizer
Sanofi
Vertex

Corporate Acknowledgments
New multimedia enhancements for key topics

► 25 New & Updated Chapters – covering malignant and classical (non-malignant) disorders
► 17 New & Updated Multi-Media features for key topics
► 260 NEW Questions in the Question and Answer Book
► 75 – CME/MOC Credits

The Question and Answer Book allows for preparation for the CME/MOC Test featuring:

• Laboratory Hematology & Cellular Therapy
• Consultative Hematology
• Anemia, Iron Physiology, and Iron Disorders
• Thrombosis & Hemostasis
• Myeloid Diseases
• Lymphoid Disorders

ORDER TODAY AT:
ASH Store on-site | hematology.org/store
## AWARDS

### RECIPIENTS OF AWARDS

#### WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>Irving Weissman</td>
<td>2016</td>
<td>Thalia Papayannopoulos</td>
<td>2010</td>
<td>Volker Diehl</td>
</tr>
<tr>
<td>2021</td>
<td>Harvey Lodish</td>
<td>2015</td>
<td>Aaron Marcus</td>
<td>2009</td>
<td>H. Franklin Bunn</td>
</tr>
<tr>
<td>2018</td>
<td>Victor Hoffbrand</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### ERNEST BEUTLER LECTURE AND PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>Takehisa Kitazawa and John Mahlangu</td>
<td>2017</td>
<td>Luigi Naldini and Marina Cavazzana</td>
<td>2011</td>
<td>Janet D. Rowley and Brian J. Druker</td>
</tr>
<tr>
<td>2022</td>
<td>John Atkinson and Peter Hillmen</td>
<td>2016</td>
<td>Hugues de Thé and Zhu Chen</td>
<td>2010</td>
<td>Barry S. Coller and Joel S. Bennett</td>
</tr>
<tr>
<td>2021</td>
<td>Margaret Shipp and Stephen Ansell</td>
<td>2015</td>
<td>Alfred Goldberg and Paul Richardson</td>
<td>2009</td>
<td>Yuet Wai Kan and Thomas Maniatis</td>
</tr>
<tr>
<td>2020</td>
<td>Courtney DiNardo and Ari Melnick</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>Siriram Krishnaswamy and Jeffrey I. Weitz</td>
<td>2014</td>
<td>Michael R. DeBaun and Robert P. Hebbel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>Alan D’Andrea and Neal Young</td>
<td>2013</td>
<td>Kenneth Kaushansky and David J. Kuter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td>2012</td>
<td>Bruce R. Blazar and Carl H. June</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### E. DONNALL THOMAS LECTURE AND PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>Katy Rezvani</td>
<td>2012</td>
<td>Timothy J. Ley</td>
<td>2001</td>
<td>Samuel E. Lux, IV</td>
</tr>
<tr>
<td>2022</td>
<td>Bruce Blazar</td>
<td>2011</td>
<td>George Q. Daley</td>
<td>2000</td>
<td>David Ginsburg</td>
</tr>
<tr>
<td>2021</td>
<td>Connie Westhoff</td>
<td>2010</td>
<td>Leonard I. Zon</td>
<td>1999</td>
<td>Irving Weissman</td>
</tr>
<tr>
<td>2016</td>
<td>David Scadden</td>
<td>2005</td>
<td>Rainer Storb</td>
<td>1994</td>
<td>Thomas P. Maniatis</td>
</tr>
<tr>
<td>2015</td>
<td>Barbara C. Furie and Bruce Furie</td>
<td>2004</td>
<td>Donald Metcalf</td>
<td>1993</td>
<td>Thomas P. Stossel</td>
</tr>
<tr>
<td>2013</td>
<td>Katherine A. High</td>
<td>2002</td>
<td>Kenneth Mann</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### WILLIAM DAMESHEK PRIZE

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>Omar Abdel-Wahab</td>
<td>2003</td>
<td>Gary Gilliland</td>
<td>1989</td>
<td>Samuel E. Lux IV</td>
</tr>
<tr>
<td>2022</td>
<td>Irene Ghobrial</td>
<td>2002</td>
<td>Catherine Verfaillie</td>
<td>1988</td>
<td>Theodore S. Zimmerman</td>
</tr>
<tr>
<td>2021</td>
<td>Elizabeth Nemeth</td>
<td>2001</td>
<td>Brian Druker</td>
<td>1987</td>
<td>Charles Sherr</td>
</tr>
<tr>
<td>2020</td>
<td>Adolfo Ferrando</td>
<td>2000</td>
<td>David A. Williams</td>
<td>1986</td>
<td>Stuart Orkin</td>
</tr>
<tr>
<td>2019</td>
<td>Emmanuelle Passegué</td>
<td>1999</td>
<td>Salvador Moncada</td>
<td>1985</td>
<td>Thomas F. Deuel</td>
</tr>
<tr>
<td>2018</td>
<td>Ross L. Levine</td>
<td>1998</td>
<td>J. Evan Sadler</td>
<td>1984</td>
<td>Barbara C. and Bruce Furie</td>
</tr>
<tr>
<td>2017</td>
<td>Benjamin L. Ebert</td>
<td>1997</td>
<td>Björn Dahibäck</td>
<td>1983</td>
<td>Thomas P. Stossel</td>
</tr>
<tr>
<td>2014</td>
<td>Scott Armstrong</td>
<td>1994</td>
<td>George J. Broze, Jr.</td>
<td>1979</td>
<td>Yuet Wai Kan</td>
</tr>
<tr>
<td>2013</td>
<td>Andrew Weyrich</td>
<td>1993</td>
<td>Owen Witte</td>
<td>1978</td>
<td>Robert D. Rosenberg</td>
</tr>
<tr>
<td>2012</td>
<td>Margaret A. Goodell</td>
<td>1992</td>
<td>Richard D. Klausner</td>
<td>1977</td>
<td>Yale Nemerson</td>
</tr>
<tr>
<td>2009</td>
<td>Louis M. Staudt</td>
<td></td>
<td></td>
<td>1974</td>
<td>Robert C. Gallo</td>
</tr>
<tr>
<td>2008</td>
<td>Kenneth Anderson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>William Vainchenker</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Riccardo Dalla-Favera</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>John Dick</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Ronald Levy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Note:** The list continues with other awards and recipients not shown here. For more information, please refer to the complete document.
ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2023 Alexis A. Thompson
2022 James Gavin and David Wilkes
2021 Deepika Darbari
2020 Edward J. Benz Jr.
2019 Griffin P. Rodgers
2018 Cage S. Johnson and José A. López
2017 Betty Pace

HENRY M. STRATTON MEDAL

2023 Rodger McEver and James B. Bussel
2022 Timothy Ley and Robert Montgomery
2021 Kwaku Ohene-Frempong and Denisa Wagner
2020 Maria Domenica Cappellini and Michelle Le Beau
2019 William Allen Eaton and Richard A. Larson
2018 Brunangelo Falini and Freda K. Stevenson
2017 Josef Tomas Prchal and Sherrill J. Slichter
2016 J. Evan Sadler and Ayalew Teferr

2015 Nancy Speck and Karl Welte
2014 Geraldine Scheckter and Timothy Springer
2013 Nancy Andrews and Elaine Jaffe
2012 Richard Aster and David Ginsburg
2011 Ching-Hon Pui
2010 Sanford Shattil
2009 Connie Eaves
2008 Clara Bloomfield
2007 Carlo Croce
2006 Jack Hirsh
2005 Barry Coller
2004 Stanley Korsmeyer

2003 Janet Rowley
2002 George Stamatoyannopoulos
2001 Harold R. Roberts
2000 H. Franklin Bunn
1999 Helen Ranney
1998 Arthur W. Nienhuis
1997 Rainer Storb
1996 Bernhard Forget
1995 David Nathan
1994 Titus H.J. Huisman
1993 Earl W. Davie
1992 Kenneth G. Mann


1991 Ralph L. Nachman
1990 Malcolm Moore
1989 Aaron J. Marcus
1988 Robert S. Schwartz
1987 Robert C. Gallo
1986 Bernard Babior
1985 Vincent DeVita
1984 Samuel Rapaport
1983 Eugene P. Cronkite
1982 Ernest A. McCulloch
1981 Clement A. Finch
1980 Yuet Wai Kan
1979 Henry S. Kaplan
1978 William N. Valentine
1977 Thomas A. Waldmann
1976 Wendell F. Rosse
1975 E. Donnall Thomas
1974 Ernest Beutler
1973 Albert S. Gordon
1972 Oscar D. Ratnoff
1971 H.G. Kunkel
1970 W.R. Bruce

ASH MENTOR AWARD

2023 Stephen Sallan and Helen Heslop
2022 Michael Caligiuri and Christopher Flowers
2021 Anthony Goldstone and Jonathan Licht
2020 Judith Gasson and Wendy Stock
2019 Michael R. DeBaun and Leonard I. Zon
2018 John E. Dick and Reed E. Drews
2017 Ronald Hoffman and Oliver W. Press
2016 Laurence Boxer and Ralph L. Nachman
2015 Curt Civin and Craig Kitchens
2014 Grover C. Bagby Jr. and John F. DiPersio
2013 John Adamson and Stanley Schrier
2012 Beverly S. Mitchell and Rainer F. Storb
2011 Nancy C. Andrews and Malcolm K. Brenner

2010 Mary M. Horowitz and Harvey F. Lodish
2009 Arthur Nienhuis and Stuart H. Orkin
2008 George R. Buchanan and Timothy J. Ley
2007 Edward J. Benz Jr and Harold R. Roberts
2006 Samuel E. Lux and Deane F. Mosher

ABSTRACT ACHIEVEMENT AWARDS

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

UNDERGRADUATE STUDENT
Rajagopalan Subramaniam
Indian Institute of Technology (IIT)

GRADUATE STUDENT
Zhao Feng Zheng
Institute of Hematology & Blood

POST-DOCTORAL FELLOW
Mirca Saurty-Seerunghen, PhD
Weill Cornell Medicine

MEDICAL STUDENT
Anagha Sheth, BSc
University of Colorado School of Medicine

RESIDENT PHYSICIAN
Moritz Fürstenau, MD
University of Cologne

Awards
ABSTRACT ACHIEVEMENT AWARDS

ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

I-Jun Lau, DPhil, BMBCh
University of Oxford

Maryam Subhan
University College London

Nikolaos Sousos, MD, MSc, PGCert, DPhil
Oxford University Hospitals

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

James Kuzich, MBBS, FRACP, FRCPath
Peter MacCallum Cancer Centre

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Kenki Saito
Nara Medical University

Satoshi Kaito, MD, PhD
The University of Tokyo

Rurika Okuda, MSc,BS
Kyoto University

ASH-SOCIETTA ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Enrico Attardi, MD
University of Rome Tor Vergata

Luca Lanino, MD
IRCCS

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Carlos Bravo-Perez, MD
Cleveland Clinic

Hiroki Mizumaki, MD, PhD
National Institutes of Health

JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Matthew Frank, MD, PhD
Stanford University
MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand’s disease.

Lucas Van Gorder
Children’s Hospital of Philadelphia

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Cristina Astrid Tentori, MD
IRCCS

MINORITY GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based Minority Graduate Student Abstract Achievement Awards to select graduate students to acknowledge the accomplishments of and recruit and retain minority graduate students in the field of hematology.

Charles Ayemoba
University of Illinois at Chicago
Corbin Azucenas
Cincinnati Children’s Hospital Medical Center
Ginette Balbin-Cuesta
University of Michigan Medical School
Claudia Cabrera
Washington University School of Medicine
Daisy Diaz Rohena
The University of Texas MD Anderson Cancer Center
Ariel Leyte-Vidal
University of California
Francisco Marchi
University of Florida
Richard Marrero
University of Florida
Jonny Mendoza-Castrejon
Washington University School of Medicine
Fathima Mohamed
University of Minnesota
Justin Thomas
Fred Hutchinson Cancer Center
Eudorah Vital
Georgia Institute of Technology and Emory University

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year’s Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Dor Abelman
Yazan Abu-Shihab
Adeebimpe Adelaja
Jele Adimora
Margo Aertgeerts
Mike Agius
Louise Ahlgren
Guirayz Ahmed
Roberto Aiolfi
Abigail Ajanel Gomez
Yu Akahoshi
Theresia Akhlaghi
Emmanuelle Alawode
Jean-Baptiste Alberge
Mohammad Alhomoud
Konstantinos Aliazis
Stefan Alig
Cecily Allen
Diana Al-Sarayfi
Othman Al-Sawaf
Sultan Alsuhaibani
Zhao-Yu An
Michael Andersen
Mathew Angelos
Kaitlin Annunziato
Tomohiro Aoki
Michelle Aranha
Mutlu Arat
Mya Arellano
Christopher Arends
Ruby Arora
Sankalp Arora
Esteban Arrieta-Bolanos
Khetwasan Arunphong
arbon Averdash
Frida Bugge Askeland
Ferdowsi Atiq
Himachandana Atluri
Franceszka Auer
Matias Autio
Edward Ayoub
Irfan Azaman
Stefanie Bachl
Maximilian Bader
Marc-Andre Baertsch
Jie Bai
Zhiliang Bai
Firas Baidoun
Shovik Bandyopadhyay
Subham Bandyopadhyay
Lauren Banner
Mei Bao
Juan Barajas
Sergio Barajas
Manpreet Barna
Aditya Barve
Fahmin Bashir
Naseer Basma
Salman Basrai
Alex Battler
Benjamin Bateman
Habin Bea
Francisco Beas
Isabelle Becker
J. Beeler
Manali Begur
Salma Benbarchi
Philipp Berning
Kalay Bertulfo
Jan Philipp Bewersdorf
Alicia Beyou
Anand Bhagwat
Dipabarna Bhattacharya
Honghao Bi
Viktoria Blumenberg
Prajwal Boddu
Marta Bortolotti
Jonas Bouhali
Ruya Boulou
Molly Brakhane
Kelsey Bria
Charlotte Brierley
Robert Briski
Pamela Brito
Maura Bueno
Marco Buttigieg
Madeline Caduc
Xuan Cai
Steven Callori
Virginia Camacho
Wenjing Cao
Bria Carrithers
William Lee  
Yoonkyu Lee  
Julien Legrand  
Allison Lehanka  
Andri Leo Lemerquis  
Thomas Lew  
Lisa Leypoldt  
Chen Li  
Lixia Li  
Menglin Li  
Na Li  
Qin Li  
Qing Li  
Xueqi Li  
Yang Li  
Yang Li  
Yiwen Li  
Zhengping Li  
Zhenlong Li  
Ziming Li  
Emily Liang  
Nora Liebers  
Katie Lien  
Raphael Lievin  
Elizabeth Lightbody  
Kenneth Lim  
Guanglan Lin  
William Lin  
Zesen Lin  
Bingyu Liu  
Boya Liu  
Jie Liu  
Yingyue Liu  
Yu Liu  
Yucheng Liu  
Alison Livada  
Amaya Llorente-Chavez  
Marissa Locastro  
Alexa Loncharich  
Zhangbiao Long  
Izabela Lopes  
Diego Lopez  
Yadith Karina Lopez-Garcia  
Joseph Lownik  
John Lozada  
Bin Lu  
Tiange Lu  
Ting Lu  
Danny Luan  
Alexandra Lubin  
Johannes Lubke  
Ahmed Ludvigsen Al-Mashhadi  
Sofia Luna  
Hanzhi Luo  
Qingyu Luo  
Efrat Luttwak  
Xiurui Lv  
Maria Lysandrou  
Mona M.Hosseini  
Rui Ma  
Shengling Ma  
Eduardo Magalhaes  
Tylan Magnusson  
Himil Mahadevia  
Kiran Majeti  
Bilal Malik  
Erica Mamauag  
Paola Manara  
Srija Manchikanti  
Aashray Mandala  
Sachdeva Bindia Mapombo Choupa  
Alfredo Marchetti  
Josue Marquez  
Alexander Marr  
Tanner Martinez  
Esperanza Martinez-Sanchez  
Shinichiro Matsui  
Meghana Matur  
Katie Maurer  
Michael McCONVILLE  
Dustin McCurry  
Danielle McQuinn  
Rabea Mecklenbrauch  
Jose Mejias  
Megan Melody  
Max Mendez-Lopez  
Ana Menezes  
Gao Mengge  
Leo Meriranta  
Lauren Meyer  
Xiaoli Mi  
Mariia Mikhailaeva  
Michelle Millions  
Jelena Milojevic  
Charles Mitrod  
Rahul Mishra  
Jayna Mistry  
Safa Mohamad  
Anna Montanaro  
Adnan Mookhtiar  
Analy Mora  
Luz Moreno Rueda  
Kristina Mott  
Junli Mou  
Jan Mueller  
Umar Munawar  
Lauren Murphy  
Jurik Mutter  
Greggory Myers  
Keiichi Nakata  
Henna Nam  
Ahmad Nanaa  
Anna Naqvi  
Anna Navarro Figueredo  
Kit Neikirk  
Niraj Neupane  
Lok Lam Ngai  
Chi Nguyen  
Daniel Nguyen  
Nam Nguyen  
Madeline Niederkorn  
Sandra Novoa Jauregui  
Andres Noyola-Perez  
Timothy O’Connor  
Yaa Ofori-Marfoh  
Olisaemeka Ogbue  
Denis Ohlstrom  
Sylvia Okonofua  
Runika Okuda  
Fathia Oladipupo  
Aina Oliver-Caldes  
Jon Thorir Oskarsson  
Anna Ossami Saidy  
Julia Paczkowska  
Andrew Palmer  
Darren Pan  
Lii PAN  
Nilesh Pandey  
Marios Papadimitriou  
Julien Papoin  
Dorien Pastoors  
Ruchi Patel  
Akshay Patwardhan  
Jean Peglisasco  
Diego Pereira-Martins  
Cristina Perez  
Kristen Peterson  
Alexander Pichler  
Alexandra Pike  
Alfredo Pinedo-Rodriguez  
Michael Poeschla  
Laura Polcik  
Kanagaraju Ponnusamy  
Marianna Ponzo  
Mansour Poorbrahim  
Vera Poort  
Bogdan Popescu  
Patrizia Porazzi  
Lakshmi Bhavani Potluri  
Narges Pourmandi  
Yuekun Qi  
Laura Quillen  
Laura Raggi  
Kathrine Rallis  
Giulia Petra Rappa  
Christian Rausch  
Molly Reed  
Kai Rejeski  
Hongwei Ren  
Kehan Ren  
Fausto Alfredo Rios Olais  
Malte Ritter  
Soaifia Rivarola  
Santiago Rivielo-Goya  
Pauline Robbe  
Karl Roberts  
Alyssa Rodriguez  
Juan Jose Rodriguez Sevilla  
Sergio Rodriguez-Rodriguez  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodriguez-Sanchez  
Saimundur Rognvaldsson  
Gregory Roloff  
Laurel Romano  
James Ropa  
Sterling Rosqvist  
Paula Rothamel  
Andrew Ropa  
Laurel Romano  
Gregory Roloff  
Sæmundur Rognvaldsson  
Alberto Rodri...
ABSTRACT ACHIEVEMENT AWARDS

Fumou Sun
Jing Sun
Ruifeng Sun
Ryan Sun
Wenyue Sun
Xueyan Sun
Teodora Supeanu
Keito Suto
Andrew Ta
Jesse Tai
Amanda Tajik
Yuki Takeuchi
Joanne Tan
Megan Tanguay
Matthew Tanner
Ishan Tate
Dylan Tatterton
Samuel Taylor
Ana Cristina Tejada Vasquez
Semaje Testamark
Erik Thiele Orberg
Zanshe Thompson
Sigrun Thorsteinsdottir
Kirsten Thus
Zheng Tian
Elizabeth Titova
Hunter Tolson
Seda Tolu
Monika Toma
Zehra Tombul
Ahmet Toprak
Dicte Træden
Marissa Traets
Jennifer Tran
Iva Tsrova
Billy Truong
Serhan Unlu
Daniela Urueta Portillo
Marc Usart
Camille Vaganay
Arti Vaishnav
Sergio Vallejo
Yannis Valtis
Niek Van Der Maas
Jort Van Der Schans
Myrthe van Dijk
Karolina Vanickova
Hector Alejandro Vaquera Alfaro
Giulia Veltri
Rathnam Venkat
Eric Vick
Junia Vieira dos Santos
Laura Volta
Sydney Wade
Joseph Walden
Christina Waldron
Sarah Waldvogel
Janek Walker
Bo Wan
Visanu Wanchai
Amy Wang
Dandan Wang
Daniel Wang
Helen Wang
Jacqueline Wang
Junyu Wang
Moran Wang
Pan Wang
Shichong Wang
Song Wang
Ximi Wang
Xin Wang
Yu-Hung Wang
Yun Wang
Zhifa Wang
Mustafa Wasifuddin
Isabel Weinhaeuser
Alisha Weiss-Haug
Tobias Wertheimer
William Wesson
Jonas Wiltkirchen
Maggie Wong
Ping Chun Wu
Xia Wu
Ye-Jun Wu
Michael Wysota
Serene Xavier
Sera Xie
Tingting Xie
Jane Xu
Ruohao Xu
Yaqun Xu
Chitresh Yadav
Kyoko Yamaguchi
Li-Ping Yang
Sen Yang
Tingting Yang
Chun En Yau
Rashmi Yawalkar
Yongjun Yi
Charles Yin
Takao Yogo
Justin Yoo
Masanori Yoshida
Satoshi Yoshimura
Chenqi Yu
Zhuoya Yu
Junyun Yuan
Yin Yuan
Saurabh Zanwar
Clare Zarka
Martha Zarou
Chi Zhang
Ellen Zhang
Jingliao Zhang
Lei Zhang
Menglu Zhang
Michelle Zhang
Ningning Zhang
Xiao-shuai Zhang
Yaping Zhang
Yi Zhang
Peng Zhao
Hao Zheng
Xinhui Zheng
Chen Zhou
Jianying Zhou
Xiang Zhou
Xinrue Zhou
Yichao Zhou
Yifan Zhou
Hongming Zhu
Xinyu Zhu
Katherine Zhuo
Bachisio Ziccheddu
Fu Ziyu
Becky Zon
Adi Zoref-Lorenz
Luciana Zuccherato
Ines Zugasti
Call for Papers

NEW FROM ASH®

blood® VTH
vessels, thrombosis & hemostasis

Blood Vessels, Thrombosis & Hemostasis seeks to publish high-quality manuscripts focused on clinical and mechanistic aspects of normal and abnormal hemostasis and vascular function. These will include inherited and acquired bleeding and thrombotic disorders, including those involving platelets, as well as disorders involving the venous, arterial, and microvasculature. We seek novel and innovative studies that will have a significant aspect on translational and basic science as well as clinical care. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the Blood Journals portfolio, anchored by our high-impact flagship, Blood, is a natural home for research in specialty areas of hematology.

WHY SUBMIT?
Blood Vessels, Thrombosis & Hemostasis helps place your research within the reputable and highly visible Blood Journals portfolio. By publishing within these journals, you align your research with the long-trusted ASH and Blood brands.

BENEFITS TO AUTHORS:
• ASH & Blood Portfolio Visibility
• Fast Peer Review
• Seamless Transfers
• Speed to Publication
• Open Science

ASH is the home for hematology. Long embraced by the hematology community, Blood Journals are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a Blood journal.

Submit your paper now
GENERAL INFORMATION

AMERICAN SOCIETY OF HEMATOLOGY
65TH ASH® ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 9-12, 2023

GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society’s annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year’s annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in San Diego and the virtual meeting platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact disabilities@hematology.org.

TWO WAYS TO ATTEND THE 65TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 65th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in San Diego or participate using ASH’s virtual meeting platform. All participants, regardless of location, will have access to the virtual meeting platform built for learning, collaboration, and networking. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual meeting platform, and attendees will have the ability to ask questions and participate in real time.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2024.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription to extend their access to the meeting’s virtual platform at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2024. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee.

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate in real time. The platform will also include on-demand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

- **Real-Time Experience: Access through January 1, 2024**
  Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 12, 2024 by viewing the qualifying sessions on the virtual meeting platform.

- **Extended Flexibility: Access through February 1, 2024**
  Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.

- **Best Value: Access through March 1, 2024**
  Provides maximum flexibility to continue accessing on-demand sessions at the best price per day of access. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.
## GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

### LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 26)

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>In-Person or Real-Time Experience (Virtual access through January 1, 2024)</th>
<th>Extended Flexibility (Virtual access through February 1, 2024)</th>
<th>Best Value (Virtual access through March 1, 2024)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member (Active and International)</td>
<td>$850</td>
<td>$950</td>
<td>$1,050</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$1,500</td>
<td>$1,600</td>
<td>$1,700</td>
</tr>
<tr>
<td>Associate or International Member</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Medical Student, Graduate Student, or Resident Member</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$250</td>
<td>$275</td>
<td>$300</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$750</td>
<td>$850</td>
<td>$950</td>
</tr>
<tr>
<td>Spouse/Guest (in person only)</td>
<td>$150</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Honorary/Emeritus (before 1/1/15)</td>
<td>$0</td>
<td>$50</td>
<td>$100</td>
</tr>
<tr>
<td>Honorary/Emeritus (after 1/1/15)</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Profit Patient Advocacy Organization Representative</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
</tbody>
</table>

**BADGE COLORS**

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

- Member ............................................ Red
- Non-Member ...................................... Green
- Associate Member .............................. Blue
- International Associate Member ......... Blue
- Non-Member in Training ........................ Blue
- Graduate/Medical Student Member .......... Blue
- Resident Member .................................. Blue
- Honorary/Emeritus Member .................... White
- Allied Health Professional ................. Purple
- Exhibitor Booth Personnel ................. Black
- Spouses/Guest .................................... Yellow
- Media ................................................ Orange

**BADGES**

Returning this year, badges will be mailed in advance of the meeting to North American attendees only. International attendees may pick up their badge at one of several registration locations in San Diego, including at the San Diego International Airport. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.
OVERVIEW OF THE MEETING SCHEDULE
PREVIEW DAYS: DECEMBER 6-7, 2023

Beginning December 6, 2023, the ASH annual meeting virtual platform will be available to all registered participants at annualmeeting.hematology.org

All registered attendees are encouraged to log in early to get acquainted with the site’s navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the meeting’s virtual platform, please contact the ASH Customer Service department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

If you have successfully accessed the meeting’s virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

FRIDAY-ONLY PROGRAMMING: December 8, 2023

There are pre-meeting activities scheduled on Friday, December 8, 2023.

- Friday Satellite Symposia
- ASH-a-Palooza
- Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

OFFICIAL MEETING DAYS: December 9-12, 2023

The 65th ASH Annual Meeting and Exposition will take place December 9-12, 2023 in San Diego, California, and on the meeting’s virtual platform. All times listed reflect the Pacific time zone.

Saturday, December 9
Refer to schedule-at-a-glance or the mobile app for specific session times

Sunday, December 10
Refer to schedule-at-a-glance or the mobile app for specific session times

Monday, December 11
Refer to schedule-at-a-glance or the mobile app for specific session times

Tuesday, December 12
All sessions will occur in the general session room beginning at 8:45 a.m.
The meeting concludes at 2:15 p.m.

All sessions will be presented at the in-person meeting in San Diego, and unless otherwise noted all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until December 16, 2023.
CATCH UP DAYS: December 13-14, 2023

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday and Thursday, December 13-14, on the meeting’s virtual platform.

BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting from December 13 through the end of their virtual meeting registration package.

GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CATCH UP DAYS: December 13-14, 2023

ASH Poster Walks will be held on Wednesday and Thursday, December 13-14, on the meeting’s virtual platform.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In San Diego, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues.

ASH’s virtual meeting platform makes connecting with colleagues in San Diego and all around the world easy. On the meeting’s virtual platform click on Networking to connect with your peers.

ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting’s virtual platform and throughout the convention center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Walls will feature a daily leaderboard ranking of the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH23, #ASHRunWalk, #ASHKudos, and #ASHHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in the Sails Pavilion at the San Diego Convention Center. All times are in Pacific time.

Speaker Ready Room Hours
Thursday, December 7 . . . . 3:00 p.m. – 6:00 p.m.
Friday, December 8 . . . . 7:00 a.m. – 6:00 p.m.
Saturday, December 9 . . . . 7:00 a.m. – 6:00 p.m.
Sunday, December 10 . . . . 7:00 a.m. – 6:00 p.m.
Monday, December 11 . . . . 7:00 a.m. – 6:00 p.m.
Tuesday, December 12 . . . . 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

6 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation is final and requires no modifications.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations, session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.
CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES
Upon completion of this educational activity, participants should be able to:

• Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
• Discuss state-of-the-art research in hematology; and
• Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION
The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of 80 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with their participation in the live activity.

CME CERTIFICATE ELIGIBILITY
ASH is accredited to provide AMA PRA Category 1 Credits™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for AMA PRA Category 1 Credits™.

HOW TO OBTAIN A CME CERTIFICATE
A processing fee of $30 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 65th ASH Annual Meeting must be completed no later than April 12, 2024.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 80 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. To receive ABIM MOC points for the 65th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 12, 2024.

CERTIFICATE OF PARTICIPATION
Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation after completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 9, 2023. The online process of filling out the annual meeting survey and printing the certificate must be completed no later than April 12, 2024. There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT
ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (http://ebah.org). For information about claiming EBAH CME for the 65th ASH Annual Meeting email cme@hematology.org.

QUALIFYING ACCREDITED SESSIONS
Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.
ASH CENTRAL
ASH Central, a place where hematologists can gather to collaborate, is located in the Sails Pavilion at the San Diego Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or make a donation to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Health Equity Studio, fASHion boutique for the hematologist with style, ASH Live: Remote Session Viewing, ASH Store, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Health Equity Studio
As part of ASH’s commitment to promoting and nurturing a diverse and inclusive hematology community, the ASH Health Equity Studio will once again be located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution. These micro-sessions will also be available on the virtual meeting platform.

ASH Live: Remote Session Viewing Area
A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session’s speakers. Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.

ASH Store
ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio
In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy worklife balance through wellness.

Collaboration Rooms
Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology.org) via the mobile application or the Collaboration Room Help Desk in the Sails Pavilion to reserve a Collaboration Room.

Collaboration Room Hours
Friday, December 8 ... 7:00 a.m. – 5:45 p.m.
Saturday, December 9 ... 7:00 a.m. – 5:45 p.m.
Sunday, December 10 ... 7:00 a.m. – 5:45 p.m.
Monday, December 11 ... 7:00 a.m. – 5:45 p.m.
Tuesday, December 12 ... 7:00 a.m. – 1:45 p.m.

fASHion
For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, ranging from outerwear, athletic wear, golf polos, hematology specialty socks, bow ties, neck ties, scarves, and kids’ apparel, too. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley
Need a new professional headshot? Get one for free at Headshot Alley in ASH Central. Your headshot will be sent to you via email for immediate downloading.

Photo Zone
Capture the excitement of the annual meeting with your friends and colleagues by taking a photo in the ASH photo zone, located in ASH Central. Various props and backdrops will be available and will change daily.

Trainee Lounge
Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Ask Red
ASH is continuing the use of AI technology in the form of “Red,” your virtual chatbot assistant who helps attendees by answering ASH-specific questions. Red will also be able to connect you with “live” customer service agents that are available to answer questions. Here are some example questions you can ask Red:
When do the shuttle buses operate?
Where is ASH Central located?
Does ASH offer child care?
Interactive Technology in Sessions
Second screen technology through Conferences i/o enables attendees to view session slides in real time from most personal devices, including smartphones, tablets, and laptop computers. Conferences i/o allows for better viewing of images that can be difficult to see from the back of the session room and allows the audience to submit questions to the moderators virtually. Some sessions will use this technology for audience polls.

Attendees in participating sessions will be given a unique URL via QR code, which will grant access to view the slides for that session only. The QR code will be displayed at the beginning of the session but may also be found by navigating to the session within the mobile app.

Mobile App
ASH’s mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2023 annual meeting. The application includes the full text of the abstracts and the articles available in Hematology 2023 (the ASH Education Program). The application will allow users to add a session to their device’s calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

PosterCast
While you are in the poster hall, use the free PosterCast app to view five-minute video presentations by the author. This tool is especially useful when away from your computer, laptop or desk, or for viewing posters while the author is not present in the in-person poster hall.

Download the app on your smartphone by searching for “PosterCast” in the App Store or by visiting the PosterCast website and signing in with your ASH credentials.

To use the app, scan the QR code on a participating poster or use the keypad to enter the poster number. You will then be able to view a five-minute video describing the poster’s content while you view the poster. A link to the PosterCast recording will also appear within the mobile app for the poster description.

ASH FOUNDATION DONOR LOUNGE
Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of $250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in the Tides Restaurant on Level 1 of the San Diego Convention Center. The Tides Restaurant is located adjacent to Hall A and can be accessed from the Hall A Lobby.

ASH MANAGEMENT OFFICE
The ASH Staff Office is located in Room 15A on the Mezzanine level of the San Diego Convention Center.

ASH PARK @ THE PLAZA
ASH Park @ the Plaza will be located in Park Plaza at the San Diego Convention Center. This area will feature early morning yoga, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the San Diego sunshine.

BUSINESS CENTER
The San Diego Convention Center has a FedEx Office that provides full-service business needs for your convenience located on the ground level across from Hall D. FedEx Office provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM
ASH has, once again, made arrangements with KiddieCorp to provide child-care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 24 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 17.

The cost for child-care service is completely free and is subsidized by ASH. However, a cancellation penalty will be assessed if you cancel after the November 17 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 8, through Tuesday, December 12.

The child-care room is located in Room 16 on the Mezzanine Level at the San Diego Convention Center.

Child Care Room Hours
- Friday, December 8 . . . . 6:30 a.m. – 7:30 p.m.
- Saturday, December 9 . . . 6:30 a.m. – 7:30 p.m.
- Sunday, December 10 . . . 6:30 a.m. – 8:00 p.m.
- Monday, December 11 . . . 6:30 a.m. – 8:00 p.m.
- Tuesday, December 12 . . . 7:30 a.m. – 3:00 p.m.

COAT/BAG CHECK
Complimentary coat and bag check is available on the Ground Level of the San Diego Convention Center in Box Office A and Hall H Lobby as well as in the East Lobby Lounge of the Marriott Marquis San Diego Marina and the Seaport Foyer at the Manchester Grand Hyatt. Electronic items will not be accepted.

Coat/Bag Check Hours
- Friday, December 8 . . . . 7:00 a.m. – 8:30 p.m.
- Saturday, December 9 . . . 7:00 a.m. – 8:00 p.m.
- Sunday, December 10 . . . 7:00 a.m. – 8:00 p.m.
- Monday, December 11 . . . 7:00 a.m. – 8:30 p.m.
- Tuesday, December 12 . . . 7:00 a.m. – 3:30 p.m.

FRIENDS OF BILL W.
A meeting room for the Friends of Bill W. is located in Conference Room 2 at the Marriott Marquis San Diego Marina in South Tower Level 3.

HEMATOLOGY MEETUPS
To encourage interaction among attendees, “Hematology Meet Up” areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that...
General Information

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

INTERNET STATIONS

Internet Stations are placed throughout the San Diego Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 14A on the Mezzanine Level of the San Diego Convention Center.

NURSING MOTHERS’ LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the San Diego Convention Center, Hilton San Diego Bayfront, Marriott Marquis San Diego Marina, and Manchester Grand Hyatt. Each nursing mothers’ lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Room 16 at the San Diego Convention Center.

Nursing Mothers’ Lounges Locations

San Diego Convention Center:
- Hall E Lobby
- Hall B1 Lobby
- Mezzanine Level

Manchester Grand Hyatt:
- Show Office 6

Hilton San Diego Bayfront:
- Aqua Level

Marriott Marquis San Diego Marina:
- Pacific Ballroom Registration Desk

QUIET ROOMS

Two quiet rooms are located in San Diego Convention Center. Show Office G is designated as the Female Quiet Room and Show Office H is designated as the Male Quiet Room.

PRESS COMPLEX

The Press Complex, open to registered members of the media, is located on the third Level of the Seaport Tower at the Manchester Grand Hyatt.

Press Room Hours

Friday, December 8........ 9:00 a.m. – 5:00 p.m.
Saturday, December 9..... 7:00 a.m. – 6:00 p.m.
Sunday, December 10..... 7:00 a.m. – 6:00 p.m.
Monday, December 11..... 7:00 a.m. – 6:00 p.m.
Tuesday, December 12..... 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS

Sodexo Live at the San Diego Convention Center offers a wide variety of dining options, including concessions in the Exhibit Hall and numerous food outlets featuring variety of cuisines. A variety of restaurants are also located near the San Diego Convention Center.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY

To stay safe during your visit to San Diego, please follow the tips provided below:

Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).

Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.

Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.

Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.

When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

SHUTTLE SERVICE

ASH will be providing complimentary shuttle service for more than 70 hotels; additionally, 15 hotels are within walking distance of the San Diego Convention Center.

Shuttle Boarding Locations

Routes 1-2
- Marriott Marquis Pacific Ballroom

Routes 3-8
- SDCC Halls A-C

Routes 9-12
- SDCC Halls F-H

Routes 13-16
- Park Blvd. (Near ASH Park @ the Plaza)
GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Shuttle Hours

Thursday, December 7 ....... No shuttle service
Friday, December 8 ....... 6:30 a.m. – 10:30 p.m.
Saturday, December 9 ....... 6:30 a.m. – 9:30 p.m.
Sunday, December 10 ....... 6:30 a.m. – 9:30 p.m.
Monday, December 11 ....... 6:30 a.m. – 9:30 p.m.
Tuesday, December 12 ....... 6:30 a.m. – 3:15 p.m.

Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the San Diego Convention Center:
• Courtyard San Diego Gaslamp/Convention Center
• Embassy Suites San Diego Bay Downtown
• Hard Rock Hotel San Diego
• Hilton San Diego Bayfront
• Hilton San Diego Gaslamp Quarter
• Horton Grand Hotel
• Hotel Indigo San Diego Gaslamp Quarter
• Hotel Z
• Manchester Grand Hyatt
• Margaritaville Hotel San Diego Gaslamp Quarter
• Marriott Marquis San Diego Marina
• Marriott San Diego Gaslamp Quarter
• Omni San Diego
• Pendry San Diego
• Residence Inn San Diego Downtown/Gaslamp Quarter

AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes between the San Diego Convention Center and the San Diego International Airport during the days and times indicated below. Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall C Lobby, Ground Level of the San Diego Convention Center. Tickets cost $25

Tickets Sales Hours

Monday, December 11 ....... 9:00 a.m. - 7:00 p.m.
Tuesday, December 12 ....... 7:00 a.m. - 2:45 p.m.

Shuttle Hours

Monday, December 11 ....... 12:00 noon - 6:00 p.m.
Tuesday, December 12 ....... 9:00 a.m. - 3:00 p.m.

Departure Location: San Diego Convention Center, Buses load outside curbside in front of Hall C Lobby. Level 1

PARKING

On-site private vehicle parking is available at the San Diego Convention Center as well as nearby parking options that serve the Downtown San Diego area. For detailed parking information, visit https://www.visitsandiego.com/parking.

GETTING AROUND

The area’s public transportation system - MTS - has routes servicing the San Diego Convention Center with connections to the San Diego International Airport and downtown San Diego. To plan your journey and obtain the latest fares, visit https://www.sdmts.com/.

Taking the MTS Trolley is one of the most convenient and least expensive ways to explore the downtown area and the San Diego Convention Center. For maps and fare information, visit the MTS Trolley website, https://www.sdmts.com/transit-services/trolley.

FRED: Free Ride Everywhere Downtown is a unique form of transport in San Diego. These electric, open-air vehicles offer completely free rides within their service area throughout downtown San Diego. Service works through a mobile app and can be a great option if the pick-up times align with your schedule. Download the Ride Circuit app to request a ride. Hours of operation can be found at ridecircuit.com/fred.

Taxis in San Diego are billed using a base fare of $3 with a charge of $3.30 per mile.

EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 65th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls B-F in the San Diego Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours

Saturday, December 9 ....... 11:00 a.m. – 5:00 p.m.
Sunday, December 10 ....... 10:00 a.m. – 5:00 p.m.
Monday, December 11 ....... 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY

Your “ticket” for lunch is encoded in your badge, which will be scanned for entry into the “ticketed” event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café areas located in the back of the exhibit hall.

Lunch Hours

Sunday, December 10 ....... 11:00 a.m. – 12:30 p.m.
Monday, December 11 ....... 12:00 noon – 1:30 p.m.
ASH BOOTH (#1215) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1215). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, and Company Showcases, which feature new research findings, company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All corporate presentations will take place on the Upper Level of the San Diego Convention Center (Rooms 1-5). Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

Theater Hours
Saturday, December 9
11:30 a.m. – 12:30 p.m.
1:30 p.m. – 1:45 p.m.
3:30 p.m. – 3:45 p.m.

Sunday, December 10
8:00 a.m. – 9:00 a.m.
11:30 a.m. – 12:30 p.m.
4:00 p.m. – 4:15 p.m.

Monday, December 11
8:00 a.m. – 9:00 a.m.
12:15 p.m. – 1:15 p.m.

Please see page 139 for detailed Corporate Presentation program information.

POSTER SESSIONS

Poster sessions are held in Halls G-H of the San Diego Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 9
9:00 a.m. – 7:30 p.m.............Poster Session I – Viewing
5:30 p.m. – 7:30 p.m.............Poster Session I – Presentations

Sunday, December 10
9:00 a.m. – 8:00 p.m. .........Poster Session II – Viewing
6:00 p.m. – 8:00 p.m..........Poster Session II – Presentations

Monday, December 11
9:00 a.m. – 8:00 p.m. .........Poster Session III – Viewing
6:00 p.m. – 8:00 p.m..........Poster Session III – Presentations

SOCIAL EVENTS

ASH FOUNDATION RUN/WALK
Sunday, December 10, 2023, 7:00 a.m. – 9:00 a.m.

Fifth Avenue Landing (on the Embarcadero and marina side of the convention center toward the Hilton San Diego Bayfront Hotel)

Begin your day in a fun, healthy, and philanthropic way by participating in the 10th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 10. Participants may run or walk through the designated event course in scenic San Diego, choosing either a 3K or 5K route. Not attending in person this year? Don’t worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Minority Recruitment Initiative Fund. ASH and the ASH Foundation may opt to designate a portion of, or all corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at https://www.hematology.org/foundation/run-walk

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2023 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.
MEETING RULES AND REGULATIONS

CODE OF CONDUCT
ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact customerservice@hematology.org as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

MEETING AND SESSION PARTICIPATION
Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties just cause for repossessing badges of any individuals involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the San Diego Convention Center:

1. I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE SAN DIEGO CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY. I agree, for myself and any heirs, not to sue ASH or the San Diego Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.

2. I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge, since the recipient would not have completed the requirement to show proof of vaccination to ASH before a badge is issued. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

PARTICIPATION OF FINANCIAL PROFESSIONALS
Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

ANNUAL MEETING DATA COLLECTION
As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:
American Society of Hematology
• Privacy Policy (hematology.org/about/privacy-policy)
• Terms of Service (hematology.org/about/terms-of-service)
SPARGO (ASH Registration and Housing provider)
• Privacy Policy (https://spargoinc.com/privacy-statement)
Freeman (Virtual Meeting Platform provider)
• Privacy Policy (https://www.freeman.com/privacy-policy/)
• Terms of Service (https://www.freeman.com/terms/)
Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PROHIBITED SESSION ROOM BEHAVIOR
In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

CHILDREN
For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE
As part of ASH’s ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.
PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or [in the case of the slides and posters] the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

Limited Right to Share: Except as provided in Sections A and B.2 of this Policy (hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

Attribution: an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;

Non-Commercial: an attendee may not use the Meeting Materials for commercial purposes; and

No Derivatives: if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.

Poster and Exhibit Hall Presentations: Attendees of the ASH annual meeting may take photographs and make recordings of Meeting Materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. Attendees are strictly prohibited from sharing Meeting Materials associated with Poster Presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such Meeting Materials.

C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of meeting materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees. Flash photography is strictly prohibited.

D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of meeting materials, including live streaming audio or video recordings, is strictly prohibited.

E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to use and distribute the registrant's image or voice in photographs, videotapes, audiotapes, or other electronic media pertaining to the ASH annual meeting events and activities.
DIVERSITY, EQUITY, AND INCLUSION AT ASH®

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care communities. ASH’s efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes.

Join us for the following events at the 65th ASH Annual Meeting to help improve diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

ASH HEALTH EQUITY STUDIO

Saturday, Sunday, Monday
Sails Pavilion, San Diego Convention Center

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

PROMOTING MINORITIES IN HEMATOLOGY ORAL PRESENTATIONS AND RECEPTION (FOR IN-PERSON PARTICIPANTS)

Saturday
6:30 p.m. – 9:00 p.m.
Marina Ballroom G, Marriott Marquis San Diego Marina

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, Minority Resident Hematology Award, ASH Minority Graduate Award, and the ASH Minority Fellowship Award program participants. A special reception will follow the presentations to mark the 20th anniversary of the ASH Minority Recruitment Initiative.

MATERNAL HEALTH – FERTILITY PRESERVATION IN HEMATOLOGY CARE

Sunday
9:30 a.m. – 11:00 a.m.
Ballroom 20AB, San Diego Convention Center

Both patients with hematologic conditions and their hematologists face a complex set of challenges when considering options for fertility preservation. With new technologies available and a broader understanding of the need for fertility preservation, there are more opportunities available. This session will explore why there has been such a marked increase in demand for these options, what exactly the options and techniques available are and what both hematologists and their patients need to expect in success rates, complications and demands on their already busy schedules.

SPECIAL SCIENTIFIC SESSION ON RACE AND SCIENCE

Sunday
9:30 a.m. – 11:00 a.m.
Hall A, San Diego Convention Center

Race and Science: Bench to Bedside to the Community. Will address DEI as it relates to basic through clinical research. The following two questions will be the core focus of the discussion: (1) How do we ensure that research is generalizable; and (2) What are the critical DEI questions that need to be addressed in the different domains of research (basic, translational, and clinical).
HEALTH EQUITY ROUNDS LUNCH (FOR IN-PERSON PARTICIPANTS)

Sunday 11:15 a.m. – 12:15 p.m.  Sapphire Ballroom CD, Hilton San Diego Bayfront

The Health Equity Rounds are interactive in-person, case-based discussions with interdisciplinary panels, including hematologists, health equity/public health experts, patients, and patient advocates, to discuss health equity issues within hematology.

WAKE UP TO DEI NETWORKING BREAKFAST (FOR IN-PERSON PARTICIPANTS)

Monday 7:00 a.m. – 8:30 a.m.  Marina Ballroom, Marriott Marquis San Diego Marina

This will be a networking gathering to allow the communities that fall within the Diversity, Equity, and Inclusion (DEI) umbrella a space to gather across communities and get to know each other. The event will include remarks from a member of the ASH Committee on Diversity, Equity, and Inclusion.

AI IN HEMATOLOGY: WHERE DO YOU STAND IN 2023?

Monday 10:30 a.m. – 12:00 p.m.  Room 11, San Diego Convention Center

Artificial intelligence (AI) and related technologies are rapidly gaining traction in a variety of industries, including healthcare. The integration of AI and machine learning (ML) has the potential to revolutionize the way we approach research and patient care in hematology, from diagnosis to prognosis and treatment selection. This session will delve into the current state of AI and ML in diagnostic hematology and clinical research. It will highlight the various ways in which AI and ML are being used in hematology, such as developing diagnostic tools and novel drug targets. Additionally, the session will discuss the use of AI and ML in prognostic models, which can help predict the outcome of a patient's disease, as well as personalized treatment plans. Finally, the session will discuss the complexity and the importance of AI ethics.

WOMEN IN HEMATOLOGY NETWORKING RECEPTION (FOR IN-PERSON PARTICIPANTS)

Monday 7:30 p.m. – 9:30 p.m.  Coronado Ballroom & Terrace, Manchester Grand Hyatt San Diego

The networking reception provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.
ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education’s (AACME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform and an up-to-date list of sessions will also be available.

Non-CME Sessions
Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

General Sessions
- Best of ASH
- Ernest Beutler Lecture and Prize
- Late-Breaking Abstracts Session
- Plenary Scientific Session

Scientific Program Sessions
- The Evolution of Multiple Myeloma: From Inside-Out
- Next Generation of Gene-Based Therapies for Bleeding Disorders
- JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy

Special Interest Sessions
- ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease
- ASH Foundation Run/Walk
- Blood Advances Meet the Editors
- Blood Advances Presents: How to Peer Review a Scientific Paper
- Blood and Beyond
- Blood Presents: How to Get Published in a Peer Review Journal
- Health Equity Rounds Lunch
- Hemostasis and Thrombosis Community Networking Reception
- Meet the Blood Editors
- Promoting Minorities in Hematology: Presentations and Reception
- Women in Hematology Networking Dinner
- Wake up to DEI Networking Breakfast

Spotlight Sessions
- The Evolution of Multiple Myeloma: From Inside-Out
- Next Generation of Gene-Based Therapies for Bleeding Disorders

Non-CME Programs
All sessions in the following programs are not accredited for CME credit:
- ASH Health Equity Studio
- ASH Poster Walks
- ASH Wellness Studio
- ASH-a-Palooza Events
- Company Showcases
- Industry Theaters
- Oral and Poster Abstracts
- Scientific Workshops
- Product Theaters
- Trainee Activities and Services
Learn more about dosing information for KEYTRUDA® (pembrolizumab)

For more information, visit keytrudahcp.com/dosing
Notes:
## Day-at-a-Glance

**Friday, December 8, 2023**

### Thursday, December 7, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 a.m.-10:00 p.m.</td>
<td>Registration at the Airport (for in-person participants)</td>
<td>San Diego International Airport</td>
</tr>
<tr>
<td>3:00 p.m.-7:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
<td>Ballroom 20 Lobby</td>
</tr>
</tbody>
</table>

### Friday, December 8, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 a.m.-10:00 p.m.</td>
<td>Registration at the Airport (for in-person participants)</td>
<td>San Diego International Airport</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Learn, Engage, and Relax in ASH Central (for in-person participants)</td>
<td>Sails Pavilion</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
<td>Ballroom 20 Lobby</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Grand Hyatt (for in-person participants)</td>
<td>Manchester Grand Hyatt San Diego, Hotel Main Lobby</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Marriott Marquis (for in-person participants)</td>
<td>Marriott Marquis San Diego Marina, East Lobby Lounge</td>
</tr>
<tr>
<td>7:00 a.m.-10:00 a.m.</td>
<td>Satellite Symposia (for in-person participants)</td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22</td>
</tr>
</tbody>
</table>

**BEYOND THE GUIDELINES:** Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)

Omni San Diego, Grand Ballroom 4

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease

Ballroom 20CD

Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

Room 6B

Myelodysplastic Syndromes 2023: What’s New?

Marriott Marquis San Diego Marina, San Diego Ballroom AB

Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

Room 6A

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care with Potent CAR-T and Bispecific Options

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

9:00 a.m.-12:00 p.m. Training Program Directors Workshop (for in-person participants)

Hilton San Diego Bayfront, Indigo 204

11:00 a.m.-2:00 p.m. Satellite Symposia

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

Marriott Marquis San Diego Marina, San Diego Ballroom AB

An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

---

**Day-At-A-Glance**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)
Omni San Diego, Grand Ballroom

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration
Room 30 A-E

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management
Ballroom 20CD

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
Room 6A

Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma
Room 6DE

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Multiple Myeloma: Clinical Challenges for the Community Clinician
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

Optimizing Myelofibrosis Management with Current and Emerging Therapies
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Show Me the Data! How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
Room 6B

Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications
Ballroom 20AB

12:45 p.m.-5:00 p.m.  ASH-a-Palooza (Open to Trainees Only)
Petco Park
Opening Song and Welcome
ASH Talks
Blood Drops
Blood Buddies

1:00 p.m.-1:20 p.m.  ASH-a-Palooza (Open to Trainees Only)
Petco Park, Sections 112 and 114

ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities
Petco Park, Sections 112 and 114

2:00 p.m.-5:00 p.m.  Scientific Workshops

Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology
Room 33

Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology
Room 28 A-D

Background to Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Room 29

Scientific Workshop on Hematology and Aging
Room 11

Scientific Workshop on the Interplay between Coagulation and Malignancy
Room 25

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Worms to Patients
Room 24

Scientific Workshop on Myeloid Development
Room 6CF

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
Room 7

Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities
Room 8

2:10 p.m.-2:30 p.m.  ASH-a-Palooza (Open to Trainees Only)
Petco Park, Sections 112 and 114

3:00 p.m.-6:00 p.m.  Satellite Symposia

A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease
Marriott Marquis San Diego Marina, San Diego Ballroom AB

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care
Room 30 A-E

Advancing cTTP Care Through Integration of the Latest Clinical Evidence
Ballroom 20AB

AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents**

**Ballroom 20CD**

- **3:20 p.m.-3:30 p.m.**
  - ASH-a-Poolza: President’s Remarks (Open to Trainees Only)

**Petco Park, Sections 112 and 114**

- **3:30 p.m.-4:15 p.m.**
  - ASH-a-Palooza: Blood Wars - Jeopardy! (Open to Trainees Only)

**Petco Park, Sections 112 and 114**

- **5:00 p.m.-7:00 p.m.**
  - Trainee Welcome Reception (Open to Trainees Only)

**Petco Park, Left Field**

- **7:00 p.m.-10:00 p.m.**
  - Satellite Symposia

**BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)**

**Omni San Diego, Grand Ballroom**

- **7:00 p.m.-10:00 p.m.**
  - Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

- **8:00 a.m.-9:00 a.m.**
  - How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

**Samedi, December 9, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.-7:45 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>ASH Yoga - ASH Park @ the Plaza</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Grand Hyatt (for in-person participants)</td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Marriott Marquis (for in-person participants)</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Coffee and Collaboration in ASH Central (for in-person participants)</td>
</tr>
</tbody>
</table>

**Acquired Hemophilia A Diagnosis and Management**

**Hilton San Diego Bayfront, Aqua Salon AB**

- Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL)

**Hilton San Diego Bayfront, Aqua Salon F**

- Advances in Myeloproliferative Neoplasms Affecting Management

**Hilton San Diego Bayfront, Aqua Salon D**

- Hematologists and the Care of Pregnant Women

**Hilton San Diego Bayfront, Aqua Salon C**

- Patients with Acute Myeloid Leukemia

**Hilton San Diego Bayfront, Aqua Salon E**

- Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle

**Hilton San Diego Bayfront, Aqua Salon 313**

- Iron and Heme in Stem Cell Maintenance and Erythropoiesis
### Saturday, 09 Dec 2023

**Genome Engineering for Enhanced Blood Cancer Immunotherapy**  
Hilton San Diego Bayfront, Aqua 313

**Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies**  
Hilton San Diego Bayfront, Aqua 300

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m.-9:30 a.m.</td>
<td>Coffee Break in Poster Hall (for in-person participants)</td>
</tr>
</tbody>
</table>

**Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health**  
Sails Pavilion - ASH Health Equity Studio

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m.-7:30 p.m.</td>
<td>Poster Session I - Viewing</td>
</tr>
</tbody>
</table>

**What’s Restoring You?**  
Sails Pavilion - ASH Wellness Studio

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m.-9:25 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
</tbody>
</table>

**An Oasis in Chaos**  
Sails Pavilion - ASH Wellness Studio

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>Education Sessions</td>
</tr>
</tbody>
</table>

**Acquired Hemophilia A Diagnosis and Management**  
Room 28 A-D

**Are We Personalizing MDS Therapy in 2023?**  
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

**CAR T Cells in ALL: Bridge or Definitive Therapy?**  
Room 6B

**How Do We Calibrate Cellular Therapy for Lymphoma in 2023?**  
Room 6CF

**What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?**  
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>Scientific Sessions</td>
</tr>
</tbody>
</table>

**Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes**  
Room 7

**Next Generation of Gene-Based Therapies for Bleeding Disorders**  
Room 31

**The Evolution of Multiple Myeloma: From Inside-Out**  
Manchester Grand Hyatt San Diego, Grand Hall C

### 9:30 a.m.-11:00 a.m. Oral Abstract Sessions

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>101</td>
<td>Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Room 25</td>
</tr>
<tr>
<td>113</td>
<td>Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease Room 29</td>
</tr>
<tr>
<td>321</td>
<td>Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies Room 33</td>
</tr>
<tr>
<td>322</td>
<td>Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders Room 30</td>
</tr>
<tr>
<td>501</td>
<td>Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress Room 24</td>
</tr>
<tr>
<td>603</td>
<td>Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13</td>
</tr>
<tr>
<td>604</td>
<td>Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Ballroom 20CD</td>
</tr>
<tr>
<td>605</td>
<td>Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Manchester Grand Hyatt San Diego, Grand Hall D</td>
</tr>
<tr>
<td>617</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26</td>
</tr>
<tr>
<td>627</td>
<td>Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Manchester Grand Hyatt San Diego, Seaport Ballroom EF GH</td>
</tr>
<tr>
<td>634</td>
<td>Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies Ballroom 20AB</td>
</tr>
<tr>
<td>641</td>
<td>Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation Manchester Grand Hyatt San Diego, Grand Hall B</td>
</tr>
<tr>
<td>651</td>
<td>Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Manchester Grand Hyatt San Diego, Harbor Ballroom</td>
</tr>
<tr>
<td>652</td>
<td>Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</td>
</tr>
<tr>
<td>703</td>
<td>Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights Room 6DE</td>
</tr>
</tbody>
</table>
Day-At-A-Glance

09 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
Room 6A

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxocities: Improving Outcomes by Reducing Transplant-Related Complications
Room 11

802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology
Marriott Marquis San Diego Marina, San Diego Ballroom AB

902. Health Services and Quality Improvement: Lymphoid Malignancies: Making a Splash In Outcomes Data
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

904. Outcomes Research: Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

9:30 a.m.-11:00 a.m. Special Session on Sickle Cell Disease Centers
Hall A

10:00 a.m.-11:00 a.m. Blood Journals Studio (for in-person participants)
Meet the Blood Advances Editors
Halls G-H - Blood Journals Studio

11:00 a.m.-11:30 a.m. Health Equity Studio
Community Partnerships: An Essential Component to Advance Health Equity
Sails Pavilion - ASH Health Equity Studio

11:00 a.m.-12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)
ASH Park @ The Plaza

11:00 a.m.-12:30 p.m. Open Time for Lunch

11:00 a.m.-5:00 p.m. Exhibits Open
Halls B-F

11:05 a.m.-11:15 a.m. ASH Wellness Studio (for in-person participants)
Fix the Way You Sit
Sails Pavilion - ASH Wellness Studio

11:15 a.m.-12:15 p.m. Blood Presents: How to get Published in a Peer Review Journal (for in-person participants)
Room 24

11:15 a.m.-12:15 p.m. ASH Grassroots Network Lunch (for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballroom DE

11:15 a.m.-12:15 p.m. Career Development Lunch (Open to Trainees Only)
Hilton San Diego Bayfront, Sapphire Ballroom ABCD

11:20 a.m.-11:30 a.m. ASH Wellness Studio (for in-person participants)

11:30 a.m.-12:30 p.m. Industry Theaters
BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape
Room 5A

COVID-19: Protecting Vulnerable Populations
Room 5B

GSK oncology: breaking barriers for patients with multiple myeloma
Room 1B

Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors
Room 1A

11:30 a.m.-12:30 p.m. Product Theaters
Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types
Room 3

Learn more about a CAR T cell therapy for relapsed/refractory multiple myeloma (RRMM)
Room 2

The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)
Room 4

11:35 a.m.-11:45 a.m. ASH Wellness Studio (for in-person participants)

Feast Better in Your Body
Sails Pavilion - ASH Wellness Studio

12:30 p.m.-1:30 p.m. Ham-Wasserman Lecture
Hall A
1:30 p.m.-1:45 p.m.  Company Showcases

Galapagos’ 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model
Room 5A

Showcase on Galleri®, a multi-cancer early detection test
Room 5B

1:30 p.m.-2:00 p.m.  Coffee Break in Exhibit Hall
(for in-person participants)
Halls B-F

1:30 p.m.-2:00 p.m.  Health Equity Studio
(for in-person participants)

How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective
Sails Pavilion - ASH Health Equity Studio

1:35 p.m.-1:45 p.m.  ASH Wellness Studio
(for in-person participants)

Finding Stillness in the Busyness
Sails Pavilion - ASH Wellness Studio

1:45 p.m.-1:55 p.m.  ASH Wellness Studio
(for in-person participants)

The Real Purpose of Your Purpose
Sails Pavilion - ASH Wellness Studio

2:00 p.m.-3:15 p.m.  Scientific Symposia

Alternative Immune Effector Cells
Room 6DE

2:00 p.m.-3:15 p.m.  Education Program

How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
Ballroom 20CD

Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult
Room 24

Ongoing Challenges in the Management of VTE
Room 29

Transfusion Support in Sickle Cell Disease
Room 28 A-D

2:00 p.m.-3:15 p.m.  Scientific Sessions

Co-Operativity in the Pathogenesis of Myeloid Malignancies
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

 Emerging Methodologies to Investigate Platelet Biology
Room 25

Spatial Genomic & Epigenomic Profiling in Hematology
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

2:00 p.m.-3:30 p.m.  Distinguished Abstract Achievement Awards Ceremony

Halls G-H - Blood Journals Studio

2:00 p.m.-3:30 p.m.  Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease
Room 33

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors
Room 31

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity
Marriott Marquis San Diego Marina, San Diego Ballroom AB

615. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents
Room 6A

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

621. Lymphomas: Translational: Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc.
Ballroom 20AB

622. Lymphomas: Translational: Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Manchester Grand Hyatt San Diego, Grand Hall B

627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients with Aggressive Lymphomas
Manchester Grand Hyatt San Diego, Grand Hall C

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation
Manchester Grand Hyatt San Diego, Grand Hall D

653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma
Manchester Grand Hyatt San Diego, Harbor Ballroom

654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines: The Spectrum of Plasma Cell Disorders
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies
Room 6B
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Day-at-a-Glance</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Day-at-a-Glance</td>
<td></td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors</td>
<td>Room 6CF</td>
</tr>
<tr>
<td></td>
<td>723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship from Clinical Trials And Observations</td>
<td>Room 7</td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td>803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology</td>
<td>Room 30</td>
</tr>
<tr>
<td></td>
<td>902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovative Care in CAR-T Therapy</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4</td>
</tr>
<tr>
<td></td>
<td>903. Health Services and Quality Improvement: Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies</td>
<td>Hall A</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>2:00 p.m.-3:30 p.m. Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care</td>
<td>Room 11</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>3:30 p.m.-3:45 p.m. Company Showcases</td>
<td>Room 5B</td>
</tr>
<tr>
<td></td>
<td>Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reimagining Cancer Care at Syndax: Clinical Development of Targeted Therapies</td>
<td>Room 5A</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>3:30 p.m.-4:00 p.m. Coffee Break in Exhibit Hall (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>4:00 p.m.-5:00 p.m. ASH Wellness Studio (for in-person participants)</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td></td>
<td>Eating With a Full Mind or Mindfully</td>
<td>Room 26</td>
</tr>
<tr>
<td></td>
<td>Sails Pavilion - ASH Wellness Studio</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>4:00 p.m.-5:15 p.m. ASH Poster Walks (for in-person participants)</td>
<td>Room 29</td>
</tr>
<tr>
<td></td>
<td>ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH</td>
<td>Halls G-H - Blood Journals Studio</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>4:00 p.m.-5:15 p.m. Education Program</td>
<td></td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>5:00 p.m.-6:00 p.m. Scientific Sessions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Iron and Heme in Stem Cell Maintenance and Erythropoies</td>
<td>Room 24</td>
</tr>
<tr>
<td></td>
<td>Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis</td>
<td>Room 31</td>
</tr>
<tr>
<td></td>
<td>Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td>6:00 p.m.-8:00 p.m. Oral Sessions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease</td>
<td>Room 28 A-D</td>
</tr>
<tr>
<td></td>
<td>301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational: The Multimodal Platelet: Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias</td>
<td>Room 33</td>
</tr>
<tr>
<td></td>
<td>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care</td>
<td>Room 30</td>
</tr>
<tr>
<td></td>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control</td>
<td>Room 6CF</td>
</tr>
</tbody>
</table>

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Manchester Grand Hyatt San Diego, Grand Hall B

627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunotherapy, CAR-T Cell and Novel Agents
Manchester Grand Hyatt San Diego, Grand Hall C

636. Myelodysplastic Syndromes: Basic and Translational: Molecular Drivers and Therapeutic Implications
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL
Manchester Grand Hyatt San Diego, Grand Hall D

5:00 p.m.-5:35 p.m.  Scientific Sessions

- What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies
  Ballroom 20AB
- Ontogeny and Myeloid Disorders of Childhood
  Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

5:00 p.m.-5:30 p.m.  Blood Journals Studio (for in-person participants)

Meet the Blood VTH Editor-in-Chief
Halls G-H - Blood Journals Studio

5:30 p.m.-7:30 p.m.  Welcome Reception in Poster Hall (for in-person participants)

5:30 p.m.-7:30 p.m.  Poster Session I - Presentations

Halls G-H

101. Red Cells and Erythropoiesis, Excluding Iron
102. Iron Homeostasis and Biology
112. Thalassemia and Globin Gene Regulation
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological
201. Granulocytes, Monocytes, and Macrophages
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
311. Disorders of Platelet Number or Function: Clinical and Epidemiological
321. Coagulation and Fibrinolysis: Basic and Translational
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
332. Thrombosis and Anticoagulation: Clinical and Epidemiological
401. Blood Transfusion
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
503. Clonal Hematopoiesis, Aging and Inflammation
506. Bone Marrow Microenvironment
508. Bone Marrow Failure: Acquired
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital
602. Myeloid Oncogenesis: Basic
603. Lymphoid Oncogenesis: Basic
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological
613. Acute Myeloid Leukemias: Clinical and Epidemiological
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
621. Lymphomas: Translational: Molecular and Genetic
622. Lymphomas: Translational: Non-Genetic
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological
625. Aggressive Lymphomas: Prospective Therapeutic Trials
627. Aggressive Lymphomas: Clinical and Epidemiological
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
632. Chronic Myeloid Leukemia: Clinical and Epidemiological
634. Myeloproliferative Syndromes: Clinical and Epidemiological
636. Myelodysplastic Syndromes: Basic and Translational
637. Myelodysplastic Syndromes: Clinical and Epidemiological
641. Chronic Lymphocytic Leukemia: Basic and Translational
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
652. Multiple Myeloma: Clinical and Epidemiological
653. Multiple Myeloma: Prospective Therapeutic Trials
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
701. Experimental Transplantation: Basic and Translational
703. Cellular Immunotherapies: Basic and Translational
704. Cellular Immunotherapies: Early Phase and Investigational Therapies
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies
711. Cell Collection and Processing
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence
731. Autologous Transplantation: Clinical and Epidemiological
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
801. Gene Therapies
802. Chemical Biology and Experimental Therapeutics
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology
901. Health Services and Quality Improvement: Non-Malignant Conditions
902. Health Services and Quality Improvement: Lymphoid Malignancies
903. Health Services and Quality Improvement: Myeloid Malignancies
904. Outcomes Research: Non-Malignant Conditions
905. Outcomes Research: Lymphoid Malignancies
906. Outcomes Research: Myeloid Malignancies

6:30 p.m.-8:00 p.m. Promoting Minorities in Hematology (PMH) Oral Presentations (for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballrooms D-F

8:00 p.m.-9:00 p.m. Promoting Minorities in Hematology (PMH) MRI Anniversary Reception (for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballroom G

SUNDAY, DECEMBER 10, 2023

7:00 a.m.-9:00 a.m. ASH Foundation Run/Walk
San Diego Bayfront Park and South Embarcadero

7:00 a.m.-5:00 p.m. Registration at the Convention Center (for in-person participants)
Ballroom 20 Lobby

7:00 a.m.-6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)
Sails Pavilion

7:30 a.m.-9:30 a.m. Medical Educators Symposium
Hilton San Diego Bayfront, Sapphire Ballroom AB

8:00 a.m.-9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)
Sails Pavilion

8:00 a.m.-9:00 a.m. How I Treat: Bringing Science to Clinical Dilemmas (Ticketed sessions, for in-person participants)
Cellular Therapy for Lymphoma
Hilton San Diego Bayfront, Aqua Salon D

Early Management of Acute Promyelocytic Leukemia (APML)
Hilton San Diego Bayfront, Aqua Salon F

Ongoing Challenges in the Management of VTE
Hilton San Diego Bayfront, Aqua Salon AB

T-Cell Redirection Therapy for Multiple Myeloma
Hilton San Diego Bayfront, Aqua Salon E
### Sunday 10 Dec 2023

**Day-At-A-Glance**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Industry Theaters</td>
<td>Classical Hematology: Looking into the Future&lt;br&gt;Room 1B&lt;br&gt;The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy&lt;br&gt;Room 1A</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Product Theaters</td>
<td>A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer&lt;br&gt;Room 2&lt;br&gt;APHEXDA (motixafortide): Learn about this new FDA approved treatment option&lt;br&gt;Room 3&lt;br&gt;Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician’s Perspective and a Patient’s Experience&lt;br&gt;Room 4&lt;br&gt;Exploring Time Off Treatment with a BCL-2 Inhibitor&lt;br&gt;Room 5B&lt;br&gt;Unveiling a Subcutaneous Therapy for 3L+ DLBCL&lt;br&gt;Room 5A</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Meet the Scientist (Ticketed sessions, for in-person participants)</td>
<td>Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (For In-person Participants)&lt;br&gt;Hilton San Diego Bayfront, Aqua 300&lt;br&gt;Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes&lt;br&gt;Hilton San Diego Bayfront, Aqua 314&lt;br&gt;Natural Killer Cells: A New Frontier for Cancer Immunotherapy&lt;br&gt;Hilton San Diego Bayfront, Aqua 300&lt;br&gt;Research in Complications Sickle Cell Disease&lt;br&gt;Hilton San Diego Bayfront, Aqua 313&lt;br&gt;The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression&lt;br&gt;Hilton San Diego Bayfront, Aqua 311</td>
</tr>
<tr>
<td>9:05 a.m.-9:15 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>How to Quiet the Mind Chatter&lt;br&gt;Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>9:15 a.m.-9:25 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Family First - 7 Steps to Living Well&lt;br&gt;Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>Scientific Symposia</td>
<td>The Impact of the Microbiota on Immunotherapy of Hematological Malignancies&lt;br&gt;Room 25&lt;br&gt;Understanding Sickle Cell Pathophysiology&lt;br&gt;Room 33</td>
</tr>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>Education Sessions</td>
<td>Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?&lt;br&gt;Room 11&lt;br&gt;Hemostasis in Patients With Severe Liver Disease&lt;br&gt;Room 31&lt;br&gt;How Do We Enhance Results in Rare Hematologic Malignancies?&lt;br&gt;Room 29&lt;br&gt;How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?&lt;br&gt;Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH&lt;br&gt;The Iron Revolution!&lt;br&gt;Room 28 A-D&lt;br&gt;What Are the Advances in Myeloproliferative Neoplasms Affecting Management?&lt;br&gt;Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6</td>
</tr>
</tbody>
</table>
Day-At-A-Glance

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response
Marriott Marquis San Diego Marina, Marriott Grand Ballroom B-9

Manchester Grand Hyatt San Diego, Grand Hall C

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

627. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs
Manchester Grand Hyatt San Diego, Harbor Ballroom

701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution
Room 6B

703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies
Room 6A

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

801. Gene Therapies: New Approaches From Bench to Bedside
Ballroom 20CD

904. Outcomes Research: Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

905. Outcomes Research: Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology
Marriott Marquis San Diego Marina, San Diego Ballroom AB

9:30 a.m.-11:00 a.m. 2023 ASH Guideline Implementation Champions
Room 7

9:30 a.m.-11:00 a.m. Maternal Health: Fertility Preservation in Hematology Care
Ballroom 20AB

9:30 a.m.-11:00 a.m. Special Scientific Session on Race and Science: Bench to Bedside to the Community
Hall A

9:30 a.m.-11:05 a.m. Scientific Sessions
Scientific Committee on Immunology and Host Defense||Scientific Committee on Transplantation Biology & Cellular Therapies:
Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Room 6CF

10:00 a.m.-11:00 a.m. Meet the Blood Editors
Halls G-H - Blood Journals Studio

10:00 a.m.-5:00 p.m. Exhibits Open
Halls B-F

11:00 a.m.-11:30 a.m. Health Equity Studio (for in-person participants)
Legally Intentional: Microlearning Session on Systemic Racism
Sails Pavilion - ASH Health Equity Studio

11:00 a.m.-12:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)
Halls B-F

11:00 a.m.-12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)
ASH Park @ The Plaza

11:05 a.m.-11:15 a.m. ASH Wellness Studio (for in-person participants)
The Real Purpose of Your Purpose
Sails Pavilion - ASH Wellness Studio

11:15 a.m.-12:15 p.m. Blood Advances Presents: How to Peer Review a Scientific Paper
Room 24

11:15 a.m.-12:15 p.m. Health Equity Rounds Lunch (for in-person participants)
Hilton San Diego Bayfront, Sapphire Ballroom CD

11:15 a.m.-12:15 p.m. Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia (Open to Trainees Only)
Room 33

11:15 a.m.-12:15 p.m. Trainee Didactic Session: The International Trainee Journey (Open to Trainees Only)
Room 31

11:15 a.m.-12:30 p.m. ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?
Marriott Marquis San Diego Marina, Marina Ballroom DE
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:20 a.m.-11:30 a.m. | ASH Wellness Studio  
(for in-person participants)  |
| 11:30 a.m.-12:30 p.m. | Product Theaters  
A Complement Inhibitor for PNH  
Room 5B  
A Discussion on a Treatment Option for Sickle Cell Disease  
Room 5A  
Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody  
Room 1B  
Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.  
Room 2  
Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)  
Room 4  
Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL  
Room 3  
Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases  
Room 1A  |
| 11:35 a.m.-11:45 a.m. | ASH Wellness Studio  
(for in-person participants)  |
| 12:00 p.m.-1:30 p.m. | Oral Abstracts Sessions  
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis  
Room 28 A-D  
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan  
Room 29  
506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease  
Room 11  
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL  
Manchester Grand Hyatt San Diego, Grand Hall B  |
| 12:30 p.m.-1:30 p.m. | ASH-EHA Joint Symposium  
Hall A  |
| 1:30 p.m.-2:00 p.m. | Health Equity Studio (for in-person participants)  
Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health  
Sails Pavilion - ASH Health Equity Studio  |
| 1:30 p.m.-4:00 p.m. | Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)  
Marriott Marquis San Diego Marina, San Diego Ballroom AB  |
| 2:00 p.m.-4:00 p.m. | Plenary Scientific Session  
Hall A  |
| 4:00 p.m.-4:15 p.m. | Company Showcases  
Halia Therapeutics- Targeting the Chronic Inflammatory Bone Marrow Microenvironment  
Room 5B  |

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Day-At-A-Glance**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m.-4:30 p.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>Halls B-F</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.-4:30 p.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
</tr>
<tr>
<td>Community Partnerships: An Essential Component to Advance Health Equity</td>
<td>Sails Pavilion - ASH Health Equity Studio</td>
</tr>
<tr>
<td>4:05 p.m.-4:15 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>The Greatest Medicine...The Right Tribe!</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>4:15 p.m.-4:25 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>Fix the Way You Sit</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>4:30 p.m.-5:30 p.m.</td>
<td>ASH Poster Walks (for in-person participants)</td>
</tr>
<tr>
<td>ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia</td>
<td>Halls G-H - Blood Journals Studio</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>Have We Optimized Therapy Yet for Patients with AML?</td>
<td>Room 6CF</td>
</tr>
<tr>
<td>Hematologists and the Care of Pregnant Women</td>
<td>Room 25</td>
</tr>
<tr>
<td>Hot Topics in Blood Donation: Donor Risks and Social Justice</td>
<td>Hall A</td>
</tr>
<tr>
<td>How Do We Tackle Remaining Clinical Challenges in CML?</td>
<td>Marriott Marquis San Diego Marina, San Diego Ballroom AB</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Education Spotlight Sessions</td>
</tr>
<tr>
<td>Debate: PCC or Andexanet alfa for Managing Bleeding in Patients in Oral Xa Inhibitors?</td>
<td>Room 29</td>
</tr>
<tr>
<td>Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials</td>
<td>Room 6A</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Scientific Spotlight Sessions</td>
</tr>
<tr>
<td>Immunometabolism as a Tool to Advance Cell Therapy</td>
<td>Room 11</td>
</tr>
<tr>
<td>Tackling Greater Burden of Multiple Myeloma in African American Patients</td>
<td>Room 6B</td>
</tr>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia</td>
<td>Room 31</td>
</tr>
<tr>
<td>113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans</td>
<td>Room 33</td>
</tr>
<tr>
<td>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care</td>
<td>Room 28 A-D</td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials</td>
<td>Room 7</td>
</tr>
<tr>
<td>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies</td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19</td>
</tr>
<tr>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches</td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26</td>
</tr>
<tr>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall D</td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall C</td>
</tr>
<tr>
<td>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies</td>
<td>Ballroom 20CD</td>
</tr>
<tr>
<td>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States</td>
<td>Manchester Grand Hyatt San Diego, Harbor Ballroom</td>
</tr>
<tr>
<td>652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>Blood and Beyond: Un-Walling Health and Well-Being: Shared Destinies at the San Diego-Tijuana Border</td>
</tr>
<tr>
<td>Room 24</td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.-6:30 p.m.</td>
<td>Systems-Based Hematology Education and Networking Session: Hematology E-Consultation</td>
</tr>
<tr>
<td>Room 30</td>
<td></td>
</tr>
<tr>
<td>5:30 p.m.-6:00 p.m.</td>
<td>Meet the Blood Neoplasia Editor-in-Chief (for in-person participants)</td>
</tr>
<tr>
<td>Halls G-H - Blood Journals Studio</td>
<td></td>
</tr>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session II - Presentations (for in-person participants)</td>
</tr>
<tr>
<td>Halls G-H</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY, DECEMBER 11, 2023

7:00 a.m.-7:45 a.m.  ASH Wellness Studio
(for in-person participants)
ASH Yoga
ASH Park @ The Plaza

7:00 a.m.-8:30 a.m.  Wake Up To DEI Networking Breakfast
(for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballroom

7:00 a.m.-5:00 p.m.  Registration at the Convention Center
(for in-person participants)
Ballroom 20 Lobby

7:00 a.m.-6:00 p.m.  Learn, Engage, and Relax in ASH Central
(for in-person participants)
Sails Pavilion

8:00 a.m.-9:00 a.m.  Coffee and Collaboration in ASH Central
(for in-person participants)
Sails Pavilion

8:00 a.m.-9:00 a.m.  Product Theaters
A new, first-in-class treatment for RRMM patients
Room 5B

Achieving Higher Factor VIII Levels in Hemophilia A
Room 3

An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
Room 1B

Latest Advancement in Allogeneic Hematopoietic Cell Transplantation
Room 5A

8:15 a.m.-8:45 a.m.  Health Equity Studio
(for in-person participants)

How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective
Sails Pavilion - ASH Health Equity Studio

9:00 a.m.-10:00 a.m.  E. Donnall Thomas Lecture and Prize
Hall A

9:00 a.m.-8:00 p.m.  Poster Session III - Viewing
Halls G-H

10:00 a.m.-10:30 a.m.  Coffee Break in Exhibit Hall (for in-person participants)
Halls B-F

10:00 a.m.-10:30 a.m.  Health Equity Studio (for in-person participants)
Using Research to Advance Equity in the LGBTQIA+ Space
Sails Pavilion - ASH Health Equity Studio

10:00 a.m.-11:00 a.m.  Meet the Blood Advances Editors
(for in-person participants)
Halls G-H - Blood Journals Studio

10:00 a.m.-2:00 p.m.  Exhibits Open
Halls B-F

10:05 a.m.-10:15 a.m.  ASH Wellness Studio
(for in-person participants)
What’s Restoring You?
Sails Pavilion - ASH Wellness Studio

10:15 a.m.-10:25 a.m.  ASH Wellness Studio
(for in-person participants)
Eating With a Full Mind or Mindfully
Sails Pavilion - ASH Wellness Studio

10:30 a.m.-11:45 a.m.  Education Sessions
Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias
Room 28 A-D
Monday 11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

10:30 a.m.-11:45 a.m.  Scientific Sessions
Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome
Room 31

10:30 a.m.-11:45 a.m.  Scientific Spotlight Sessions (for in-person participants)
Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma
Manchester Grand Hyatt San Diego, Grand Hall D

10:30 a.m.-12:00 p.m.  Oral Abstract Sessions
201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes
Room 24
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis
Room 30
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia
Hall A
Room 29
401. Blood Transfusion: Advances in Transfusion Medicine
Room 33
508. Bone Marrow Failure: Acquired: Immune AA and VEXAS: Biology, Diagnosis and Treatment
Room 6DE
602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication
Room 6B
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/AML
Room 6A
623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents
Manchester Grand Hyatt San Diego, Grand Hall B
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context
Ballroom 20AB

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs
Ballroom 20CD
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström’s Macroglobulinemia
Manchester Grand Hyatt San Diego, Harbor Ballroom
652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
Room 6CF
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9
731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
901. Health Services and Quality Improvement: Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

10:30 a.m.-12:00 p.m.  AI in Hematology: Where Do You Stand in 2023?
Room 11

10:30 a.m.-12:00 p.m.  ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults
Manchester Grand Hyatt San Diego, Grand Hall C

10:30 a.m.-12:00 p.m.  Junior Faculty Career Development Session
Room 25

11:00 a.m.-12:00 p.m.  Blood Advances in a Different Vein: Live (for in-person participants)
Halls G-H - Blood Journals Studio

12:00 p.m.-1:00 p.m.  The ABCs of Publishing for Authors (for in-person participants)
Halls G-H - Blood Journals Studio
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m.-1:30 p.m.</td>
<td>Complimentary Light Lunch in the Exhibit Hall (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>12:00 p.m.-1:30 p.m.</td>
<td>Live Music and Outdoor Lunch Seating (for in-person participants)</td>
<td>ASH Park @ The Plaza</td>
</tr>
<tr>
<td>12:05 p.m.-12:15 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Feel Better in Your Body, Sails Pavilion - ASH Wellness Studio</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Emerging AstraZeneca Hematology Pipeline</td>
<td>Room 5B</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Gilead and Kite Oncology Pipeline</td>
<td>Room 1A</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease</td>
<td>Room 5A</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Product Theaters</td>
<td>Room 3</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions</td>
<td>Room 7</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Trainee Didactic Session: Show Me the Money - Funding Your Research (Open to Trainees Only)</td>
<td>Room 31</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Trainee Didactic Session: What to Ask For in an Interview (Open to Trainees Only)</td>
<td>Room 33</td>
</tr>
<tr>
<td>12:20 p.m.-12:30 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>12:35 p.m.-12:45 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>1:00 p.m.-1:30 p.m.</td>
<td>Legally Intentional: Microlearning Session on Systemic Racism, Sails Pavilion - ASH Health Equity Studio</td>
<td>Health Equity Studio</td>
</tr>
<tr>
<td>1:30 p.m.-2:30 p.m.</td>
<td>Ernest Beutler Lecture and Prize, Hall A</td>
<td>Halls G-H</td>
</tr>
<tr>
<td>2:30 p.m.-2:45 p.m.</td>
<td>Coffee Break in Poster Hall (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>2:35 p.m.-2:45 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Multi-Omics Driven Precision Hematology</td>
<td>Room 30</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall B</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together</td>
<td>Ballroom 20AB</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Interplay of Coagulation and Complement in Transfusion Medicine</td>
<td>Room 29</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL</td>
<td>Room 7</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution</td>
<td>Hall A</td>
</tr>
<tr>
<td></td>
<td>Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes</td>
<td>Room 11</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Scientific Spotlight Session (for in-person participants)</td>
<td>Room 31</td>
</tr>
<tr>
<td>2:45 p.m.-4:15 p.m.</td>
<td>Oral Abstract Sessions</td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.-4:00 p.m.</td>
<td>Meet the Blood Editors (for in-person participants)</td>
<td>Halls G-H - Blood Journals Studio</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Education Sessions</td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>Scientific Symposia</td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>Oral Abstract Sessions</td>
<td></td>
</tr>
</tbody>
</table>

**Monday, 11 Dec 2023**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Oral Abstract Sessions**

- 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation
  **Room 28 A-D**

- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations
  **Room 25**

  **Room 33**

- 503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries
  **Room 24**

- 613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML : De Novo and Myelodysplasia-Related
  **Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

  **Manchester Grand Hyatt San Diego, Grand Hall C**

- 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML
  **Marriott Marquis San Diego Marina, San Diego Ballroom AB**

- 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features
  **Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

- 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis
  **Manchester Grand Hyatt San Diego, Grand Hall D**

- 621. Lymphomas: Translational: Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics
  **Room 6DE**

- 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas
  **Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery
  **Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches
  **Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

**Scientific Symposium**

- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions
  **Manchester Grand Hyatt San Diego, Harbor Ballroom**

- 652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes
  **Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

  **Room 6B**

- 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies
  **Room 6A**

- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation
  **Ballroom 20CD**

- 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology
  **Room 6CF**

- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias
  **Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

- 906. Outcomes Research: Myeloid Malignancies: Symptom Burden and Supportive Therapies
  **Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**Meet the Blood Editors** (for in-person participants)
### DAY-AT-A-GLANCE

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Monday</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>ASH Guidelines on Venous Thromboembolism (VTE): What's New Room 28 A-D</td>
</tr>
<tr>
<td>6:00 p.m.-7:30 p.m.</td>
<td>ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants) East Terrace (Upper Level)</td>
</tr>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Hall Reception (for in-person participants) Halls G-H</td>
</tr>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session III - Presentations Halls G-H</td>
</tr>
<tr>
<td>101. Red Cells and Erythropoiesis, Excluding Iron Poster III</td>
<td></td>
</tr>
<tr>
<td>102. Iron Homeostasis and Biology Poster III</td>
<td></td>
</tr>
<tr>
<td>112. Thalassemia and Globin Gene Regulation Poster III</td>
<td></td>
</tr>
<tr>
<td>113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Poster III</td>
<td></td>
</tr>
<tr>
<td>114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological Poster III</td>
<td></td>
</tr>
<tr>
<td>201. Granulocytes, Monocytes, and Macrophages: The Long and the Short of Clinical Trials in Blood Disorders Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4</td>
<td></td>
</tr>
<tr>
<td>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Poster III</td>
<td></td>
</tr>
<tr>
<td>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational Poster III</td>
<td></td>
</tr>
<tr>
<td>302. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Poster III</td>
<td></td>
</tr>
<tr>
<td>311. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Poster III</td>
<td></td>
</tr>
<tr>
<td>321. Coagulation and Fibrinolysis: Basic and Translational Poster III</td>
<td></td>
</tr>
</tbody>
</table>
TUESDAY, DECEMBER 12, 2023

7:00 a.m.-1:30 p.m.  Registration at the Convention Center
Ballroom 20 Lobby

6:00 p.m.-6:00 p.m.  ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)
Room 28E & Plaza Terrace

7:00 a.m.-6:00 p.m.  Learn, Engage, and Relax in ASH Central (for in-person participants)
Sails Pavilion

641. Chronic Lymphocytic Leukemias: Basic and Translational Poster III
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological Poster III
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Poster III
652. Multiple Myeloma: Clinical and Epidemiological Poster III
653. Multiple Myeloma: Prospective Therapeutic Trials Poster III
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Poster III
701. Experimental Transplantation: Basic and Translational Poster III
703. Cellular Immunotherapies: Basic and Translational Poster III
704. Cellular Immunotherapies: Early Phase and Investigational Therapies Poster III
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies Poster III
711. Cell Collection and Processing Poster III
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities Poster III
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence Poster III
731. Autologous Transplantation: Clinical and Epidemiological Poster III
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Poster III
801. Gene Therapies Poster III
802. Chemical Biology and Experimental Therapeutics Poster III
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster III
901. Health Services and Quality Improvement - Non-Malignant Conditions Poster III
902. Health Services and Quality Improvement - Lymphoid Malignancies Poster III
903. Health Services and Quality Improvement - Myeloid Malignancies Poster III
904. Outcomes Research: Non-Malignant Conditions Poster III
905. Outcomes Research: Lymphoid Malignancies Poster III
906. Outcomes Research: Myeloid Malignancies Poster III

6:00 a.m.-8:00 p.m.  ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)
Room 28E & Plaza Terrace

7:30 p.m.-9:30 p.m.  Women In Hematology Networking Event (for in-person participants)
Manchester Grand Hyatt San Diego, Coronado Ballroom & Terrace
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 a.m.-11:30 a.m.</td>
<td>Coffee and Late-Breaking Abstracts</td>
<td>Hall A</td>
</tr>
<tr>
<td>8:45 a.m.-9:00 a.m.</td>
<td>Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals</td>
<td>Hall A</td>
</tr>
<tr>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Coffee Available in General Session Room (for in-person participants)</td>
<td>Hall A</td>
</tr>
<tr>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Late-Breaking Abstracts Session</td>
<td>Hall A</td>
</tr>
<tr>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Presidential Symposium</td>
<td>Hall A</td>
</tr>
<tr>
<td>12:30 p.m.-2:00 p.m.</td>
<td>Best of ASH</td>
<td>Hall A</td>
</tr>
<tr>
<td>2:00 p.m.-2:15 p.m.</td>
<td>Business Meeting</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**WEDNESDAY, DECEMBER 13, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>ASH Poster Walks (Virtual Program)</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>5:00 p.m.-6:00 p.m.</td>
<td>ASH Poster Walk on What’s Hot in Sickle Cell Disease Clinical Research in 2023</td>
<td>Virtual Program</td>
</tr>
</tbody>
</table>

**THURSDAY, DECEMBER 14, 2023**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>5:00 p.m.-6:00 p.m.</td>
<td>ASH Poster Walk on Time to Examine Time Toxicity in Hematology</td>
<td>Virtual Program</td>
</tr>
</tbody>
</table>
The editors of the *Blood* journal take this opportunity to highlight the intersection of hematology and the humanities in a session entitled Blood and Beyond. For this year, in complement to the celebration of the 20th anniversary of ASH’s Minority Recruitment Initiative, the session: Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border will be presented by Teddy Cruz and Fonna Forman and will consider the intersection of diversity, equity and inclusion, migration and social policy.

**ASH® 2023 Annual Meeting in San Diego**

**Sunday, December 10, 2023**

**4:30 PM – 6:00 PM**

**SDCC, Room 24**

- Register to attend this session in-person, or via the Virtual Platform/Webcast* [hematology.org/annual-meeting](http://hematology.org/annual-meeting)

Teddy Cruz and Fonna Forman are principals in Estudio Teddy Cruz + Fonna Forman, a research-based political and architectural practice in San Diego transgressing conventional boundaries between theory and practice, and merging the fields of architecture and urbanism, political theory, and urban policy.

**SPEAKERS:**

- **Teddy Cruz** (MDes Harvard), Professor, Public Culture and Urbanism, Visual Arts Department, University of California, San Diego
- **Fonna Forman** (JD, PhD Chicago), Professor, Political Science and Founding Director of the Center on Global Justice, University of California, San Diego

**CO-CHAIRS:**

- **Nancy Berliner, MD**, Brigham and Women’s Hospital, Boston, MA
- **Alison Walker, MD, MPH, MBA**, Moffet Cancer Center, Tampa, FL

*Requires ASH 2023 registration or webcast purchase*
Join our panels of

LEADING EXPERTS FOR ENGAGING DISCUSSIONS

at the Friday Satellite Symposia on December 8!

TURN OVER TO EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!

MAKE A DIFFERENCE!

For each in-person attendee, we will be donating $10 to Make-A-Wish Foundation

To learn more visit gotoper.com/friday23
**EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!**

<table>
<thead>
<tr>
<th><strong>BREAKFAST</strong> SERVED AT 6:30 AM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BTKi</strong>&lt;br&gt;Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies</td>
</tr>
<tr>
<td><strong>MM</strong>&lt;br&gt;Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We Are Moving Care Forward Today</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BRUNCH</strong> SERVED AT 10:30 AM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALL</strong>&lt;br&gt;Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL</td>
</tr>
<tr>
<td><strong>IDA</strong>&lt;br&gt;Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients With Cancer-Related Anemia?</td>
</tr>
<tr>
<td><strong>MPN</strong>&lt;br&gt;Show Me the Data®: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?</td>
</tr>
<tr>
<td><strong>AML</strong>&lt;br&gt;Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations, and Beyond!</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HAPPY HOUR</strong> SERVED AT 2:30 PM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CML</strong>&lt;br&gt;Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes From Frontline to R/R</td>
</tr>
<tr>
<td><strong>ALL LBL</strong>&lt;br&gt;Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care</td>
</tr>
<tr>
<td><strong>SCD</strong>&lt;br&gt;Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Life Spans</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>DINNER</strong> SERVED AT 6:30 PM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GvHD</strong>&lt;br&gt;How Do We Treat GvHD Today...And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease</td>
</tr>
</tbody>
</table>

**SCAN HERE TO LEARN MORE**
These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential Symposium. Many of the General Sessions also honor distinguished leaders in the field through awards and special lectures.

**SATURDAY**

**Ham-Wasserman Lecture**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>Thrombocytopenia Due to Platelet Activation Syndromes: HIT and Beyond</td>
</tr>
</tbody>
</table>

**SUNDAY**

**ASH-EHA Joint Symposium**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>Stem Cell Transcriptomics in the Niche</td>
</tr>
</tbody>
</table>

**Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award</td>
</tr>
</tbody>
</table>

**Plenary Scientific Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>Plenary Scientific Session</td>
</tr>
</tbody>
</table>

**Chair:**

- Robert Brodsky, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**

- Andreas Greinacher, MD, University of Greifswald, Greifswald, Germany

**Co-Chairs:**

- Antonio Medina Almeida, MD, PhD, President, European Hematology Association Universidade Catolica Portuguesa, Rio de Mouro, Portugal

**Speakers:**

- Alexander Medvinsky, PhD, The University of Edinburgh, Edinburgh, Scotland, UK
- Linheng Li, PhD, Stowers Institute for Medical Research, Kansas City, MO

- Narla Mohandas, DSc, New York Blood Center, New York, NY
### Monday

**E. Donnall Thomas Lecture and Prize**

**Monday** 9:00 a.m. – 10:00 a.m.  
Hall A

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speaker:**  
KATAYOUN REZVANI, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, TX  
*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*

---

**Ernest Beutler Lecture and Prize**

**Monday** 1:30 p.m. – 2:30 p.m.  
Hall A

*Non-Replacement Therapy in Hemophilia Management: The Evolution of FVIII Mimetics from Basic Science to Clinical Translation*

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**  
TAKEHISA KITAZAWA, DMV, PhD, Chugai Pharmaceutical, Totsuka-Ku, Japan  
*Basic Science*  
JOHNNY MAHLANGU, MBBCh, MMEd, University of the Witwatersrand, Johannesburg, South Africa  
*Clinical/Translational Science*

### Tuesday

**Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals**

**Tuesday** 8:45 a.m. – 9:00 a.m.  
Hall A

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Late-Breaking Abstracts Session**

**Tuesday** 9:00 a.m. – 10:30 a.m.  
Hall A

**Co-Chairs:**  
JEAN M. CONNORS, MD, Dana-Farber Cancer Institute, Boston, MA  
AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD

**Presidential Symposium**

**Tuesday** 11:00 a.m. – 12:30 p.m.  
Hall A

*The Complement System and Targeted Therapies*

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

---

**Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals**

**Tuesday** 8:45 a.m. – 9:00 a.m.  
Hall A

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Late-Breaking Abstracts Session**

**Tuesday** 9:00 a.m. – 10:30 a.m.  
Hall A

**Co-Chairs:**  
JEAN M. CONNORS, MD, Dana-Farber Cancer Institute, Boston, MA  
AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD

**Presidential Symposium**

**Tuesday** 11:00 a.m. – 12:30 p.m.  
Hall A

*The Complement System and Targeted Therapies*

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

---

**Ernest Beutler Lecture and Prize**

**Tuesday** 12:30 p.m. – 2:00 p.m.  
Hall A

**Chair:**  
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**  
LUBKA T. ROUMENINA, PhD, Centre De Recherche Des Cordeliers, Paris, France  
*Complement and Innate Immunity*  
CLAUDIA KEMPER, PhD, National Heart, Lung, and Blood Institute, Bethesda, MD  
*Intracellular Complement and Adoptive Immunity*  
ELENI GAVRILAKI, MD, PhD, George Papanicolaou General Hospital, Thessaloniki, Greece  
*Targeting Complement to Treat Hematologic Disease*  
KOJO S.J. ELENTOBA-JOHNSON, MD, Memorial Sloan Kettering Cancer Center, New York, NY
These smaller sessions provide the opportunity for ASH’s various communities to focus on specific topics of interest.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

Training Directors’ Workshop
(for in-person participants)

Friday 9:00 a.m. – 12:00 p.m.
Indigo 204
Hilton San Diego Bayfront

Chair:
SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Speakers:
TAMARA J. DUNN, MD,
Stanford University, Stanford, CA
Diversity, Equity, and Inclusion Considerations & Recruitment

MARTHA ARELLANO, MD, Emory University School of Medicine, Atlanta, GA
Diversity, Equity, and Inclusion Considerations & Recruitment

Sanjay Mohan, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
Combatting Virtual Learning

Gerald Hsu, MD, PhD, University of California, San Francisco, San Francisco, CA
Combatting Virtual Learning

Jessica M. Stempel, MD, Yale School of Medicine, New Haven, CT
Combatting the Stigma of Being an International Medical Graduate

Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Combatting the Stigma of Being an International Medical Graduate

ASH Wellness Studio, Sails Pavilion
(for in-person participants)

7:00 a.m. - 7:45 a.m. ASH Yoga (ASH Park @ the Plaza)
9:05 a.m. - 9:15 a.m. What’s Restoring You
9:15 a.m. - 9:25 a.m. An Oasis in Chaos
11:05 a.m. - 11:15 a.m. Fix the Way You Sit
11:20 a.m. - 11:30 a.m. Life-Saving Lessons from Plant-Based Eaters
11:35 a.m. - 11:45 a.m. Feel Better in Your Body
1:35 p.m. - 1:45 p.m. Finding Stillness in the Busyness
1:45 p.m. - 1:55 p.m. The Real Purpose of Your Purpose
3:35 p.m. - 3:45 p.m. Workday Tension Timeout
3:45 p.m. - 3:55 p.m. Eating With a Full Mind or Mindfully

Health Equity Studio, Sails Pavilion

9:00 a.m. - 9:30 a.m. Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health
11:00 a.m. - 11:30 a.m. Community Partnerships: An Essential Component to Advance Health Equity
1:30 p.m. - 2:00 p.m. How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective
3:30 p.m. - 4:00 p.m. Using Research to Advance Equity in the LGBTQIA+ Space

Not of interest to PhD attendees. CME credit is not offered.
SPECIAL INTEREST SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Friday – Monday 8–11 Dec 2023**

**SPECIAL INTEREST SESSIONS**

**All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.**

---

**Blood Journals Studio, Halls G-H (for in-person participants)**

- **10:00 a.m. - 11:00 a.m.**
  - Meet the Blood Advances Editors
- **2:00 p.m. - 3:30 p.m.**
  - Distinguished Abstract Achievement Awards Ceremony
- **5:00 p.m. - 5:30 p.m.**
  - Meet the Blood VTH Editor-in-Chief

---

**SATURDAY**

**Special Session on Sickle Cell Disease Centers**

**Saturday 9:30 a.m. – 11:00 a.m.**
**Hall A**
**San Diego Convention Center**

**Co-Chairs:**
- **PAYAL DESAI,** MD, Atrium Health, Charlotte, NC
- **JULIE KANTER,** MD, University of Alabama at Birmingham, Birmingham, AL

**Speakers:**
- **SOPHIE LANZKRON,** MD, Johns Hopkins Medical Institute, Baltimore, MD
- **Maximizing Revenue from an Infusion Center**
- **JULIE KANTER,** MD, University of Alabama at Birmingham, Birmingham, AL
- **Partnering With Your Hospital On 340B**
- **ALEXIS KRISTINE LEONARD,** MD, St. Jude Children’s Research Hospital, Germantown, TN
- **Getting Ready to Provide Genetic Therapies**

**ASH Grassroots Network Lunch (for in-person participants)**

**Saturday 11:15 a.m. – 12:15 p.m.**
**Marina Ballroom DE**
**Marriott Marquis San Diego Marina**

**Chair:**
- **JENNIFER HOLTER-CHAKRABARTY,** MD, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK

**Blood Presents: How to get Published in a Peer Review Journal (for in-person participants)**

**Saturday 11:15 a.m. – 12:15 p.m.**
**Room 24**
**San Diego Convention Center**

**Panelists:**
- **NANCY BERLINER,** MD, Brigham and Women’s Hospital, Boston, MA

---

**Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care**

**Saturday 2:00 p.m. – 3:30 p.m.**
**Room 11**
**San Diego Convention Center**

**Co-Chairs:**
- **MING Y YEONG LIM,** MBBCHR, University of Utah, Salt Lake City, UT
- **JACOB Cogan,** MD, University of Minnesota, Minneapolis, MN

**Speakers:**
- **GEOFFREY BARNES,** MD, MSc, University of Michigan, Ann Arbor, MI
- **IVC Filter Retrieval**
- **ALEXANDRA POWER-HAYS,** MD, Cincinnati Children’s Hospital, Cincinnati, OH
- **Hydroxyurea in Sickle Cell Disease**
- **ALLISON BURNETT,** PHARMD, University of New Mexico Health Sciences Center, Albuquerque, NM
- **Patient Education Prior to Anticoagulation**

**Promoting Minorities in Hematology (PMH) Oral Presentations (for in-person participants)**

**Saturday 6:30 p.m. – 9:00 p.m.**
**Marina Ballrooms D-F**
**Marriott Marquis San Diego Marina**

---

**Promoting Minorities in Hematology (PMH) MRI Anniversary Reception (for in-person participants)**

**Saturday 8:00 p.m. – 9:00 p.m.**
**Marian Ballroom G**
**Marriott Marquis San Diego Marina**

---

(of interest to PhD attendees)

(CME credit is not offered)
ASH Wellness Studio, Sails Pavilion  (for in-person participants)

9:05 a.m. - 9:15 a.m. How to Quiet the Mind Chatter
9:15 a.m. - 9:25 a.m. Family First – 7 Steps to Living Well
11:05 a.m. - 11:15 a.m. The Real Purpose of Your Purpose
11:20 a.m. - 11:30 a.m. Straight Spine, Big Smile
11:35 a.m. - 11:45 a.m. Stress Doesn’t Exist
4:05 p.m. – 4:15 p.m. The Greatest Medicine...The Right Tribe!
4:15 p.m. - 4:25 p.m. Fix the Way You Sit

Health Equity Studio, Sails Pavilion  (for in-person participants)

9:00 a.m. - 9:30 a.m. Systemic Racism in Hematology
11:00 a.m. - 11:30 a.m. Legally Intentional: Microlearning Session on Systemic Racism
1:30 p.m. - 2:00 p.m. Epidemiology of Social Determinants of Health: Inequities and Outcomes of Hematologic Diseases
4:00 p.m. - 4:30 p.m. Community Partnerships: An Essential Component to Advance Health Equity

Blood Journals Studio, Halls G-H  (for in-person participants)

10:00 a.m. - 11:00 a.m. Meet the Blood Advances Editors
5:30 p.m. - 6:00 p.m. Meet the Blood Neoplasia Editor-in-Chief

SUNDAY

Medical Educators’ Symposium

Sunday 7:30 a.m. – 9:30 a.m.
Sapphire Ballroom AB
Hilton San Diego Bayfront

Chair: PALLAWI TORKA, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers: ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI

General Session 1: Utilizing Social Media in Learning

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

General Session 2: Making the Most of Virtual Teaching

SCOTT MOERDLER, MD, Children’s Hospital at Montefiore, New Brunswick, NJ

General Session 2: Making the Most of Virtual Teaching

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN

General Session 3: Diversity, Equity, and Inclusion in Educational Material Development

ERIN G. REID, MD, MS, Moores University of California, San Diego Cancer Center, La Jolla, CA

Breakout 1: Technology and Medical Education: Remote Learning

RITA PASCHAL, MD, University of Alabama at Birmingham Medical Center, Birmingham, AL

Breakout 2: How to be a Good Mentor

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN

Breakout 3: DEI and Implicit Bias in Case Development

ARIEL A. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Philadelphia, PA

Breakout 4: Teaching Across the Learner Spectrum and Integrating APPs

ALICE MA, MD, FACP, University of North Carolina at Chapel Hill, Chapel Hill, NC

Breakout 5: Giving Good Feedback to Trainees
2023 ASH Guideline Implementation Champions

Sunday 9:30 a.m. – 11:00 a.m.
Room 7
San Diego Convention Center

Co-Chairs:
Rachel P. Rosovsky, MD, MPH, Massachusetts General Hospital, Boston, MA
Amy Billett, MD, Dana-Farber Cancer Institute, Wilmington, DE

Speakers:
Christina Marie Ruiz, MD, University of California San Diego School of Medicine, San Diego, CA
Improving the Outpatient Pain Management Plan for Patients with Sickle Cell Disease with Innovative Pain Action Plan
Gabriella Nguyen, MD, Children’s Health, University of Texas Southwestern, Dallas, TX
Steering Change with Compass: Clinical Pathway to Optimize the Management of Pediatric Acute Stroke in Sickle Cell Disease

Maternal Health: Fertility Preservation in Hematology Care

Sunday 9:30 a.m. – 11:00 a.m.
Ballroom 20AB
San Diego Convention Center

Chair:
Sarah O’Brien, MD, MSc, Nationwide Children’s Hospital, Columbus, OH

Speakers:
Erica Marsh, MD, MSCI, FACOG, University of Michigan, Ann Arbor, MI
Fertility Health Equity and the Fertility Preservation Process
Alison Loren, MD, MSCE, University of Pennsylvania, Philadelphia, PA
Fertility Care for Patients with Hematologic Conditions
Mindy Christianson, MD, MBA, Cleveland Clinic, Cleveland, OH
Fertility Care for Physicians

Special Scientific Session on Race and Science: Bench to Bedside to the Community

Sunday 9:30 a.m. – 11:00 a.m.
Hall A
San Diego Convention Center

Co-Chairs:
Elizabeta Nemeth, PhD, University of California, Los Angeles, Los Angeles, CA
Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH

Speakers:
Shonta Chambers, MSW, Patient Advocate Foundation, Hampton, VA
Community and Patient Advocate Perspective
Saad Z. Usmani, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Clinical Trial Perspective
Nicole Gormley, MD, Food and Drug Administration, Bethesda, MD
Regulatory Perspective
Alisa S. Wolberg, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC
Basic Science Perspective

Blood Advances Presents: How to Peer Review a Scientific Paper

Sunday 11:15 a.m. – 12:15 p.m.
Room 24
San Diego Convention Center

ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?

Sunday 11:15 a.m. – 12:30 p.m.
Marina Ballroom DE
Marriott Marquis San Diego Marina

Chair:
Chancellor Donald, MD, Tulane University School of Medicine, New Orleans, LA

Speakers:
Aaron Goodman, MD, University of California, San Diego, San Diego, CA
Financial Toxicity: How to Determine Value of Hematology Treatments for Patients?
**Health Equity Rounds Lunch**  
(for in-person participants)

**Sunday**  
11:15 a.m. – 12:15 p.m.  
Sapphire Ballroom CD  
Hilton San Diego Bayfront

**Moderator:**  
**Yvonne Efekera, MD,** Ohio Health, Columbus, OH

**Speakers:**
- **Shakira J. Grant, MBBS, MSCR,** University of North Carolina at Chapel Hill, Chapel Hill, NC  
  *Health Workforce Diversity and Equity*
- **Srinivas Devarakonda, MD,** The Ohio State University, Columbus, OH  
  *Health Workforce Diversity and Equity*

**Blood and Beyond**

**Sunday**  
4:30 p.m. – 6:00 p.m.  
Room 24  
San Diego Convention Center

**Co-Chairs:**
- **Nancy Berliner, MD,** Brigham and Women’s Hospital, Boston, MA
- **Alison R. Walker, MD,** Moffitt Cancer Center, Tampa FL

**Health Workforce Diversity and Equity**

**Sunday**  
11:15 a.m. – 12:15 p.m.  
Sapphire Ballroom CD  
Hilton San Diego Bayfront

**Moderator:**  
**Yvonne Efekera, MD,** Ohio Health, Columbus, OH

**Speakers:**
- **Shakira J. Grant, MBBS, MSCR,** University of North Carolina at Chapel Hill, Chapel Hill, NC  
  *Health Workforce Diversity and Equity*
- **Srinivas Devarakonda, MD,** The Ohio State University, Columbus, OH  
  *Health Workforce Diversity and Equity*

**Systems-Based Hematology Education and Networking Session: Hematology E-Consultation**

**Sunday**  
4:30 p.m. – 6:30 p.m.  
Room 30  
San Diego Convention Center

**Chair:**  
**Marc Stuart Zumberg, MD,** University of Florida, Gainesville, FL

**Speakers:**
- **Sandra R. Panch, MD,** Fred Hutchinson Cancer Center, Seattle, WA  
  *Start up, Resource Allocation, Insurance, and Work Flow for Hematology E-Consultation*
- **Surbhi Shah, MD,** Mayo Clinic, Scottsdale, AZ  
  *Lessons Learned in Hematology E-Consultation: Advantages, Disadvantages, and Applicability to Other Academic Centers and Smaller Institutions*
**MONDAY**

**Wake Up to DEI Networking Breakfast**
(for in-person participants)

**Monday** 7:00 a.m. – 8:30 a.m.
Marina Ballroom
Marriott Marquis San Diego Marina

**AI in Hematology: Where Do You Stand in 2023?**

**Monday** 10:30 a.m. – 12:00 p.m.
Room 11
San Diego Convention Center

**Chair:**
TORGSTEN HAFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany

**Speakers:**
WEIDA TONG, PhD, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR
*Can AI Be Used in Drug Discovery?*

YATES COLEY, PhD, Kaiser Permanente Washington Health Research Institute, Seattle, WA

---

**AI Ethics: More Complex Than What You Think**

MATTHEW LUNGEN, MD, MPH, Microsoft+Nuance Communications, Burlington, MA
*The Application of Artificial Intelligence in Medical Imaging: Lessons Learned from Radiology, Ophthalmology and Oncology*

TORGSTEN HAFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany
*The Future Is Now: AI in the Hematology Clinic*

**ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults**

**Monday** 10:30 a.m. – 12:00 p.m.
Grand Hall C Manchester
Grand Hyatt San Diego

**Chair:**
MATTHEW C. CHEUNG, MD, MSc, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
SPECIAL INTEREST SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Speakers:

WENDY STOCK, MD, The University of Chicago, Chicago, IL

Initial Therapy for ALL in Adolescents and Young Adults

JULIE WOLFSON, MD, MSHS, The University of Alabama at Birmingham, Birmingham, AL

Initial Therapy for ALL in Adolescents and Young Adults

KRISTEN M. O’DWYER, MD, University of Rochester Medical Center, Rochester, NY

Management of Remission and Relapse of ALL in Adolescents and Young Adults

SUMIT GUPTA, MD, PhD, Hospital for Sick Children, Toronto, ON, Canada

Management of Remission and Relapse of ALL in Adolescents and Young Adults

Junior Faculty Career Development Session

Monday 10:30 a.m. – 12:00 p.m.
Room 25
San Diego Convention Center

Chair:
SANJAY MOHAN, MD, MSCi, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Speakers:

OVERIMPE ADESINA, MD, MS, University of California, Davis, Sacramento, CA

Individual Career Development Awards- K23/K08

CASSANDRA JOSEPHSON, Children’s Healthcare of Atlanta, Atlanta, GA

Individual Career Development Awards- K07

SRINIVAS DEVARAKONDA, MD, The Ohio State University, Columbus, OH

Funding Your Medical Education Research

ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions

Monday 12:15 p.m. – 1:15 p.m.
Room 7
San Diego Convention Center

Chair:
MING Y. YEONG LIM, MBBCHIR, University of Utah, Salt Lake City, UT

Speakers:

VILMARIE RODRIGUEZ, MD, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH

Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia

Alessandra Ferrajoli, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in Patients with Hematological Malignancies

ASH Guidelines on Venous Thromboembolism (VTE): What’s New

Monday 4:30 p.m. – 6:00 p.m.
Room 28 A-D,
San Diego Convention Center

Chair:
ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Speakers:

SAKIA MIDDENDORP, MD, PhD, Academic Medical Center, Nijmegen, Netherlands

ASH Guidelines on Thrombophilia

DEBORAH SEGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada

Next Steps for ASH Guidelines on Use of Anticoagulation in Patients with COVID-19

SUELY M. REZENDE, MD, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Updates on Adaptation of ASH VTE Guidelines for Latin America

ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Monday 6:00 p.m. – 7:30 p.m.
East Terrace (Upper Level),
San Diego Convention Center

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)

Monday 6:15 p.m. – 8:15 p.m.
Room 28 A-D & Plaza Terrace,
San Diego Convention Center

Women In Hematology Networking Event (for in-person participants)

Monday 7:30 p.m. – 9:30 p.m.
Coronado Ballroom & Terrace,
Manchester Grand Hyatt, San Diego

Moderators:
AIRELA L. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Rochester, MN

TAMARA J. DUNN, MD, Stanford University, Stanford, CA

of interest to PhD attendees. CME credit is not offered.
Panelists:
ALEXIS A. THOMPSON, MD, MPH, Childrens’ Hospital of Philadelphia, Philadelphia, PA
IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA
KONSTANZE DÖHNER, University Hospital of Ulm, Ulm, Germany

Speakers:
VILMARIE RODRIGUEZ, MD, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH
Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia

ALESSANDRA FERRAJOLI, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in
AYMAN ALHEJAZI, MD, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
Outpatient Versus Inpatient Delivery of Intensive Chemotherapy for Patients with Hematological Neoplasms: A 5-Year Experience from a Tertiary Center

ASH Guidelines on Venous Thromboembolism (VTE): What’s New

Monday 4:30 p.m. – 6:00 p.m.
Room 28 A-D, San Diego Convention Center

Chair:
ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Speakers:
SASKIA MIDDELDORP, MD, PhD, Academic Medical Center, Nijmegen, Netherlands

ASH Guidelines on Thrombophilia

DEBORAH SIEGAL, MD, MSc, University of Ottawa, Ottawa, ON, Canada

Next Steps for ASH Guidelines on Use of Anticoagulation in Patients with COVID-19

SUELY M. REZENDE, MD, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Updates on Adaptation of ASH VTE Guidelines for Latin America

ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Monday 6:00 p.m. – 7:30 p.m.
East Terrace (Upper Level), San Diego Convention Center

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)

Monday 6:00 p.m. – 8:00 p.m.
Room 28E & Plaza Terrace, San Diego Convention Center

Women in Hematology Networking Event (for in-person participants)

Monday 7:30 p.m. – 9:30 p.m.
Coronado Ballroom & Terrace, Manchester Grand Hyatt San Diego
ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience. The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows. These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

ASH-a-Palooza

Friday 12:45 p.m. – 5:00 p.m.
Petco Park

This is ASH’s premier trainee event complete with micro-learning sessions, mentorship opportunities, and more! It is only open to trainees wearing a blue badge. Blood Buddies are one-on-one, ten-minute sessions to discuss career tracks and seek advice for faculty members.

ASH Talk Opening Song and Welcome

Friday 12:45 p.m. – 1:00 p.m.
Sections 112 and 114
Petco Park

Speaker:
RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children’s Hospital, Houston, TX

ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities

Friday 1:00 p.m. – 1:20 p.m.
Sections 112 and 114
Petco Park

Chair:
MAYA ABDALLAH, MD, Boston University, Boston, MA

Speaker:
JULIE SILVER, MD, Harvard Medical School, Boston, MA

Blood Buddies (In-Person)

Friday 1:30 p.m. – 2:00 p.m., 2:40 p.m. – 3:10 p.m., 4:35 p.m. – 5:00 p.m.
Petco Park, Sections 122 and 124

Adult Clinical Classical Hematology
MOREY BLINDER, MD, Washington University, Saint Louis, MO
MARC CARRIER, MD, The Ottawa Hospital, Ottawa, ON, Canada
JULIE KANTER, MD, University of Alabama At Birmingham, Birmingham, AL
ALICE MA, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC
SANA SAIF UR REHMAN, MD, Washington University in St. Louis, St. Louis, MO

Adult Clinical Malignant Hematology
JULIE E CHANG, MD, University of Wisconsin, Madison, WI
ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA
MATTHEW L. ULRICKSON, MD, MD Anderson Medical Center/Banner Health, Gilbert, AZ
ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
AMY YUAN WANG, MD, MPH, University of Chicago, Chicago, IL

BMT Peds and Adult
EMILY K. CURRAN, MD, University of Chicago, Cincinnati, OH
HANY ELMARIAH, MD, MS, Moffitt Cancer Center, Tampa, FL
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepa Jagadeesh, MD</td>
<td>Cleveland Clinic, Solon, OH</td>
</tr>
<tr>
<td>Sajad Khazal, MD</td>
<td>Anderson Medical Center, Houston, TX</td>
</tr>
<tr>
<td>Satyajit Kosuri, MD</td>
<td>University of Chicago, Chicago, IL</td>
</tr>
<tr>
<td>Kristin M. Page, MD</td>
<td>Medical College of Wisconsin, Milwaukee, WI</td>
</tr>
<tr>
<td>Reshma Ramlal, MD</td>
<td>University of Kentucky, Lexington, KY</td>
</tr>
<tr>
<td>Santosh L. Saraf, MD</td>
<td>University of Illinois, Chicago, IL</td>
</tr>
<tr>
<td>Adrianna Vlachos, MD</td>
<td>Steven and Alexandra Cohen Children’s Medical Center, New York, NY</td>
</tr>
</tbody>
</table>

**Diversity, Equity, and Inclusion (DEI)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maureen Okam Achebe, MD</td>
<td>MD, MPH, Hematology Division Brigham and Women’s, Boston, MA</td>
</tr>
<tr>
<td>Leon Bernal-Mizraci, MD</td>
<td>MD, Emory University School of Medicine, Atlanta, GA</td>
</tr>
<tr>
<td>Lanetta Bronte-Hall, MD</td>
<td>MD, MPH, MSPH, Foundation for Sickle Cell Disease Research, Hollywood, FL</td>
</tr>
<tr>
<td>Chancellor Donald, MD</td>
<td>MD, Tulane University School of Medicine, New Orleans, LA</td>
</tr>
<tr>
<td>Titilope Fasipe, MD, PhD</td>
<td>Texas Children’s Cancer &amp; Hematology Centers, Rosharon, TX</td>
</tr>
<tr>
<td>Patrick T. McGann, MD, PhD</td>
<td>Children’s Hospital Medical Center, Providence, RI</td>
</tr>
<tr>
<td>Jonathan Moreira, MD</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>Kerice A. Pinkney, MD, Joe DiMaggio Children’s Hospital, Hollywood, FL</td>
<td></td>
</tr>
<tr>
<td>Deirdra Terrell, PhD</td>
<td>University of Oklahoma Health Sciences Ctr, Oklahoma City, OK</td>
</tr>
<tr>
<td>Angela C. Weyand, MD</td>
<td>MD, University of Michigan Medical School, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

**Medical Education**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex A. Boucher, MD</td>
<td>MD, University of Minnesota Medical School, Plymouth, MN</td>
</tr>
<tr>
<td>Caroline Cromwell, MD</td>
<td>MD, Mount Sinai School of Medicine, New York, NY</td>
</tr>
<tr>
<td>Usha Perepu, MBBS, MRCP</td>
<td>University of Iowa, Iowa City, IA</td>
</tr>
<tr>
<td>Alexandra P. Wolanskyj-Spinner, MD</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Ida Wong-Sefidan, MD</td>
<td>University of California San Diego, San Diego, CA</td>
</tr>
</tbody>
</table>

**Pediatric Clinical Malignant Hematology**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimee C. Talleur, MD</td>
<td>St. Jude Children’s Research Hospital, Memphis, TN</td>
</tr>
<tr>
<td>Kara M. Kelly, MD</td>
<td>Roswell Park Cancer Center, Buffalo, NY</td>
</tr>
<tr>
<td>Leslie Kersun, MD, MSED</td>
<td>Children’s Hospital of Philadelphia, Swarthmore, PA</td>
</tr>
<tr>
<td>Jennifer McNeer, MD, MS</td>
<td>University of Utah, Salt Lake City, UT</td>
</tr>
<tr>
<td>Andrew E. Place, MD, PhD</td>
<td>Dana-Farber Cancer Institute, Inc., Boston, MA</td>
</tr>
<tr>
<td>Rayne Rouce, MD</td>
<td>Texas Children’s Hospital, Houston, TX</td>
</tr>
</tbody>
</table>

**Pediatric Clinical Classical Hematology**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Leila Jerome Clay, MD</td>
<td>MD, Novo Nordisk, Tampa, FL</td>
</tr>
<tr>
<td>Melanie E. Fields, MD</td>
<td>MD, The Washington University, Saint Louis, MO</td>
</tr>
<tr>
<td>Lewis Hsu, MD, PhD</td>
<td>University of Illinois, Chicago, IL</td>
</tr>
<tr>
<td>Seethal A. Jacob, MD, MS</td>
<td>Riley Hospital For Children, Indianapolis, IN</td>
</tr>
<tr>
<td>Akshat Jain, MD, MPH</td>
<td>North Shore LIJ, Redlands, CA</td>
</tr>
<tr>
<td>Jeffrey D. Lebenshuber, DO</td>
<td>The University of Alabama, Birmingham, AL</td>
</tr>
</tbody>
</table>

**Quality Improvement**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam F. Binder, MD</td>
<td>Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA</td>
</tr>
<tr>
<td>Rachel F. Grace, MD</td>
<td>MD, The Children’s Hospital Corporation, Boston, MA</td>
</tr>
<tr>
<td>Allison A. King, MD, PhD</td>
<td>MPH, Washington University, St. Louis, MO</td>
</tr>
<tr>
<td>Jordan K. Schaefer, MD</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

**Blood Drops**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex F. Herrera, MD</td>
<td>City of Hope, Duarte, CA</td>
</tr>
</tbody>
</table>

**Hematology Opportunities for the Next Generation (HONORS)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brittaney-Belle Elizabeth Gordon, MD</td>
<td>University of North Carolina, Chapel Hill, NC</td>
</tr>
</tbody>
</table>

**Malignant Hematology**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alison W. Loren, MD, PhD</td>
<td>Penn Medicine Perelman Center for Advanced Medicine, Philadelphia, PA</td>
</tr>
</tbody>
</table>

**MEJ**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pamela B. Allen, MD</td>
<td>Emory University, Decatur, GA</td>
</tr>
</tbody>
</table>

**PhD**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wei Tong, PhD</td>
<td>Children’s Hospital of Philadelphia, Philadelphia, PA</td>
</tr>
</tbody>
</table>
Research Training Award Fellows (RTAF)
R Amazi Abboud, MD, Washington University School of Medicine, Clayton, MO

Sickle Cell Disease
Luke R. Smart, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Quality Improvement
Ming Y. Yeong Lim, MBChir, University of Utah, Salt Lake City, UT

Wellness
Jacqueline C. Barrientos, MD, MS, Mount Sinai Medical Center, Miami Beach, Florida

ASH Talk #2 - Approaches to Team Management
Friday 2:10 p.m. – 2:30 p.m.
Sections 112 and 114
Petco Park

Chair:
Maya Abdallah, MD, Boston University, Boston, MA

Speaker:
Ifeyinwa Osunkwo, MD, Novo Nordisk Rare Disease, Waltham, MA

Blood Drops
Friday 2:40 p.m. – 2:50 p.m., 3:00 p.m. – 3:10 p.m.
Left Field Concourse
Petco Park

Diversity, Equity, and Inclusion
Alison W. Loren, MD, Perelman Center for Advanced Medicine, Philadelphia, PA

Hematology Opportunities for the Next Generation (HONORS)
Georgios E. Christakopoulos, MD, University of Minnesota Medical School, Masonic Children's Hospital, Memphis, TN

Malignant Hematology
Hira Mian, MD, McMaster University, Hamilton, ON, Canada

PhD
Ze Zheng, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI

Physician-Scientist Award (Phy-Sci)
Christina Snider, MD, Cleveland Clinic Lerner College of Medicine, Nashville, TN

Quality Improvement
Elizabeth J. Shipall, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Scholar
Stephen S. Chung, MD, UT Southwestern Medical Center, Dallas, TX

Sickle Cell Disease
Deepika S. Darbari, MD, Children’s National Center for Cancer and Blood Disorders, Washington, DC

Translational Research Training in Hematology (TRTH)
Anna M. Eiring, PhD, Texas Tech University Health Science Center, El Paso, TX

Wellness
Leslie R. Ellis, MD, MSHPED, Wake Forest University School of Medicine, Winston Salem, NC

President’s Remarks
Friday 3:20 p.m. – 3:30 p.m.
Sections 112 and 114
Petco Park

Blood Wars - Jeopardy!
Friday 3:30 p.m. – 4:15 p.m.
Sections 112 and 114
Petco Park

Blood Drop
Friday 4:35 p.m. – 4:45 p.m., 4:50 p.m. – 5:00 p.m.
Left Field Concourse
Petco Park

CRTI
Surbhi Sidana, MD, Stanford University, Stanford, CA

Diversity, Equity, and Inclusion
Alison R. Walker, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Malignant Hematology
Kah Poh (Melissa) Loh, MBCh BAO, MS, University of Rochester Medical Center, Rochester, NY

MMSAP
Natasha Stanley, DO, Children’s Hospital of Philadelphia, Philadelphia, PA
**PhD**
HEATHER O’LEARY, PhD, Northeast Ohio Medical University, Rootstown, OH

**Physician-Scientist Award (Phy-Sci)**
ALEXANDER F. M. CRAIG, MPHIL, Stanford University Medical Center, Stanford, CA

**Quality Improvement**
ALLISON A. KING, MD, PhD, MPH, Washington University in St. Louis, St. Louis, MO

---

**Sickle Cell Disease**
JEFFREY D. LEBENSBURGER, DO, The University of Alabama, Birmingham, AL

**Wellness**
RONAK H. MISTRY, DO, Vanderbilt University Medical Center, Nashville, TN

---

**Career Development Lunch**

**Saturday 11:15 a.m. – 12:15 p.m.**  
Hilton San Diego Bayfront  
Sapphire Ballroom ABCD

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

A boxed lunch is provided. There will be one hematology leader, assigned with a topic, at a table where trainees are welcome to eat lunch and chat about that topic.

**Adult and Pediatric BMT**
DARIA V BABUSHOK, MD, PhD, University of Pennsylvania, Merion Station, PA

SHARON SAVAGE, MD, National Cancer Institute, NIH, Bethesda, MD

KRIS MICHAEL MAHADEO, MD, MD Anderson Medical Center, Houston, TX

ADRIANNA VLACHOS, MD, Steven and Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, NY

**Adult Clinical Classical Hematology**
OYEBOIMPE ADESINA, MD, MS, University of California Davis, Mountain View, CA

BETH MARTIN-KOOL, MD, Stanford University, Palo Alto, CA

ANNA L. PARKS, MD, University of Utah, Salt Lake City, UT

LAYLA VAN DOREN, MD, Yale School of Medicine, New Haven, CT

**Adult Clinical Malignant Hematology**
BRANDON BLUE, MD, Moffitt Cancer Center, Tampa, FL

KIERON DUNLEAVY, MD, Georgetown University, Washington, DC

MARLISE R. LUSKIN, MD, Dana-Farber Cancer Institute, Boston, MA

KENDRA SWEET, MD, Moffitt Cancer Center, Tampa, FL

**Clinical Careers in Hematology (Private Practice Careers)**
JOHN M. BURKE, MD, Rocky Mountain Cancer Centers, Aurora, CO

KAREN CHEE, MD, University of California, San Francisco, CA

PAUL FISHKIN, MD, Illinois Cancer Care, Peoria, IL

EMILY MEIER, MD, MSc, Pfizer, South San Francisco, CA

**Geriatric Hematology**
CHARITY I. OYEDEJI, MD, Duke University, Durham, NC

ASHLEY E ROSKO, MD, The Ohio State University, Columbus, OH

**Global Hematology**
LUIS ENRIQUE MALPICA CASTILLO, MD, University of Texas MD, Anderson cancer Center, Pearland, TX

DIEGO VILA CLE, MD, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil

ADLETTE INATI, MD, Rafik Hariri University Hospital, Tripoli, Lebanon

**Government Careers (NIH and FDA)**
ANGELO DE CLARO, MD, Food and Drug Administration, Silver Spring, MD

LAUREL MENAPACE, MD, Sanofi, Washington, DC

WILLIAM MERRITT, Germantown, MD
Industry Careers  
**GREGORY J. KATO**, MD, University of Pittsburgh Medical Center, Pittsburgh, PA  
**IFEYINWA OSUNKWO**, MD, Novo Nordisk Rare Disease, Waltham, MA  
**WEILI SUN**, MD, PhD, Janssen Pharmaceutical, Los Angeles  

Laboratory and Translational Hematology  
**EUGENE KHANDROS**, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA  
**BRIDGET MARCELLINO**, MD, PhD, Mount Sinai School of Medicine, New York, NY  
**SEONGSEOK YUM**, MD, PhD, University of Arizona, Tucson, AZ  

Lifespan Hematology  
**SEETHAL A JACOB**, MD, MS, Riley Hospital for Children, Indianapolis, IN  
**JULIE KANTER**, MD, University of Alabama, Birmingham, AL  

Maternal Health  
**ARIEL L. MARSHALL**, MD, Mayo Clinic, Rochester, MN  
**BETHANY T. SAMUELSON BANNOW**, MD, Oregon Health and Science University, Portland, OR  

Medical Educators in Hematology  
**TAMARA J. DUNN**, MD, Stanford University, Stanford, CA  
**ANNE IM**, MD, University of Pittsburgh Medical Center, Pittsburgh, PA  

PhD Careers  
**GABRIEL GHIAUR**, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD  
**ANDREW VULK**, PhD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH  

Systems-Based Hematology  
**HARRIET A. BERING**, MD, Harvard Vanguard Medical Associates, Lexington, MA  
**NATHAN T. CONNELL**, MD, MPH, Brigham and Woman’s Hospital, Boston, MA  

---

**SUNDAY – MONDAY**

**Trainee Didactic Sessions**  
Offered during lunch on Sunday and Monday, the Trainee Didactic Sessions are designed to offer trainees an overview of timely and relevant career-oriented issues.

**Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia**  
**Chair:**  
**IFEYINWA OSUNKWO**, MD, Novo Nordisk, Waltham, MA  
**Speakers:**  
**AMBER YATES**, MD, Agios Pharmaceuticals, Houston, TX  
**TIMOTHY KUBAL**, MD, MBA, Moffitt Cancer Center, Tampa, FL  

<table>
<thead>
<tr>
<th>Sunday</th>
<th>11:15 a.m. – 12:15 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 33</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

---

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---
**Trainee Didactic Session: Show Me the Money - Funding Your Research**

**Monday 12:15 p.m. – 1:15 p.m.**  
Room 31  
San Diego Convention Center

**Chair:**  
Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA

**Speakers:**  
Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA  
Cassandra Josephson, MD, Johns Hopkins University, St Petersburg, FL

**Trainee Didactic Session: The International Trainee Journey**

**Sunday 11:15 a.m. – 12:15 p.m.**  
Room 31  
San Diego Convention Center

**Chair:**  
Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA

**Speakers:**  
Eloisa Riva, MD, MEd, Hospital Británico, Montevideo, Uruguay  
Andres Gomez-De Leon, MD, Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico

**Trainee Didactic Session: What to Ask for in an Interview**

**Monday 12:15 p.m. – 1:15 p.m.**  
Room 33  
San Diego Convention Center

**Chair:**  
Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA

**Speakers:**  
Alison R. Walker, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL  
Ze Zhang, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI
Covalent Menin Inhibition
unlocking powerful potential

Covalency aims to achieve:
Higher Selectivity
Deeper Target Engagement
Greater Therapeutic Window
Durability

Biomea Fusion is developing BMF-219, an investigational, oral, covalent menin inhibitor, currently being evaluated in multiple clinical trials. We are enrolling patients with known menin inhibitor sensitive mutations in various heme malignancies, KRAS mutant solid tumors, as well as adults with diabetes.

A COVALENT small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of novel covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. **Visit us at the 2023 ASH Annual Meeting Booth #3223.**

To learn more about Biomea Fusion’s covalent menin inhibitor (BMF-219) clinical trials, contact us at 1-844-245-0490, clinicaltrials@biomeafusion.com or visit clinicaltrials.gov.
EDUCATION SESSIONS

The Education Program will be held from Saturday, December 9 – Monday, December 11. A question-and-answer period will occur following the conclusion of all the session's presentations. Chapters based on these sessions will be published in Hematology 2023, the ASH Education Program.

Education Program Co-Chairs:

Jean M. Connors, MD, Dana-Farber Cancer Institute, Boston, MA
Amy E. DeZern, MD, Johns Hopkins University, Baltimore, MD

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Acquired Hemophilia A Diagnosis and Management

- **Saturday 9:30 a.m. – 10:45 a.m.**
  - Room 28 A-D
  - San Diego Convention Center

**Chair:**

Andreas Tiede, MD, Hannover Medical School, Hannover, Germany

**Speakers:**

Sean Platt, MSc, CSci, FIBMS, Barts Health NHS Trust, London, England
Diagnosis and Laboratory Monitoring of Acquired Hemophilia A

Andreas Tiede, MD, Hannover Medical School, Hannover, Germany
Immunotherapy of Acquired Hemophilia A

Rebecca Kruse-Jarres, MD, MPH, Puget Sound Blood Center, Seattle, WA
The Role of Emicizumab in Acquired Hemophilia A

Are We Personalizing MDS Therapy in 2023?

- **Saturday 9:30 a.m. – 10:45 a.m.**
  - Marriott Grand Ballroom 5-6
  - Marriott Marquis San Diego Marina

**Chair:**

David A. Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL

**Speakers:**

Reena R. Xian, MD, Johns Hopkins University, Baltimore, MD
How to Classify Risk Based On Clinical and Molecular Modeling: Integrating molecular markers in the risk assessment of myelodysplastic syndrome

Marie Sebert, MD, PhD, Institution, Paris, France
Next-Generation Therapy for Lower Risk MDS

CAR T Cells in ALL: Bridge or Definitive Therapy?

- **Saturday 9:30 a.m. – 10:45 a.m.**
  - Marriott Grand Ballroom 5-6
  - Marriott Marquis San Diego Marina

**Chair:**

Alice Bertaina, MD, PhD, Stanford University, Palo Alto, CA

**Speakers:**

Nirali N. Shah, M.D., National Institutes of Health, Bethesda, MD
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Alice Bertaina, MD, PhD, Stanford University, Palo Alto, CA
Stem Cell Transplantation for ALL: You’ve Always Got a Donor, Why Not Always Use It?

Stephen Gottschalk, MD, St. Jude’s Children’s Research Hospital, Memphis, TN
Preventing Relapse after CD19-CAR T-cell Therapy for Pediatric ALL: Role of Transplant and Enhanced CAR T cells

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

- **Saturday 9:30 a.m. – 10:45 a.m.**
  - Marriott Grand Ballroom 5-6
  - Marriott Marquis San Diego Marina

**Chair:**

Manali K. Kamdar, MD, MBBS, University of Colorado, Denver, CO

**Speakers:**

Anna Maria Sureda Balari, MD, PhD, Institut Catala D’Oncologia, Barcelona, Spain
CAR T-Cell Therapy in Aggressive Lymphomas-Identifying Prognostic and Predictive Markers

Of interest to PhD attendees. CME credit is not offered.
LoReta J. Nastoupil, MD, MD Anderson Cancer Center, Houston, TX
Management of Aggressive Lymphoma After CAR T-Cell Therapy Failure

Manali K. Kamdar, MD, MBBS, University of Colorado, Denver, CO
Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas

What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?

Saturday 9:30 a.m. – 10:45 a.m.
Pacific Ballroom Salons 15-17
Marriott Marquis San Diego Marina

Chair:
Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH

Speakers:
Jacqueline Cloos, PhD, VU University Medical Center, Amsterdam, Netherlands
Understanding Differential Technologies for Detection of MRD and How to Incorporate into Clinical Practice
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Muenchen, Bavaria, Germany
Novel Immunotherapies in the Treatment of AML, Is There a Hope?
Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Ctr., Powell, OH
Novel Therapies upon Failure of HMA + Venetoclax

How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?

Saturday 2:00 p.m. – 3:15 p.m.
Ballroom 20CD
San Diego Convention Center

Chair:
Chaitra S. Ujjani, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA

Speakers:
Chaitra S. Ujjani, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA
Dual Targeted Regimens for the Front-line Treatment of CLL

Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult

Saturday 2:00 p.m. – 3:15 p.m.
Room 24
San Diego Convention Center

Chair:
Emma M. Groarke, MD, National Institutes of Health, Bethesda, MD

Speakers:
Emma M. Groarke, MD, National Institutes of Health, Bethesda, MD
When to Consider Inherited Marrow Failure Syndromes in Adults
Timothy S. Olson, MD, PhD, Children's Hospital of Philadelphia, Merion Station, PA
Management of Fanconi Anemia Beyond Childhood
Marena R. Niewisch, MD, Hannover Medical School, Hannover, Germany
Clinical Manifestations of Telomere Biology Disorders in Adults

Ongoing Challenges in the Management of VTE

Saturday 2:00 p.m. – 3:15 p.m.
Room 29
San Diego Convention Center

Chair:
Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, Boston, MA

Speakers:
Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, Boston, MA
Talk #1 The Do’s, Don’ts, and Nuances of Thrombophilia Testing
Cecilia Becattini, MD, University of Perugia, Perugia, Italy
Provoked vs Minimally Provoked vs Unprovoked VTE—Does it Matter?
EDUCATION SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

KEITH R. McCRAE, MD, Cleveland Clinic, Cleveland, OH
How to Diagnose and Manage Antiphospholipid Syndrome

Transfusion Support in Sickle Cell Disease

Saturday 2:00 p.m. – 3:15 p.m.
Room 28 A-D
San Diego Convention Center

Chair: FRANCE PIRENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France

 Speakers:
ANOOSHA HABIBI, MD, Henri-Mondor University Hospital- UPEC, Creteil Cedex, France
Managing Pregnancy in Patients with Sickle Cell Disease from a Transfusion Perspective

SHANNON KELLY, Vitalant Research Institute (formerly Blood Systems Research Institute), San Francisco, CA
Suppressing HbS With Chronic Exchange Transfusions

FRANCE PIRENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France
Alloimmunization and Hyperhemolysis in Sickle Cell Disease

Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

Saturday 4:00 p.m. – 5:15 p.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

Chair: MUNA QAYED, MD, Emory University, Atlanta, GA

Speakers:
KIRK R. SCHULTZ, B.C. Children’s Hospital, Vancouver, BC, Canada
Planning GVHD Preemptive Therapy: Risk factors, Biomarkers, and Prognostic Scores

MUNA QAYED, MD, Emory University, Atlanta, GA
Novel Approaches to Acute GVHD Prevention

IDORENYI AMANAM, MD, City of Hope, Duarte, CA
Chronic GVHD: Review Advances in Prevention, Novel Endpoints and Targeted Strategies

Hematologic Toxicity of Immunotherapies

Saturday 4:00 p.m. – 5:15 p.m.
Room 6DE
San Diego Convention Center

Chair: FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL

Speakers: FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL
CAR-T

MICHAEL KROLL, MD, MD Anderson Cancer Center, Houston, TX
Checkpoint Inhibitors

MARTIN HUTCHINGS, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Bispecific Antibody Therapies

How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

Saturday 4:00 p.m. – 5:15 p.m.
Ballroom 20CD
San Diego Convention Center

Chair: ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ

Speakers: ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ
Hodgkin Lymphoma Treatment for Older Persons in the Modern Era

SAIRAH AHMED, MD, The University of Texas M D Anderson Cancer Center, Houston, TX
Management of Limited Stage Hodgkin Lymphoma

NATALIE S. GROVER, MD, University of North Carolina, Chapel Hill, NC
The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post-Brentuximab and Checkpoint Inhibitor Failure
### Why Am I Getting Paged at 2AM?

**Microangiopathic Emergencies**

**Saturday**
- **4:00 p.m. – 5:15 p.m.**
- **Room 29**
- **San Diego Convention Center**

**Chair:**
- **Shruti Chaturvedi,** MBBS, Johns Hopkins University School of Medicine, Baltimore, MD

**Speakers:**
- **Jennifer Jury McIntosh,** DO, Medical College of Wisconsin, Milwaukee, WI
  - *Labor and Delivery: DIC, HELLP, Pre-eclampsia*
- **Shruti Chaturvedi,** MBBS, Johns Hopkins University School of Medicine, Baltimore, MD
  - *Medical Consult—aHUS, TTP—How to Distinguish and What to Do*
- **Beverley Jane Hunt,** MD, FMCPATH, FRCP, King’s College, London, England
  - *Consumptive Coagulopathy in the ICU*

### Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

**Sunday**
- **9:30 a.m. – 10:45 a.m.**
- **Room 11**
- **San Diego Convention Center**

**Chair:**
- **Sunee Agarwal,** MD, PhD, Children’s Hospital Boston, Boston, MA

**Speakers:**
- **Kristen E. Schratz,** MD, Johns Hopkins Hospital, Baltimore, MD
  - *Clonal Evolution in Inherited Marrow Failure Syndromes Predicts Disease Progression*
- **Sunee Agarwal,** MD, PhD, Children’s Hospital Boston, Boston, MA
  - *Minimal Intensity Conditioning Strategies for Bone Marrow Failure – Is It Time for “Preventative” Transplants?*
- **Kasiani Myers,** MD, Cincinnati Children’s Hospital, Cincinnati, OH
  - *Post-transplant Complications in Patients With Marrow Failure Syndromes—Are We Improving Long-Term Outcomes?*

### Hemostasis in Patients with Severe Liver Disease

**Sunday**
- **9:30 a.m. – 10:45 a.m.**
- **Room 31**
- **San Diego Convention Center**

**Chair:**
- **Lara N. Roberts,** MD, MBBS, King’s College Hospital, London, England

**Speakers:**
- **Ton Lisman,** PhD, University Medical Centre Groningen, Groningen, Netherlands
  - *How to Assess Hemostasis in Patients with Severe Liver Disease*
- **Lara N. Roberts,** MD, MBBS, King’s College Hospital, London, England
  - *How to Manage Hemostasis in Patients with Liver Disease During Interventions*
- **Walter Ageno,** MD, University of Insubria, Varese, Italy
  - *How to Manage Splanchnic Vein Thrombosis in Patients with Liver Disease*

### How Do We Enhance Results in Rare Hematologic Malignancies?

**Sunday**
- **9:30 a.m. – 10:45 a.m.**
- **Room 29**
- **San Diego Convention Center**

**Chair:**
- **Anita D’Souza,** MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI

**Speakers:**
- **Oussama Abla,** MD, Hospital for Sick Children, Toronto, ON, Canada
  - *Langerhans Cell Histiocytosis: Promises and Caveats of Targeted Therapies in High-risk and CNS Disease*
- **Deepti H. Radia,** MD, FRCPATH, Guy’s and St. Thomas’ Hospital, London, United Kingdom
  - *Mastocytosis Demystified*
- **Anita D’Souza,** MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI
  - *Amyloid Consults Do Not Have to be Vexing*
### How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

**Sunday** | 9:30 a.m. – 10:45 a.m.  
Seaport Ballroom EFGH  
Manchester Grand Hyatt San Diego

**Chair:**  
FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy

**Speakers:**  
FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy  
A Rational Approach to Functionally High-Risk Myeloma  
MONIQUE A. HARTLEY-BROWN, MD, Dana-Farber Cancer Institute, Boston, MA  
Considerations for Next Therapy After ANTI CD38 Monoclonal Antibodies Used as First Line  
ADAM D. COHEN, The Trustees of The University of Pennsylvania, Philadelphia, PA  
Options at the Time of Relapse After ANTI BCMA Therapy

---

### The Iron Revolution!

**Sunday** | 9:30 a.m. – 10:45 a.m.  
Room 28 A-D  
San Diego Convention Center

**Chair:**  
THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR

**Speakers:**  
THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR  
Sex, Lies, and Iron Deficiency: A Call to Change Ferritin Reference Ranges  
MICHAEL AUERBACH, MD, Auerbach Hem-Onc Associates, Inc., Baltimore, MD  
IV Iron Formulations and Use in Adults  
JACQUELYN POWERS, MD, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX  
Intravenous Iron Therapy in Pediatrics: Who Should Get It and When Is the Right Time?
Hematologists and the Care of Pregnant Women

Sunday 4:30 p.m. – 5:45 p.m.
Room 25
San Diego Convention Center

Chair: Fionnuala Ni Ainle, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

Speakers:
Adam K. Lewkowitz, MD, Brown University School of Medicine, Women & Infants Hospital In Rhode Island, Providence, RI
Identifying and Treating Iron Deficiency in Pregnancy

Andra H. James, MD, Duke University School of Medicine, Durham, NC
Management of Pregnant Women Who Have Bleeding Disorders

Fionnuala Ni Ainle, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
Prevention, Diagnosis and Management of PE & DVT in Pregnant Women

Hot Topics in Blood Donation: Donor Risks and Social Justice

Sunday 4:30 p.m. – 5:45 p.m.
Hall A
San Diego Convention Center

Chair: Richard M. Kaufman, MD, Brigham and Women’s Hospital, Boston, MA

Speakers:
Mindy Goldman, MD, Canadian Blood Services, Ottawa, ON, Canada
MSM and Blood Donation: Shifting to Individualized Risk Assessment

Darja Karpova, MD, Washington University in St. Louis, Saint Louis, MO
Clonal hematopoiesis in Frequent Whole Blood Donors

Richard M. Kaufman, MD, Brigham and Women’s Hospital, Boston, MA
T-cell Lymphopenia in Frequent Platelet Donors

How Do We Tackle Remaining Clinical Challenges in CML?

Sunday 4:30 p.m. – 5:45 p.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

Chair: Naranie Shanmuganathan, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

Speakers:
Naranie Shanmuganathan, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
Accelerated phase CML–de Novo and Transformed

Simona Soverini, PhD, University of Bologna School of Medicine, Castel Maggiore, Bologna, Italy
Resistance Mutations in CML and How We Approach Them

Massimo Breccia, Hematology-Sapienza University, Rome, Italy
Atypical CML-Diagnosis and Treatment

Energizing the Red Cell: Novel Therapies for Hereditary Hemolytic Anemias

Monday 10:30 a.m. – 11:45 a.m.
Room 28 A-D
San Diego Convention Center

Chair: Rachel F. Grace, MD, The Children’s Hospital Corporation, Boston, MA

Speakers:
Rachel F. Grace, MD, The Children’s Hospital Corporation, Boston, MA
PK Activators in Pyruvate Kinase Deficiency

Eduard J. Van Beers, MD, PhD, University Medical Centre Utrecht, Utrecht, Netherlands
PK Activators for Sickle Cell Disease

Kevin H.M. Kuo, MD, FRCP, MSc, University of Toronto, Toronto, ON, Canada
PK Activators for Thalassemia
### How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies

**Chair:**
Nizar J. Bahlis, MD, University of Calgary, Alberta, Canada

**Speakers:**
Nizar J. Bahlis, MD, University of Calgary, Alberta, Canada  
*Current Use of Bispecific Antibodies to Treat Multiple Myeloma*

Sham Malankody, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY  
*Current Use of CAR T-Cells to Treat Multiple Myeloma*

Surbhi Sidana, MD, Stanford University, Stanford, CA  
*Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma*

**Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?**

**Chair:**
Tamara P. Miller, MD, MSCE, Emory University, Decatur, GA

**Speakers:**
John C. Molina, MD, MEd, Shaker Heights, OH  
*Leveraging Health Care Technology to Improve Health Outcomes and Reduce Outcome Disparities in AYA Leukemia*

Tamara P. Miller, MD, MSCE, Emory University, Decatur, GA  
*Adolescent and Young Adults (AYA) Versus Pediatric Patients: Survival, Risks and Barriers to Enrollment*

Emily K. Curran, MD, University of Cincinnati, Cincinnati, OH  
*Acute Lymphoblastic Leukemia in Young Adults: Which Treatment?*

### What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

**Chair:**
Roni Shouval, MD, PhD, Memorial Sloan-Kettering, New York, NY

**Speakers:**
Reena Jayani, MD, Vanderbilt University Medical Center, Nashville, TN  
*How Old Is Too Old? Frailty and Geriatric Assessments of Older Patients Undergoing Allogeneic HCT*

Roni Shouval, MD, PhD, Memorial Sloan-Kettering, New York, NY  
*The Sum of the Parts: What We Can and Cannot Learn from Comorbidity Scores in Allogeneic Transplantation*

Asmita Mishra, MD, MBA, Moffitt Cancer Center, Tampa, FL  
*Approaches to Optimize Outcomes in Transplant Recipients*

### Alphabet Soup - Challenging Consults on the Pediatric Units

**Chair:**
Nicole Kucine, MD, MS, Weill Cornell Medical College, New York, NY

**Speakers:**
Ashish Kumar, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH  
*Inflamed – HLH, MAS, or Something Else?*

Nicole Kucine, MD, MS, Weill Cornell Medical College, New York, NY  
*Too Many White Cells – TAM, JMML, or Something Else?*

Clifford M. Takemoto, MD, St Jude's Children's Research Hospital, Memphis, TN  
*Where Have All the Platelets Gone – HIT, DIC, or Something Else?*
### Hematologists as Lifesavers: Inpatient Hematology Emergencies

**Monday 4:30 p.m. – 5:45 p.m.**  
Marriott Grand Ballroom 5-6  
Marriott Marquis San Diego Marina

**Chair:**  
STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL

**Speakers:**  
MARTIN S. TALLMAN, MD, Northwestern University, Highland Park, IL  
*How to Avoid Early Mortality in APL*  
STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL  
*How to manage ITP with life-threatening bleeding*  
ADI ZOREF-LORENZ, MD, Hematology Institute, Meir Medical Center, Kfar Saba, Israel  
*Inpatient Recognition and Management of HLH*

**How Can We Manage High-Risk Hematologic Malignancies in the Community?**

**Monday 4:30 p.m. – 5:45 p.m.**  
Grand Hall B  
Manchester Grand Hyatt San Diego

**Chair:**  
DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA

**Speakers:**  
DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA  
*Acute Leukemias and Complicated Lymphomas: Pearls to Optimize Management When Patients Stay Local*  
JESUS G. BERDEJA, MD, Sarah Cannon Center For Blood Cancers, Nashville, TN  
*Multiple Myeloma: A Paradigm for Blending Community and Academic Care*  
RUEMU EJEDAFETA BIRHRAY, MD, Hem.-Onc. of Indiana, PC, Indianapolis, IN  
*Clinical Research in the Community*

### Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?

**Monday 4:30 p.m. – 5:45 p.m.**  
Room 29  
San Diego Convention Center

**Chair:**  
COURTNEY FITZHUGH, National Institutes of Health (Hematology), Bethesda, MD

**Speakers:**  
KENNETH I. ATAGA, MD, University of Tennessee Health Sciences Center, Memphis, Nashville, TN  
*Using Disease Modifying Therapies in Sickle Cell Disease*  
ADETO A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN  
*The Range of Haploidentical Transplant Protocols in Sickle Cell Disease: All Haplos Are Not Created Equally*  
JOHN F. TISDALE, MD, National Institutes of Health Molecular & Clinical Hematology, Bethesda, MD  
*Gene Therapy for Sickle Cell Disease*
We invite you to attend the sessions below at the Blood Journals Studio or stop by to meet journal staff during the poster hall hours
LOCATED IN THE POSTER HALL, G-H

**NEW IN 2023 • IN-PERSON EVENT ONLY**

**TIME** | **SATURDAY, DECEMBER 9**
--- | ---
10:00 AM | Meet the Blood Advances Editors | Alisa Wolberg, PhD; Constantine Tam, MBBS, MD
2:00 PM | Distinguished Abstract Achievement Award Ceremony | Lisa Baumann Kreuziger, MD, MS. Versiti, Menomonee Falls, WI; Harvey Roweth, PhD,BSc. Brigham and Women’s Hospital, Boston, MA; Marie Hollenhorst, MD, PhD. Brigham and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
4:00 PM | ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood Vessels, Thrombosis & Hemostasis (VTH) | Organized by: ASH SCIENTIFIC AFFAIRS
5:00 PM | Meet the Blood VTH Editor-in-Chief | Keith McCrae, MD, Editor-in-Chief, Blood VTH

**TIME** | **SUNDAY, DECEMBER 10**
--- | ---
10:00 AM | Meet the Blood Editors | Helen Heslop, MD; Bertie Göttgens, DPhil
4:30 PM | ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia | Organized by: ASH SCIENTIFIC AFFAIRS
5:30 PM | Meet the Blood Neoplasia Editor-in-Chief | Jonathan Licht, MD. Editor-in-Chief, Blood Neoplasia

**TIME** | **MONDAY, DECEMBER 11**
--- | ---
10:00 AM | Meet the Blood Advances Editors | Geoffrey R. Hill, MD, FRCPA, FRACP: Olatoyosi Odenike, MD
11:00 AM | Best Practices for Peer Review: ASH Clinical News interviews Blood Advances Editors | Aaron T. Gerds, MD, ASH Clinical News Editor-in-Chief
Catherine M. Bollard, MD. Editor-in-Chief, Blood Advances; Andrew S. Weyrich, PhD. Deputy Editor, Blood Advances
12:00 PM | The ABCs of Publishing for Authors: The Hematologist interviews the Blood Editors | Shaji Kumar, MD. Editor-in-Chief, The Hematologist; Nancy Berliner, MD, Editor-in-Chief, Blood; Andrew Roberts, MBBS, PhD. Deputy Editor, Blood
3:00 PM | Meet the Blood Editors | Erica Wood. MBBS: Philippe Armand, MD, PhD

* Pacific Daylight Time (PDT)
EDUCATION SPOTLIGHT SESSIONS

These sessions are intended to provide an in-depth review on specific scientific topics. This year, speakers will discuss current challenges and controversies in two exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 90-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SUNDAY

Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?

Sunday 4:30 p.m. – 5:45 p.m.
Room 29, San Diego Convention Center

Chair:
DAVID GARCIA, MD, University of Washington, Seattle, WA

Speakers:
SAM SCHULMAN, MD, PhD, McMaster University, Hamilton, Ontario, Canada
PCC Should Be Used to Reverse Xai Anticoagulants

DEBORAH SEGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada
Andexanet Should Be Used to Reverse Xai Anticoagulants

Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials

Sunday 4:30 p.m. – 5:45 p.m.
Room 6A, San Diego Convention Center

Chair:
JUSTIN TAYLOR, MD, University of Miami, Miami, FL

Speakers:
VALERIA SANTINI, AOU Careggi-University of Florence, Firenze, Italy
Laboratory Scientists Don’t Care

MONDAY

Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL

Monday 2:45 p.m. – 4:00 p.m.
Room 7, San Diego Convention Center

Chair:
GREGORY A. ABEL, MD, MPH, DFCI, Boston, MA

Speakers:
ZHUOER XIE, MD, MS, Lutz, FL
CCUS is Increasingly Significant in Clinical Practice

PAOLO GHIA, MD, PhD, Vita-Salute San Raffaele University, Milano, Italy
Monoclonal B-cell Lymphocytosis: at a Crossroad Between Disease and Senescence
### What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution

**Monday**  
2:45 p.m. – 4:00 p.m.  
Hall A, San Diego Convention Center

**Chair:**  
Maureen Okam Achebe, MD, MPH, Hematology Division Brigham and Women’s, Boston, MA

**Speakers:**  
Lauren E. Merz, MD, MSc, Dana-Farber Cancer Institute, Boston, MA  
Duffy-null Associated Neutrophil Counts--What is Normal  
John Mark Sloan, MD, Boston Medical Center, Boston, MA  
Clinical Implications of the Duffy Antigen

### Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes

**Monday**  
2:45 p.m. – 4:00 p.m.  
Room 11, San Diego Convention Center

**Chair:**  
Dean Anthony Lee, MD, PhD, The Research Institute at Nationwide Children’s Hospital, Columbus, OH

**Speakers:**  
Carlos A. Ramos, MD, The Methodist Hospital, Houston, TX  
Off-the-shelf αβ- or NK-T Cells for Cancer Therapy  
Jonathan P. H. Fisher, University College London, London, United Kingdom  
Engineering T cells: A New Tool for Cancer Immunotherapy
HOW I TREAT: BRINGING SCIENCE TO CLINICAL DILEMMAS

These sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

Attention Trainees!
A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket. Training will be required to purchase a ticket.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Acquired Hemophilia A Diagnosis and Management (for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Aqua Salon AB
Hilton San Diego Bayfront

Speaker:
Andreas Tiede, MD, Hannover Medical School, Hannover, Germany

Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) (for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Aqua Salon F
Hilton San Diego Bayfront

Speaker:
John C. Molina, MD, ME, National Cancer Institute, Shaker Heights, OH

Advances in Myeloproliferative Neoplasms Affecting Management (for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Aqua Salon D
Hilton San Diego Bayfront

Speaker:
Jeanne Palmer, MD, Mayo Clinic, Scottsdale, AZ

Hematologists and the Care of Pregnant Women (for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Aqua 310
Hilton San Diego Bayfront

Speaker:
Fionnuala Ní Ainle, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
### Patients with Acute Myeloid Leukemia (for in-person participants)

**Saturday**  
8:00 a.m. – 9:00 p.m.  
Aqua Salon C  
Hilton San Diego Bayfront

**Speaker:**  
CHRISTOPH RÖLLIG, MD, MSc, University Hospital, Dresden, Germany

### SUNDAY

#### Cellular Therapy for Lymphoma (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua Salon D  
Hilton San Diego Bayfront

**Speaker:**  
LORETTA J. NASTOUPIL, MD, MD Anderson Cancer Center, Houston, TX

#### Early Management of Acute Promyelocytic Leukemia (APML) (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua Salon F  
Hilton San Diego Bayfront

**Speaker:**  
MARTIN TALLMAN, MD, Northwestern University Feinberg School of Medicine, Highland Park, IL

#### Ongoing Challenges in the Management of VTE (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua Salon AB  
Hilton San Diego Bayfront

**Speaker:**  
KENNETH A. BAUER, MD, Beth Israel Deaconess Medical Center, Boston, MA

#### T-Cell Redirection Therapy for Multiple Myeloma (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua Salon E  
Hilton San Diego Bayfront

**Speaker:**  
SURBHI SIDANA, MD, Stanford University, Stanford, CA
LIFT PLATELETS. NO SWEAT.

No food-type restrictions: Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.¹

No liver monitoring: Doptelet does not require additional liver-function monitoring; no significant hepatotoxicity seen in Doptelet clinical trials.¹,²

No injections: Doptelet can be taken anytime, anywhere, without adding trips to the doctor (platelet monitoring required).¹*

*After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50×10⁹/L has been achieved, and then obtain platelet counts monthly thereafter.

INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; 1/274) in DOPTELET-treated patients and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; 9/128) in DOPTELET-treated patients. Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, confusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, chocking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com.

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

Please see Brief Summary of Full Prescribing Information on the adjacent page.

Visit us at LiftPlatelets.com, or scan the QR code:


Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) D2022 Sobi, Inc. All rights reserved. PP:13394 01/2022
For the Low Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 7% (11/159) in the 60 mg DOPELET treatment group. For the High Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 3% (9/315) in the 40 mg DOPELET treatment group. The most common serious adverse reaction reported with DOPELET was hypotension. Two DOPELET-treated patients (3.7%) developed hypotension.

Adverse reactions resulting in discontinuation of DOPELET were anemia, pancytopenia, and myalgia; each was reported in a single (0.4%) patient in the DOPELET (60 mg) treatment group.

**Patients with Chronic Immune Thrombocytopenia**

The safety of DOPELET was evaluated in four clinical trials in patients with chronic immune thrombocytopenia: two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial, and one open-label extension trial) in 161 patients with chronic immune thrombocytopenia in both the double-blind and open-label extension phases.

The pooled safety data from these four clinical trials includes 128 patients who received 2.5 mg to 40 mg of DOPELET once daily for a median duration of exposure of 29.1 weeks and had 1 post-dose safety assessment. The majority of patients were female (63%) and median subject age was 50.5 years (range from 18-88 years of age). The racial and ethnic distribution was White (84%), Black (6%), Asian (6%) and Other (6%).

The most common adverse reactions (those occurring in ≥10% of patients) in the DOPELET-treated patients across the pooled safety data from three of the four clinical trials are summarized in Table 6.

### Table 6: Adverse Reactions with a Frequency ≥10% in Patients with Chronic Immune Thrombocytopenia Treated with DOPELET – Pooled Data from Clinical Trials

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>DOPELET (N=128)</th>
<th>Placebo (N=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>32</td>
<td>14</td>
</tr>
<tr>
<td>Fatigue</td>
<td>28</td>
<td>9</td>
</tr>
<tr>
<td>Constipation</td>
<td>26</td>
<td>19</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>15</td>
<td>18</td>
</tr>
<tr>
<td>Urosepsis</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Gingival Bleeding</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Petechiae</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

The incidence of serious adverse reactions was 9% (12/128) in the DOPELET treatment group. Serious adverse reactions reported in more than 1 individual DOPELET-treated patient included headache, occurring in 1.6% (2/128).

Adverse reactions resulting in discontinuation of DOPELET that were reported in more than one patient included headache, occurring in 1.6% (2/128).

### 6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of DOPELET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Immune System Disorders:** Hypersensitivity reactions including pruritus, rash, choking sensation, erythema, pharyngeal edema, pruritus generalized, rash macular, swelling face, and swollen tongue.

### 7 DRUG INTERACTIONS

#### 7.1 Effect of Other Drugs on DOPELET in Patients with Chronic Immune Thrombocytopenia

**Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 increases avatrombopag AUC [see Clinical Pharmacology (12.3)], which may increase the risk of DOPELET toxicities. Reduce the starting dosage of DOPELET when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4) [see Dosage and Administration (2.5)].

In patients starting moderate or strong dual inhibitors of CYP2C9 and CYP3A4 while receiving DOPELET, monitor platelet counts and adjust DOPELET dose as necessary (see Table 3) [see Dosage and Administration (2.5)].

**Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 decreases avatrombopag AUC [see Clinical Pharmacology (12.3)], which may reduce DOPELET efficacy. Increase the recommended starting dosage of DOPELET when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4) [see Dosage and Administration (2.5)].
Patients with Chronic Liver Disease
No dosage adjustments are required for patients with chronic liver disease.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
Based on findings from animal reproduction studies, DOPELTE may cause fetal harm when administered to a pregnant woman (see Data). The available data on DOPELTE in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, oral administration of avatrombopag resulted in adverse developmental outcomes when administered during organogenesis in rabbits and during organogenesis and the lactation period in rats. However, these findings were observed at exposures based on an AUC substantially higher than the AUC observed in patients at the maximum recommended dose of 60 mg once daily.

Advising pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In embryofetal development studies, avatrombopag was administered during organogenesis at doses of 100, 300, and 1000 mg/kg/day in rats and doses of 100, 300, and 600 mg/kg/day in rabbits. Minimal decreases in fetal weights were observed in rats at the maternally toxic dose of 1000 mg/kg/day with exposures 190 times the human exposure based on AUC. Spontaneous abortions were observed at all doses tested in rabbits and were associated with decreased body weights and food consumption at 300 and 600 mg/kg/day; exposures at the lowest dose of 100 mg/kg/day were 10 times the AUC in patients at the maximum recommended dose of 60 mg once daily. There were no embryofetal effects in rats administered avatrombopag doses of 100 mg/kg/day (53 times the human exposure based on AUC) or rabbits administered avatrombopag at doses of 600 mg/kg (35 times the human exposure based on AUC).

In pre- and postnatal development studies in rats, avatrombopag was administered during both the organogenesis and lactation periods at doses ranging from 5 to 600 mg/kg/day. Doses of 100, 300, and 600 mg/kg/day caused maternal toxicity leading to fetal litter losses, decreased body weight in pups, and increased pup mortality, with the majority of the pup mortality occurring from postnatal days 14 to 21. At a dose of 50 mg/kg/day that did not produce clear maternal toxicity, avatrombopag increased pup mortality from postnatal days 4 to 21, and mortality continued through postnatal day 25. The 50 mg/kg/day dose also decreased pup body weight gain in the pups, resulting in a delay in sexual maturation. There were no effects on behavioral or reproductive functions in the offspring. The 50 mg/kg/day dose resulted in maternal exposures 43 times and pup exposures approximately 3 times the AUC observed in patients at the maximum recommended dose of 60 mg once daily.

8.2 Lactation

Risk Summary

There is no information regarding the presence of avatrombopag in human milk, the effects on the neonate, or the effects on milk production. Avatrombopag was present in the milk of lactating rats. When a drug is present in animal milk, it is likely the drug will be present in human milk. Due to the potential for serious adverse reactions in a breastfed child from DOPELTE, breastfeeding is not recommended during treatment with DOPELTE and for at least 2 weeks after the last dose (see Clinical Considerations).

Clinical Considerations

Minimizing Exposure

A lactating woman receiving DOPELTE for brief periods, such as prior to an invasive procedure, should interrupt breastfeeding and pump and discard breast milk during treatment and for two weeks after the last dose of DOPELTE in order to minimize exposure to a breastfed child. Advise lactating women receiving chronic DOPELTE therapy not to breastfeed during treatment with DOPELTE and for at least 2 weeks after the last dose.

8.4 Pediatric Use

Safely and effectiveness in pediatric patients have not been established.

In a 10-week juvenile toxicology study in rats, avatrombopag was administered at doses ranging from 20 to 30 mg/kg/day. There was no test article-related mortality and there were no clinical signs at doses up to 30 mg/kg/day. In the stomach, dose-dependent degeneration, regenerative hyperplasia, and atrophy of the glanular epithelium occurred at 100 and 300 mg/kg/day; exposures at 100 mg/kg/day in male rats were 14 times the AUC in patients at the highest recommended dose of 60 mg once daily. An increased incidence of background focal mineralization was also observed in the kidneys of females at 300 mg/kg/day (female rat exposure was 60 times the human exposure based on AUC at the 60 mg daily dose).

8.5 Geriatric Use

Clinical studies of DOPELTE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients.

10 OVERDOSAGE

In the event of overdose, platelet count may increase excessively and result in thrombotic or thromboembolic complications. Closely monitor the patient and platelet count. Treat thrombotic complications in accordance with standard of care.

No antidote for DOPELTE overdose is known.

Haemodialysis is not expected to enhance the elimination of DOPELTE because DOPELTE is only approximately 6% renally excreted and is highly bound to plasma proteins.

17 PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).

Prior to treatment, patients should fully understand and be informed of the following risks and considerations for DOPELTE.

Risks

Thrombotic/Thromboembolic Complications

DOPELTE is a thromboxane A2 (TXA2) receptor agonist and the TXA2 receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Various thromboembolic complications (arterial and venous) have been reported in patients treated with DOPELTE [see Warnings and Precautions (5.1)].

Drug Interactions

DOPELTE may be affected by other drugs and may require a dose adjustment when co-administered with other drugs; therefore, advise patients to report their use of any other prescription or nonprescription medications or dietary supplements [see Dosage and Administration (2.3), Drug Interactions (7)].

Pregnancy

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1)].

Lactation

Advise women not to breastfeed during treatment with DOPELTE and for at least 2 weeks after the last dose [see Use in Specific Populations (8.2)].

Rx Only

Please see package insert for Full Prescribing Information at www.DopleteHC.com.

This Brief Summary is based on Doplete (avatrombopag) Prescribing Information P10002 R6 July 2021

DOPELTE is a registered trademark of AkaRx, Inc. Manufactured for AkaRx, Inc., Durham, North Carolina 27707

Sobi is a trademark of Swedish Orphan Bi vitrum AB (publ) © 2021 Sobi, Inc.

For more information, go to www.DOPELTE.com or call 1-855-454-3887.

PP-13400 11/21
Blood Neoplasia joins Blood and Blood Advances in the Blood Journals portfolio, expanding our journal footprint. This new specialty journal will publish open access original research and will focus on hematologic malignancies, including leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, myeloproliferative neoplasms, minimal residual disease, and precursor conditions to neoplasia. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the Blood Journals portfolio, anchored by our high-impact flagship, Blood, is a natural home for research in specialty areas of hematology.

WHY SUBMIT?

Blood Neoplasia helps place your research within the reputable and highly visible Blood Journals portfolio. By publishing within these journals, you align your research with the long-trusted ASH and Blood brands.

BENEFITS TO AUTHORS:

• ASH & Blood Portfolio Brand Visibility
• Fast Peer Review
• Seamless Transfers
• Speed to Publication
• Open Science

ASH is the home for hematology. Long embraced by the hematology community, the Blood Journals are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a Blood journal.

Submit your paper now
Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes

Saturday 9:30 a.m. – 10:45 a.m.
Room 7
San Diego Convention Center

Scientific Committee on Bone Marrow Failure
Chair:
Marcin W. Wlodarski, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Speakers:
Jean Soulier, MD, Hôpital Saint-Louis, Paris, France
Revertant Mosaicism in Fanconi Anemia

Alyssa Kennedy, MD, PhD, Boston Children's Hospital, Boston, MA
Clonal Hematopoiesis in Shwachman Diamond Syndrome

Sushree S. Sahoo, PhD, St. Jude Children’s Research Hospital, Memphis, TN
Somatic Genetic Rescue in SAMD9 and SAMD9L Syndromes

Next Generation of Gene-Based Therapies for Bleeding Disorders

Saturday 9:30 a.m. – 10:45 a.m.
Room 31
San Diego Convention Center

Scientific Committee on Hemostasis
Chair:
Denise E. Sabattino, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA

The Evolution of Multiple Myeloma: From Inside-Out

Saturday 9:30 a.m. – 10:45 a.m.
Grand Hall C
Manchester Grand Hyatt San Diego

Scientific Committee on Plasma Cell Neoplasia
Chair:
Nina Shah, MD, AstraZeneca, San Francisco, CA

Speakers:
Marta Chesi, PhD, Mayo Clinic Arizona, Scottsdale, AZ
The Big Myc – What We Know About Myc Signaling in Myelomagenesis

Eugenio Morelli, MD, Dana Farber Cancer Institute, Boston, MA
Alternate Code: The Role of Non-Coding RNAs in Multiple Myeloma

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
Co-Operativity in the Pathogenesis of Myeloid Malignancies

Saturday 2:00 p.m. – 3:15 p.m.
Marriott Grand Ballroom 11-13
Marriott Marquis San Diego Marina

Scientific Committee on Myeloid Neoplasia

Chair:
SAA R G I L L, MD, PhD, University of Pennsylvania, Philadelphia, PA

Speakers:
S E S H I O G A W A, MD, PhD, Kyoto University, Kyoto, Japan
Interplay Between Chromosomal Alterations and Gene Mutations

L I N D E A. M I L E S, PhD, Cincinnati Children’s Hospital, Cincinnati, OH
Single Cell Mutation Analysis of Clonal Evolution and Its Clinical Implications

M A R K A. D A W S O N, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Beyond Somatic Mutations in the Pathogenesis of Myeloid Neoplasia

Emerging Methodologies to Investigate Platelet Biology

Saturday 2:00 p.m. – 3:15 p.m.
Room 25
San Diego Convention Center

Scientific Committee on Megakaryocytes and Platelets

Chair:
H E R V E F A L E T, PhD, Versiti Blood Research Institute, Milwaukee, WI

Speakers:
A N I T A E C K L Y, PhD, Inserm-Université De Strasbourg, Strasbourg, France
High-Resolution 3D Imaging of Megakaryocytes

F L O R I A N G A E R T N E R, MD, PhD, Institute of Science and Technology Austria, Klosterneuburg, Austria
Dynamic Live Imaging of Platelets

Spatial Genomic & Epigenomic Profiling in Hematology

Saturday 2:00 p.m. – 3:15 p.m.
Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

Scientific Committee on Epigenetics and Genomics

Chair:
D I N E S H R A O, MD, PhD, University of California, Los Angeles, CA

Speakers:
F E I C H E N, PhD, Broad Institute of MIT, Boston, MA
Spatial Mapping of Immune Cells & Clonal Heterogeneity in Tissues

E L H A M A Z I Z I, PhD, Columbia University, New York, NY
Understanding the Spatial-contextual Regulatory Mechanisms That Shape Cellular Identity and Heterogeneity

R O N G F A N, PhD, Yale School of Engineering and Applied Science, New Haven, CT
Spatial Mapping of Chromatin and Proteomes

Iron and Heme in Stem Cell Maintenance and Erythropoiesis

Saturday 4:00 p.m. – 5:15 p.m.
Room 24
San Diego Convention Center

Scientific Committee on Iron and Heme

Chair:
L A U R A S I L V E S T R I, PhD, San Raffaele Scientific Institute, Università Vita-Salute, Milan, Italy

Speakers:
D A C H U A N Z H A N G, PhD, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Iron and Heme Shape the Hematopoietic Stem Cell Fate and the Erythron Function

A N N A M A R I A A P R I L E, PhD, Ospedale San Raffaele, Milan, Italy
Iron and Hematopoietic Stem Cell in Ineffective Erythropoiesis
LEON KAUTZ, PhD, Inserm, Toulouse, France
Mechanisms Controlling the Iron Supply to the Erythron and Their Pathophysiological Contributions

Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis

Saturday 4:00 p.m. – 5:15 p.m.
Room 31
San Diego Convention Center

Scientific Committee on Thrombosis & Vascular Biology
Chair:
Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

Speakers:
Kimberly Martinod, PhD, KU Leuven, Leuven, Belgium
Neutrophil Extracellular Traps and Thrombosis in Different Disease States
Evi X. Stavrou, MD, University Hospitals Cleveland Medical Center, Cleveland, OH
Role of Neutrophils in In Vivo Models of Thrombosis
Ioannis Mitroulis, MD, PhD, Democritus University of Thrace, Alexandroupolis, Greece
Role of Immune Cells in the Pathophysiology of Thrombosis

Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis

Saturday 4:00 p.m. – 5:15 p.m.
Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

Scientific Committee on Hematopoiesis
Chair:
Marieke Essers, PhD, HI-STEM GgmbH, Heidelberg, Germany

Speakers:
Tiago C. Luis, PhD, University of Oxford, Oxford, United Kingdom
Niche Regulation of HSCs in Homeostasis and Emergency Hematopoiesis
Maria C. Florian, PhD, The Bellvitge Institute for Biomedical Research, Barcelona, Spain
Ageing in the Hematopoietic Stem Cells Niche

Scientific Committee on Hematopathology & Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia

CO-Chairs:
Parul Bhargava, MD, University of California San Francisco, Redwood City, CA
Caron A. Jacobson, MD, MMSc, Dana-Faber Cancer Institute, Boston, MA

The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.

Saturday 4:00 p.m. – 5:15 p.m.
Room 25
San Diego Convention Center

Scientific Committee on Red Cell Biology
Chair:
Jane A. Little, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Speakers:
Mitchell J. Weiss, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN
Understanding Fetal Hgb Regulation: HIF1alpha and LNC RNA
Ann Dean, PhD, National Institutes of Health, Bethesda, MD
Understanding Fetal Hgb Regulation: LNC RNA
Gerd A. Blobel, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
Mechanisms of Developmental Globin Gene Expression Control Revealed via Functional CRISPR Screens

JOINT SESSION: Lymphomagenesis - What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies

Saturday 4:00 p.m. – 5:35 p.m.
Ballroom 20AB
San Diego Convention Center

Scientific Committee on Hematopathology & Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia

CME credit is not offered.
Saturday–Monday 09–11 Dec 2023

SCIENTIFIC SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

**Aswin Sekar, MD, PhD, Dana-Farber Cancer Institute, Boston, MA**
*Mutations in Healthy Humans Associated with Lymphoid Malignancies*

**Laura Pasqualucci, MD, Columbia University, New York, NY**
*Aberrant Germinal Center Expansion and Lymphomagenesis*

**Christian Munz, PhD, University of Zurich, Zurich, Switzerland**
*Infections and Lymphomagenesis*

**Mandeep Singh, PhD, University of New South Wales, Sydney, Australia**
*Immune Dysregulation and Lymphomagenesis*

**JOINT SESSION: Ontogeny and Myeloid Disorders of Childhood**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:35 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marriott Grand Ballroom 5-6</td>
<td></td>
</tr>
<tr>
<td>Marriott Marquis San Diego Marina</td>
<td></td>
</tr>
</tbody>
</table>

*Scientific Committee on Myeloid Biology & Scientific Committee on Stem Cells and Regenerative Medicine*

**Co-Chairs:**

**Eirini Papapetrou, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY**

**Jeffrey Magee, MD, PhD, Washington University School of Medicine, Saint Louis, MO**

**Speakers:**

**Shannon McKinney-Freeman, PhD, St. Jude Children’s Research Hospital, Memphis, TN**
*Normal Hematopoietic Ontogeny*

**Jan-Henning Klusmann, MD, Goethe University Frankfurt, Frankfurt, Germany**
*Ontogeny and Malignant Disorders of Childhood*

**Alan B. Cantor, MD, PhD, Boston Children’s Hospital, Boston, MA**
*Ontogeny and Inherited Myeloid Disorders*

**Anna E. Beaudin, PhD, University of Utah, Salt Lake City, UT**
*Microenvironmental Contributions to Fetal/Neonatal Blood Development and Diseases*

**JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy**

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 11:05 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 6CF</td>
<td></td>
</tr>
<tr>
<td>San Diego Convention Center</td>
<td></td>
</tr>
</tbody>
</table>

*Scientific Committee on Immunology and Host Defense & Scientific Committee on Transplantation Biology & Cellular Therapies*

**Co-Chairs:**

**Todd A. Feinberg, MD, PhD, Washington University School of Medicine, Saint Louis, MO**

**Carl June, MD, University of Pennsylvania, Philadelphia, PA**

**Speakers:**

**Alexander Marxon, MD, PhD, University of California, San Francisco, San Francisco, CA**
*Decoding and Rewriting Immune Cells to Advance Immune Responses to Cancer*

**Dan S Kaufman, MD, PhD, University of California San Diego, La Jolla, CA**
*Engineering Alternative Immune Cells as Blood Cancer Immunotherapy*

**Chiara Bonini, MD, Ospedale San Raffaele, Milano, Italy**
*TCR Engineering of Immune Cells to Enhance Responses to Blood Cancers*

**Carl June, MD, University of Pennsylvania, Philadelphia, PA**
*Applying Genome Engineering to Enhance CAR T Cell Responses to Blood Cancers*
## Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome

**Monday** 10:30 a.m. – 11:45 a.m.  
Room 31  
San Diego Convention Center

*Scientific Committee on Blood Disorders in Childhood*

**Chair:** NATASHA ARCHER, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Boston, MA

**Speakers:**
- JORDAN SHAVIT, MD, PhD, University of Michigan, Ann Arbor, MI  
  *Genetics of Thrombosis*
- PAVEL DAVIZON-CASTILLO, MD, University of Colorado, Denver, Denver, CO  
  *The Role of Inflammation in Thrombosis*
- SUZAN WILLIAMS, MD, Hospital for Sick Children, Toronto, ON, Canada  
  *Post-Thrombotic Syndrome*

## Interplay of Coagulation and Complement in Transfusion Medicine

**Monday** 2:45 p.m. – 4:00 p.m.  
Room 29  
San Diego Convention Center

*Scientific Committee on Transfusion Medicine*

**Chair:** SEAN STOWELL, MD, Harvard University, Boston, MA

**Speakers:**
- SATHEESH CHONAT, MD, Children’s Healthcare of Atlanta, Atlanta, GA  
  *The Role of Complement in Bystander Hemolysis*
- RICK KAPUR, MD, PhD, Sanquin Research, Utrecht, Netherlands  
  *Complement and TRALI*
- DEMIN WANG, PhD, The Blood Research Institute, Milwaukee, WI  
  *Role of Complement in HIT*
**ASH® Clinical Practice Guidelines**

Evidence-based guidelines covering the prevention, diagnosis, and treatment of blood disorders.

The American Society of Hematology (ASH) Clinical Practice Guidelines support clinicians and their patients with hematologic conditions to make decisions about diagnostic and treatment options based on a systematic review of the best available evidence. The guidelines are published in ASH’s open access scientific journal *Blood Advances*.

The guidelines are monitored annually for currency by experts. ASH will revise its guidelines when there is new evidence that could substantially change published recommendations.

**Mobile Access to Guidelines and Pocket Guides**

**ASH Guidelines App:** Easily access all ASH guideline recommendations from the convenience of your smartphone or tablet.

**ASH Pocket Guides App:** Get interactive versions of all the Society’s clinical pocket guides right on your smartphone or tablet, as well as various tools and calculators to aid in clinical decision making.

hematology.org/guidelines

---

**Sickle Cell Disease (SCD)**
- Stem Cell Transplantation
- Cardiopulmonary and Kidney Disease
- Transfusion Support
- Cerebrovascular Disease
- Management of Acute and Chronic Pain

**Venous Thromboembolism (VTE)**
- Treatment
- Prophylaxis in Medical Patients
- Prevention in Surgical Patients
- Diagnosis
- Anticoagulation Therapy
- Heparin-Induced Thrombocytopenia (HIT)
- Pregnancy
- Pediatrics
- Cancer Thrombophilia Testing
- VTE Guidelines Adapted for Latin America
- Anticoagulation in Patients with COVID-19

**Immune Thrombocytopenia (ITP)**

**Von Willebrand Disease (VWD)**
- Diagnosis
- Management

**Acute Myeloid Leukemia (AML)**
- Treatment of Newly Diagnosed Acute Myeloid Leukemia in Older Adults

**Coming Soon:**
- Aplastic Anemia
- Acute Lymphoblastic Leukemia in Adolescents and Young Adults
- Amyloidosis
SCIENTIFIC SYMPOSIA

The Scientific Symposia features transformative basic, translational, and clinical research poised to advance the field of hematology. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Alternative Immune Effector Cells

<table>
<thead>
<tr>
<th>Saturday</th>
<th>2:00 p.m. – 3:15 p.m.</th>
<th>Room 6DE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Fabiana Perna, MD, PhD, Moffitt Cancer Center, Indianapolis, IN

Speakers:

Evan Weber, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
Optimizing Use of Immune Effector Cells

Marie Bleakley, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
Advances in TCR Based Therapeutics for Hematologic Malignancies

SUNDAY

The Impact of the Microbiota on Immunotherapy of Hematological Malignancies

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
<th>Room 25</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA

Speakers:

Ami S. Bhatt, MD, PhD, Stanford University, Stanford, CA
Microbiota and the Development of Hematological Malignancies

Marcel R.M. Van den Brink, MD, PhD, Memorial Sloan Kettering Cancer Center, New York
Microbiota’s Impact on Stem Cell Transplant Outcomes and GVHD

Kate A. Markey, MBBS, PhD, FRACP, MPH, Fred Hutchinson Cancer Center, Seattle, WA
The Role of the Microbiota on Hemopoiesis and Immune Reconstitution after Therapy

Understanding Sickle Cell Pathophysiology

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
<th>Room 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Payal Desai, MD, Wake Forest University, Charlotte, NC

Speakers:

Enrico M Novelli, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
The Role of Heme in Acute and Chronic Sickle Cell Complications

Lucia De Franceschi, MD, University of Verona & AOUI Verona, Policlinico GB Rossi, Verona, Italy
The Role of Complement Activation in Complications of Sickle Cell Disease

Jeffrey Chalmers, PhD, The Ohio State University, Columbus, OH
Novel Testing Techniques in SCD

of interest to PhD attendees. CME credit is not offered.
MONDAY

Multi-Omics Driven Precision Hematology

<table>
<thead>
<tr>
<th>Monday</th>
<th>2:45 p.m. – 4:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 30</td>
<td></td>
</tr>
<tr>
<td>San Diego Convention Center</td>
<td></td>
</tr>
</tbody>
</table>

Chair: Pamela S. Becker, MD, PhD, City of Hope, Duarte, CA

Speakers:
- Jun J. Yang, PhD, St. Jude Children’s Research Hospital, Memphis, TN
  *Innovations in Precision Medicine Approaches to Hematologic Malignancies: Beyond NextGen Sequencing*
- Mika Kontro, MD, PhD, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
  *Functional Screening for Precision Medicine Approaches in Acute Myeloid Leukemia*
- Pamela S. Becker, MD, PhD, City of Hope, Duarte, CA
  *Precision Medicine Approaches to Rare Blood Disorders*

Special Symposium on the Basic Science in Hemostasis and Thrombosis

<table>
<thead>
<tr>
<th>Monday</th>
<th>4:30 p.m. – 6:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 30</td>
<td></td>
</tr>
<tr>
<td>San Diego Convention Center</td>
<td></td>
</tr>
</tbody>
</table>

Co-Chairs:
- Denise E. Sabatino, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
- Herve Falet, PhD, Versiti Blood Research Institute, Milwaukee, WI
- Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

Speakers:
- Caterina Casari, PhD, University Paris-Saclay, Le Kremlin-Bicêtre, France
  *Antibody-Based Strategies As Potential New Treatments for Von Willebrand Disease*
- Matthew J. Flick, PhD, University of North Carolina, Chapel Hill, NC
  *Novel Mechanisms for Targeting Fibrin(ogen) to Suppress Thrombosis*
- Marie Lordkipanidze, Research Center, Montreal Heart Institute, Montreal, Quebec, Canada
  *Platelets As Biomarkers and Vectors of Neuroactive Agents*
The Scientific Spotlight sessions are crowdsourced from the hematology community and cover niche topic areas that are of interest to specific communities. Sessions will be held Sunday, December 10, through Monday, December 11. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

### SUNDAY

#### Immunometabolism as a Tool to Advance Cell Therapy

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Room 11</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Co-Chairs:**

Greg Delgoffe, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA  
May Daher, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

**Speakers:**

May Daher, MD, The University of Texas MD Anderson Cancer Center, Houston, TX  
Metabolic Reprogramming to Enhance the Anti-tumor Activity of Adoptive Cell Therapy

Greg Delgoffe, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA  
Intersection of Metabolism and Immunity in Cancer

#### Tackling Greater Burden of Multiple Myeloma in African American Patients

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Room 6B</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Co-Chairs:**

Yvonne Efegbe, MD, OhioHealth, Columbus, OH  
Srinivas Devarakonda, MD, Louisiana State University Health, Columbus, OH

**Speakers:**

Yvonne Efegbe, MD, OhioHealth, Columbus, OH  
Interplay of Healthcare Access and Outcomes in Multiple Myeloma

Srinivas Devarakonda, MD, Louisiana State University Health, Columbus, OH  
Redesigning Clinical Trials in Multiple Myeloma - Need of the Hour

---

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

* of interest to PhD attendees.
MONDAY

**Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma**

**Monday 10:30 a.m. – 11:45 a.m.**
Grand Hall D
Manchester Grand Hyatt, San Diego

**Co-Chairs:**
RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada
LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD

**Speakers:**
RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada
Divide and Conquer: The Emerging Molecular Subdivisions of BL

LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD
Genome-wide Association Study of Burkitt Lymphoma: Insights About Host Genetic Architecture and Risk

**The Mysteries of Factor XI**

**Monday 2:45 p.m. – 4:00 p.m.**
Room 31
San Diego Convention Center

**Co-Chairs:**
DAVID GAILANI, MD, Vanderbilt University, Nashville, TN
OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel

**Speakers:**
DAVID GAILANI, MD, Vanderbilt University, Nashville, TN
Mechanistic Understanding of Factor XI inhibitors

OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel
Conundrums of Factor XI Deficiency
Leaders in Cellular Therapy Care & Research

The physician scientists at the University of Chicago Medicine are world renowned for cellular therapy research and clinical care. As leaders in stem cell transplantation, cellular therapies, and clinical trials, they continue to discover breakthrough treatments and therapeutic approaches for patients.

OUTCOMES & QUALITY

• The 2020, 2021 and 2022 CIBMTR® Annual report results showed that UChicago Medicine had the best one-year outcomes in Chicago and the highest relative to their predicted outcomes.

• Our pediatric program at Comer Children’s Hospital also ranked highly, with actual survival numbers surpassing predicted outcomes.

SOLID TUMOR & BLOOD CANCER TRIALS

• Our portfolio of clinical trials for patients with hematologic malignancies is one of the largest in the country.

• We have some of the latest Phase I and II trials and our portfolio also has extensive solid tumor cell therapy trials, which are showing promising results. These targeted therapies have wide applicability across various tumor types.

TRANSPLANT OPTIMIZATION PROGRAM FOR OLDER ADULTS

• The Transplant Optimization Program (TOP) at UChicago Medicine plays a vital role in addressing hematopoietic cell transplantation treatment options for older adults.

• For patients that are at least 60 years old, our TOP clinic provides a personalized supportive care plan including a multidisciplinary team approach that fosters more successful outcomes.

AYA EXPERTS

• Adolescents and young adults (AYA) often confront different personal, psychosocial and medical challenges.

• Our nationally known AYA team includes pediatric and adult hematologists/oncologists, dedicated nurse practitioners, social workers, psychologists and physical therapists who work collaboratively to provide a comprehensive, one-stop model of care for young adults (ages 15-39) in significant life transition.

JONAS CENTER FOR CELLULAR THERAPY

• Physicians and scientists at the David and Etta Jonas Center for Cellular Therapy are working to develop novel cellular therapy products for hematologic malignancies and solid tumors. This team is aided by the state-of-the-art Advanced Cellular Therapeutics Facility (ACTF).

• The ACTF is a 10,000 square feet facility dedicated to both manufacturing cells for existing therapies, but also for developing and scaling up new cellular therapies from investigator-initiated and pharmaceutical company sponsored clinical trials for blood cancers, solid tumors, and benign conditions such as sickle cell disease.

SPECIALIZED HIGH-RISK CLINICS

• Our newly launched High-Risk Lymphoma and Complex Leukemias Clinics provide the full spectrum of treatments for the most complex cases, including options not widely available at most hospitals.

• These aggressive cancers require prompt, focused care from a team of highly skilled interdisciplinary specialists, which is why we created these clinics to meet the unique needs of patients.

Learn more at UChicagoMedicine.org/cellular-therapy
The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops at no additional fee.

**Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology**

**2:00 p.m. – 5:00 p.m.**
**Room 33**
**San Diego Convention Center**

**Co-Chair:**
**Arushi Khurana**, MBBS, Virginia Commonwealth University, Rochester, MN

**Alain E. Mast**, MD, PhD, Blood Center of Wisconsin, Milwaukee, WI

2:00 p.m. – 2:05 p.m. Opening Remarks
2:05 p.m. – 3:00 p.m. Current State and Anticipated Barriers in Increasing DEI in Hematology Clinical Trials
3:00 p.m. – 3:55 p.m. Setting Realistic Goals for DEI in Hematology Trials
3:55 p.m. – 4:55 p.m. Tools for Enhancing DEI in Hematology Trials
4:55 p.m. – 5:00 p.m. Closing Remarks

**Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology**

**2:00 p.m. – 5:00 p.m.**
**Room 28 A-D**
**San Diego Convention Center**

**Co-Chairs:**
**Piers Blombery**, PhD, MBBS, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

**Bruno Fattizzo**, MD, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Milano, Italy

**Torsten Hafelbach**, MD, PhD, MLL Munich Leukemia Laboratory, Munich, Germany

**Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure**

**2:00 p.m. – 5:00 p.m.**
**Room 29**
**San Diego Convention Center**

**Co-Chairs:**
**Lucy Godley**, MD, PhD, University of Chicago Medical Center, Chicago, IL

**Marcin W. Wlodarski**, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

**Irina Murakhovskaya**, MD, Montefiore Medical Center, Brooklyn, NY

2:00 p.m. – 2:05 p.m. Opening Remarks
2:05 p.m. – 2:30 p.m. Diagnostic Testing in Classical Hematologic Disorders
3:20 p.m. – 4:25 p.m. Translational Molecular Diagnostics
4:25 p.m. – 4:55 p.m. Molecular Hematology Case-Based Discussion
4:55 p.m. – 5:00 p.m. Closing Remarks

**Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure**

2:00 p.m. – 2:01 p.m. Opening Remarks
2:01 p.m. – 2:42 p.m. Preclinical Development of Model Systems and Organisms
2:42 p.m. – 2:58 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 1
2:58 p.m. – 3:14 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 2
3:14 p.m. – 3:30 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 3
3:37 p.m. – 4:18 p.m. Germline Predisposition That Intersects With Lymphoid Malignancies, Solid Tumors, and DNA Repair Pathways

of interest to PhD attendees. CME credit is not offered.
Friday 08 Dec 2023

### Scientific Workshops

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Scientific Workshop on Hematology and Aging

**2:00 p.m. – 5:00 p.m.**

**Room 11**

**San Diego Convention Center**

**Co-Chairs:**

**Ashley E Rosko, MD**, The Ohio State University, Columbus, OH

**Megan Weivoda, PhD**, Mayo Clinic, Rochester, MN

- **2:00 p.m. – 2:05 p.m.** Opening Remarks
- **2:05 p.m. – 2:45 p.m.** Biomarkers of Biological Aging in Hematologic Malignancies
- **2:45 p.m. – 3:20 p.m.** Gauging Response of BiTes and CAR-T in Aging Adults
- **3:30 p.m. – 4:20 p.m.** Mechanisms of Microbiome-Immune Cross talk in Hematologic Disorders
- **4:20 p.m. – 4:58 p.m.** Mechanisms By Which Cell Stress Drives Aging vs Malignant Adaptation
- **4:58 p.m. – 5:00 p.m.** Closing Remarks

### Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Worms to Patients

**2:00 p.m. – 5:00 p.m.**

**Room 24**

**San Diego Convention Center**

**Co-Chairs:**

**Marina Y. Konopleva, MD, PhD**, Albert Einstein College of Medicine, Bronx, NY

**Aaron D. Schimmer, MD, PhD**, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

- **2:00 p.m. – 2:10 p.m.** Opening Remarks
- **2:10 p.m. – 2:55 p.m.** Mitochondrial and Metabolism - Fundamental Discovery and Model Organisms
- **3:05 p.m. – 3:50 p.m.** Translational Research - Targeting Mitochondria and Metabolism in Cancer
- **4:10 p.m. – 4:55 p.m.** Mitochondria and Metabolism - Blood Cancer Clinical Trials
- **4:55 p.m. – 5:00 p.m.** Closing Remarks

### Scientific Workshop on Myeloid Development

**2:00 p.m. – 5:00 p.m.**

**Room 6CF**

**San Diego Convention Center**

**Co-Chairs:**

**Patricia Ernst, PhD**, University of Colorado Denver, Aurora, CO

**Ulrich Steidl, MD, PhD**, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY

- **2:00 p.m. – 2:03 p.m.** Opening Remarks
- **2:03 p.m. – 2:45 p.m.** Stem Cell Biology
- **2:45 p.m. – 3:33 p.m.** Signaling and Development
- **3:33 p.m. – 4:15 p.m.** Myeloid Malignancies
- **4:15 p.m. – 4:57 p.m.** Gene Regulation in Myeloid Differentiation
- **4:57 p.m. – 5:00 p.m.** Closing Remarks
Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

2:00 p.m. – 5:00 p.m.
Room 7
San Diego Convention Center

Co-Chairs:

Christina Glytsou, PhD, Rutgers University, Newark, NJ
Panagiotis Ntziachristos, PhD, Ghent University, Ghent, Belgium
Daniel T. Starczynowski, PhD, University of Cincinnati College of Medicine, Cincinnati, OH

2:00 p.m. – 2:01 p.m. Opening Remarks
2:01 p.m. – 2:45 p.m. Epigenetic and Chromatin Mechanisms Implicated in Therapy Resistance
2:45 p.m. – 3:29 p.m. Post-Transcriptional Mechanisms Controlling Therapy Response
3:29 p.m. – 4:14 p.m. Post-Translational Underpinnings of Therapy Response and Resistance to Therapy
4:14 p.m. – 4:59 p.m. Metabolic Mechanisms and Mitochondria Biology Behind Therapy Resistance
4:59 p.m. – 5:00 p.m. Closing Remarks

Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities

2:00 p.m. – 5:00 p.m.
Room 8
San Diego Convention Center

Co-Chairs:

Maher K. Gandhi, PhD, University of Queensland Diamantina Institute, Brisbane, QLD, Australia
Helen Elisabeth Heslop, MD, DSc (Hon), Baylor College of Medicine, Houston, TX
Rayne Rouce, MD, BS, Texas Children’s Hospital, Houston, TX
Keri Toner, MD, Children’s National Hospital, Washington, DC

2:00 p.m. – 2:03 p.m. Opening Remarks
2:03 p.m. – 2:43 p.m. Background to Virally Driven Lymphoproliferative Disorders
2:43 p.m. – 3:33 p.m. Emerging Vulnerabilities in Special Populations
3:33 p.m. – 4:13 p.m. The Landscape of Viral Reactivation After Transplantation
4:13 p.m. – 4:53 p.m. Anti-Viral Cellular Immunotherapies
4:53 p.m. – 5:00 p.m. Closing Remarks
2023 ASH Annual Meeting Webcasts

Get access to more than 400 hours of recorded content from the 2023 ASH Annual Meeting, including oral abstract sessions.

### WEBCAST PACKAGES AVAILABLE FOR PURCHASE

<table>
<thead>
<tr>
<th>Included Sessions</th>
<th>WEBCAST PACKAGES</th>
<th>Poster Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Invited Program Plus Oral Abstracts</td>
<td>Invited Program</td>
</tr>
<tr>
<td>Education Program*</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>General Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Special-Interest Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Trainee Didactic Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Oral Abstract Sessions*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note that webcast packages do not include the poster sessions.

* Please note that the oral abstract sessions are only included as part of the Invited Program Plus Oral Abstracts webcast package.

### WEBCAST PURCHASE PRICING

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>BEST VALUE</th>
<th>Invited Program Plus Oral Abstracts</th>
<th>Invited Program</th>
<th>Education Program Only</th>
<th>Scientific Program Only</th>
<th>Poster Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active or International Member</td>
<td>$450</td>
<td>$350</td>
<td>$250</td>
<td>$250</td>
<td>$250</td>
<td>$99</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$650</td>
<td>$550</td>
<td>$350</td>
<td>$350</td>
<td>$350</td>
<td>$125</td>
</tr>
<tr>
<td>Associate, International Associate, Medical Student, Graduate Student, or Resident Member</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
<td></td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
<td></td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$650</td>
<td>$550</td>
<td>$350</td>
<td>$350</td>
<td>$25</td>
<td></td>
</tr>
<tr>
<td>Honorary/Emeritus Member</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
<td></td>
</tr>
</tbody>
</table>

SPECIAL CONFERENCE PRICES
ASH STORE — SAILS PAVILION, UPPER LEVEL
ASH POSTER WALKS

ASH Poster Walks as of October 24, 2023.

The ASH Poster Walks highlight posters selected for the Annual Meeting that showcase emerging science in hematology. Two of the Poster Walks will take place as in-person sessions in the Blood Journals Studio during the Annual Meeting, while four will take place virtually following the Annual Meeting.

ASH Poster Walks are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CME credit is not offered.

SATURDAY

ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH (for in-person participants)

4:00 p.m. – 5:00 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Co-Chairs:
MARIE HOLLENHORST, MD, PhD, Brigham and Women’s Hospital, Boston, MA
Harvard Medical School, Boston, MA

Chair:
LISA BAUMANN KREUZIGER, MD, MS, Versiti, Menomonee Falls, WI

SUNDAY

ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia (for in-person participants)

4:30 p.m. – 5:30 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Chair:
KLAUS METZELER, MD, University of Leipzig, Germany, Leipzig, Germany

ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia

10:00 a.m. – 11:00 a.m.
Virtual Program

Chair:
KARUN NEUPANE, MD, MBBS, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY

ASH Poster Walk on What’s Hot in Sickle Cell Disease Clinical Research in 2023

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
ELIZABETH KLINGS, MD, Boston University, Boston, MA

THURSDAY

ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology

10:00 a.m. – 11:00 a.m.
Virtual Program

Co-Chairs:
ELNA SAAH, MD, Emory School of Medicine, Atlanta, GA

ASH Poster Walk on Time to Examine Time Toxicity in Hematology

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
RAHUL BANERJEE, MD, Fred Hutchinson Cancer Center, Seattle, WA
Share Your Expertise Treating R/R AML With a FLT3 Mutation

What should your patient’s next step be?

Compare your approach at BOOTH 2311

AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; R/R=relapsed or refractory.

Not a real patient.
MEET THE SCIENTIST

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

Ticket Prices (per session)

- Active or Internationa Member: $75
- Non-Member: $75
- Associate, International Associate, Resident, or Graduate/Medical Student, or honorary/Emeritus Member: $50
- Non-Member in Training: $50
- Allied Health Professional: $50
- Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

SATURDAY

**Genome Engineering for Enhanced Blood Cancer Immunotherapy (for in-person participants)**

**Saturday** 8:00 a.m. – 9:00 a.m.
Aqua 314
Hilton San Diego Bayfront

**Speaker:**
CARL JUNE, MD, University of Pennsylvania, Philadelphia, PA
*Genome Engineering for Enhanced Blood Cancer Immunotherapy*

**Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle (for in-person participants)**

**Saturday** 8:00 a.m. – 9:00 a.m.
Aqua 313
Hilton San Diego Bayfront

**Speaker:**
ADETOLE A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN
*Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle*

**Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (for in-person participants)**

**Saturday** 8:00 a.m. – 9:00 a.m.
Aqua 300
Hilton San Diego Bayfront

**Speaker:**
LAURA PASQUALUCCI, MD, Columbia University, New York, NY
*Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies*
SUNDAY

**Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes (for in-person participants)**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| Sunday | 8:00 a.m. – 9:00 a.m. | Aqua 314          | **Jean Soulier**, MD, University of Paris, Saint-Louis Hospital, Paris, France  
**Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes** |

**Natural Killer Cells: A New Frontier for Cancer Immunotherapy (for in-person participants)**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| Sunday | 8:00 a.m. – 9:00 a.m. | Aqua 300          | **Katayoun Rezvani**, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX  
**Natural Killer Cells: A New Frontier for Cancer Immunotherapy** |

**Research in Complications Sickle Cell Disease (for in-person participants)**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| Sunday | 8:00 a.m. – 9:00 a.m. | Aqua 313          | **Oyebi Adesina**, MD, MS, University of California, Mountain View, CA  
Research in Complications Sickle Cell Disease  
**The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression (for in-person participants)**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| Sunday | 8:00 a.m. – 9:00 a.m. | Aqua 311          | **Mitchell Weiss**, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN  
The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression |

CME credit is not offered.
For the 65th ASH Annual Meeting, abstracts were submitted in 66 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number. Oral Abstract Sessions’ titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.

### 2023 SCIENTIFIC CATEGORIES

#### 100s—Red Cell Physiology and Disorders
- **101** Red Cells and Erythropoiesis, Excluding Iron
- **102** Iron Homeostasis and Biology
- **112** Thalassemia and Globin Gene Regulation
- **113** Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
- **114** Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

#### 200s—Leukocytes, Inflammation, and Immunology
- **201** Granulocytes, Monocytes, and Macrophages
- **203** Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

#### 300s—Hemostasis, Thrombosis, and Vascular Wall Biology
- **301** Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
- **311** Disorders of Platelet Number or Function: Clinical and Epidemiological
- **321** Coagulation and Fibrinolysis: Basic and Translational
- **322** Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
- **331** Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological
- **332** Thrombosis and Anticoagulation: Clinical and Epidemiological

#### 400s—Transfusion Medicine
- **401** Blood Transfusion

#### 500s—Hematopoiesis
- **501** Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
- **503** Clonal Hematopoiesis, Aging and Inflammation
- **506** Bone Marrow Microenvironment
- **508** Bone Marrow Failure: Acquired
- **509** Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

#### 600s—Hematologic Malignancy
- **602** Myeloid Oncogenesis: Basic
- **603** Lymphoid Oncogenesis: Basic
- **604** Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
- **605** Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
- **612** Acute Lymphoblastic Leukemias: Clinical and Epidemiological
- **613** Acute Myeloid Leukemias: Clinical and Epidemiological
- **614** Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
- **615** Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
- **616** Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
- **617** Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
618 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

621 Lymphomas: Translational—Molecular and Genetic

622 Lymphomas: Translational—Non-Genetic

623 Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological

624 Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological

626 Aggressive Lymphomas: Prospective Therapeutic Trials

627 Aggressive Lymphomas: Clinical and Epidemiological

631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational

632 Chronic Myeloid Leukemia: Clinical and Epidemiological

634 Myeloproliferative Syndromes: Clinical and Epidemiological

636 Myelodysplastic Syndromes—Basic and Translational

637 Myelodysplastic Syndromes—Clinical and Epidemiological

641 Chronic Lymphocytic Leukemias: Basic and Translational

642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological

651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

652 Multiple Myeloma: Clinical and Epidemiological

653 Multiple Myeloma Prospective Therapeutic Trials

654 MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological

700s—Transplantation and Adoptive Cell Therapies

701 Experimental Transplantation: Basic and Translational

703 Cellular Immunotherapies: Basic and Translational

704 Cellular Immunotherapies: Early Phase and Investigational Therapies

705 Cellular Immunotherapies: Late Phase and Commercially Available Therapies

711 Cell Collection and Processing

721 Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities

722 Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution

723 Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence

731 Autologous Transplantation: Clinical and Epidemiological

732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

800s—Gene Therapies, Chemical Biology, and Emerging Diagnostics

801 Gene Therapies

802 Chemical Biology and Experimental Therapeutics

803 Emerging Tools, Techniques and Artificial Intelligence in Hematology

900s—Health Services, Quality Improvement, and Outcomes Research

901 Health Services and Quality Improvement—Non-Malignant Conditions

902 Health Services and Quality Improvement—Lymphoid Malignancies

903 Health Services and Quality Improvement—Myeloid Malignancies

904 Outcomes Research—Non-Malignant Conditions

905 Outcomes Research—Lymphoid Malignancies

906 Outcomes Research—Myeloid Malignancies
Breakthrough Discoveries. Life-Changing Results.

City of Hope® is renowned for rapidly translating hematologic breakthroughs into lifesaving treatment. A leader in treating blood cancers and improving outcomes for patients, we deliver world-class, personalized care to patients from all over the United States and the world.

Visit us at Booth 2204 during the 2023 ASH Annual Meeting.

CityofHope.org/ash23
ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 9, through Monday, December 11. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter.

The Plenary Scientific Session will be held Sunday, September 10, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt
All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

SATURDAY

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions

Room 25

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease (13–18)
Room 29

321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies (19–24)
Room 33

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders (25–30)
Room 30

Room 24

603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression (37–42)
Marriott Grand Ballroom 11-13

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies (43–48)
Ballroom 20CD

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma (49–54)
Grand Hall D

Pacific Ballroom Salons 21-22

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response (61–66)
Pacific Ballroom Salons 24-26

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL (67–72)
Seaport Ballroom EFGH

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies (73–78)
Ballroom 20AB

641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation (79–84)
Grand Hall B

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment (85–90)
Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications (91–96)
Seaport Ballroom ABCD

703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights (97–102)
Room 6DE

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data (103–108)
Room 6A

Room 11

802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders (115–120)
Marriott Grand Ballroom 8-9

Oral Abstract Sessions CME credit is not offered.
ORAL ABSTRACT SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology (121–126)
San Diego Ballroom AB

902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data (127–132)
Marriott Grand Ballroom 2-4

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors (145–150)
Room 31

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity (151–156)
San Diego Ballroom AB

Room 6A

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics (163–168)
Pacific Ballroom Salons 24-26

621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc. (169–174)
Ballroom 20AB

622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma (175–180)
Seaport Ballroom ABCD

Grand Hall B

627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas (187–192)
Grand Hall C

Pacific Ballroom Salons 18-19

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation (199–204)
Grand Hall D

653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma (205–210)
Harbor Ballroom

904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients (133–138)
Pacific Ballroom Salons 18-19

Seaport Ballroom EFGH

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies (217–222)
Room 6B

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors (223–228)
Room 6CF

Marriott Grand Ballroom 5-6

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship From Clinical Trials And Observations (235–240)
Room 7

903. Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies (259–264)
Hall A

905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data (265–270)
Pacific Ballroom Salons 21-22
4:00 p.m. – 5:30 p.m.  Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease (271–276)  
Room 28 A-D

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias (277–282)  
Room 33

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care (283–288)  
Room 30

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control (289–294)  
Room 6CF

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL (295–300)  
Seaport Ballroom ABCD

Grand Hall B

Grand Hall C

636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications (313–318)  
Pacific Ballroom Salons 21-22

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS (319–324)  
Pacific Ballroom Salons 18-19

Grand Hall D

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment (331–336)  
Seaport Ballroom EFGH

652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics (337–342)  
Harbor Ballroom

Room 7

Room 6A

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity (355–360)  
Room 6B

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes (361–366)  
Room 11

901. Health Services and Quality Improvement – Non-Malignant Conditions: Access to Quality Care in Classical Hematology (367–372)  
Marriott Grand Ballroom 2-4

903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies (373–378)  
Pacific Ballroom Salons 15-17

Hall A

Marriott Grand Ballroom 11-13

9:30 a.m. – 11:00 a.m.  Oral Abstract Sessions

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes (391–396)  
Room 30

Room 24

602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms (403–408)  
Marriott Grand Ballroom 11-13

Pacific Ballroom Salons 24-26
### ORAL ABSTRACT SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited. All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt. All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

<table>
<thead>
<tr>
<th>Room</th>
<th>ORAL ABSTRACT SESSIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>506. Bone Marrow Microenvironment</strong>: Bone Marrow Microenvironment in Health and Disease (511–516)</td>
<td>Room 11</td>
</tr>
<tr>
<td><strong>621. Lymphomas</strong>: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma (523–528)</td>
<td>Harbor Ballroom</td>
</tr>
<tr>
<td><strong>301. Vasculature, Endothelium, Thrombosis and Platelets</strong>: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis (499–504)</td>
<td>Room 28 A-D</td>
</tr>
<tr>
<td><strong>322. Disorders of Coagulation or Fibrinolysis</strong>: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan (505–510)</td>
<td>Room 29</td>
</tr>
<tr>
<td><strong>508. Bone Marrow Failure</strong>: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials (571–576)</td>
<td>Room 7</td>
</tr>
<tr>
<td><strong>112. Thalassemia and Globin Gene Regulation</strong>: Finding New Pathways to Treat Thalassemia (553–558)</td>
<td>Room 31</td>
</tr>
<tr>
<td>**113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans (559–564)</td>
<td>Room 33</td>
</tr>
<tr>
<td><strong>617. Acute Myeloid Leukemias</strong>: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response (421–426)</td>
<td>Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td><strong>626. Aggressive Lymphomas</strong>: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma (433–438)</td>
<td>Seaport Ballroom ABCD</td>
</tr>
<tr>
<td><strong>632. Chronic Myeloid Leukemia</strong>: Clinical and Epidemiological: Treatment-Free Remission and Prognostication (445–450)</td>
<td>Pacific Ballroom Salons 21-22</td>
</tr>
<tr>
<td><strong>651. Multiple Myeloma and Plasma Cell Dyscrasias</strong>: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs (451–456)</td>
<td>Harbor Ballroom</td>
</tr>
<tr>
<td><strong>701. Experimental Transplantation</strong>: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution (457–462)</td>
<td>Room 6B</td>
</tr>
<tr>
<td><strong>703. Cellular Immunotherapies</strong>: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies (463–468)</td>
<td>Room 6A</td>
</tr>
<tr>
<td><strong>722. Allogeneic Transplantation</strong>: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology (475–480)</td>
<td>Marriott Grand Ballroom 2-4</td>
</tr>
<tr>
<td><strong>801. Gene Therapies</strong>: New Approaches From Bench to Bedside (481–486)</td>
<td>Ballroom 20CD</td>
</tr>
<tr>
<td><strong>905. Outcomes Research – Lymphoid Malignancies</strong>: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology (493–498)</td>
<td>San Diego Ballroom AB</td>
</tr>
</tbody>
</table>

**CME credit is not offered.**
ORAL ABSTRACT SESSIONS

Monday

10:30 a.m. – 12:00 p.m.  Oral Abstract Sessions (non-CME)

201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes (673–678)
   Marriott Grand Ballroom

   Room 30

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia (685–690)
   Hall A

   Room 29

   Room 33

508. Bone Marrow Failure: Acquired: Immune AA and VEXAS – Biology, Diagnosis and Treatment (703–708)
   Room 6DE

   Marriott Grand Ballroom

   Pacific Ballroom Salons 15-17

   Room 6B

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL (727–732)
   Room 6A

623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents (733–738)
   Grand Hall B

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context (739–744)
   Ballroom 20AB

   Pacific Ballroom Salons 21-22

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia (631–636)
   Seaport Ballroom ABCD

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States (637–642)
   Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma (643–648)
   Seaport Ballroom EFGH

   Marriott Grand Ballroom 8-9

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification (655–660)
   Marriott Grand Ballroom 5-6

901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders (661–666)
   Pacific Ballroom Salons 15-17

   Marriott Grand Ballroom 2-4

906. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)
   Marriott Grand Ballroom 11-13

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)
   Pacific Ballroom Salons 18-19

   Pacific Ballroom Salons 24-26

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)
   Grand Hall D

623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy (601–606)
   Grand Hall C

   Grand Hall B

   Ballroom 20AB

   Ballroom 20CD

635. Acute Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL (727–732)
   Room 6A

   Pacific Ballroom Salons 24-26

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia (631–636)
   Seaport Ballroom ABCD

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States (637–642)
   Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma (643–648)
   Seaport Ballroom EFGH

   Marriott Grand Ballroom 8-9

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification (655–660)
   Marriott Grand Ballroom 5-6

901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders (661–666)
   Pacific Ballroom Salons 15-17

   Marriott Grand Ballroom 2-4
## ORAL ABSTRACT SESSIONS

**Saturday–Monday 09–11 Dec 2023**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited. All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt. All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

### 2:45 p.m. – 4:15 p.m.

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>634. Myeloproliferative Syndromes: Clinical and Epidemiological:</strong></td>
<td>Ballroom 20CD</td>
</tr>
<tr>
<td>Treatment and Outcomes in MPNs (745–750)</td>
<td></td>
</tr>
<tr>
<td><strong>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational:</strong></td>
<td>Harbor Ballroom</td>
</tr>
<tr>
<td>Advancing Therapies in Multiple Myeloma and Waldenström’s Macroglobulinemia (751–756)</td>
<td></td>
</tr>
<tr>
<td><strong>652. Multiple Myeloma: Clinical and Epidemiological:</strong></td>
<td>Seaport Ballroom EFGH</td>
</tr>
<tr>
<td>Immunological Effects of Sustained Responses in Multiple Myeloma (757–762)</td>
<td></td>
</tr>
<tr>
<td><strong>703. Cellular Immunotherapies: Basic and Translational:</strong></td>
<td>Marriott Grand Ballroom 5-6</td>
</tr>
<tr>
<td>Exploring Novel Platforms for Next-Gen CAR-Based Therapies (763–768)</td>
<td></td>
</tr>
<tr>
<td><strong>901. Health Services and Quality Improvement – Non-Malignant:</strong></td>
<td>Marriott Grand Ballroom 2-4</td>
</tr>
<tr>
<td>Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education (787–792)</td>
<td></td>
</tr>
</tbody>
</table>

### 2:45 p.m. – 4:15 p.m.

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>704. Cellular Immunotherapies: Early Phase and Investigational Therapies:</strong></td>
<td>Room 6CF</td>
</tr>
<tr>
<td>Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas (769–774)</td>
<td></td>
</tr>
<tr>
<td><strong>722. Allogeneic Transplantation:</strong></td>
<td>Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td>Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management (775–780)</td>
<td></td>
</tr>
<tr>
<td><strong>731. Autologous Transplantation:</strong></td>
<td>Pacific Ballroom Salons 18-19</td>
</tr>
<tr>
<td>Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach (781–786)</td>
<td></td>
</tr>
<tr>
<td><strong>902. Health Services and Quality Improvement – Lymphoid Malignancies:</strong></td>
<td>Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td>Improving Processes and Outcomes in Plasma Cell Dyscrasias (907–912)</td>
<td></td>
</tr>
</tbody>
</table>

### 2:45 p.m. – 4:15 p.m.

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Room/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>903. Emerging Tools, Techniques and Artificial Intelligence in Hematology:</strong></td>
<td>Room 6A</td>
</tr>
<tr>
<td>Image-Based Machine Learning in Hematology (901–906)</td>
<td></td>
</tr>
<tr>
<td><strong>906. Outcomes Research – Myeloid Malignancies:</strong></td>
<td>Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td>Symptom Burden and Supportive Therapies (913–918)</td>
<td></td>
</tr>
</tbody>
</table>

---

*Note: CME credit is not offered. Oral Abstract Sessions*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Oral Abstract Sessions</td>
<td></td>
</tr>
<tr>
<td>102.</td>
<td>Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis (919–924)</td>
<td>Room 25</td>
</tr>
<tr>
<td>201.</td>
<td>Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias (931–936)</td>
<td>Room 33</td>
</tr>
<tr>
<td>503.</td>
<td>Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations (937–942)</td>
<td>Room 24</td>
</tr>
<tr>
<td>509.</td>
<td>Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc. (943–948)</td>
<td>Room 7</td>
</tr>
<tr>
<td>613.</td>
<td>Acute Myeloid Leukemias: Clinical and Epidemiological: AML– Molecular Targets, Ethnicity, and Age (955–960)</td>
<td>Pacific Ballroom Salons 24-26</td>
</tr>
<tr>
<td>617.</td>
<td>Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant (973–978)</td>
<td>Pacific Ballroom Salons 15-17</td>
</tr>
<tr>
<td>623.</td>
<td>Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy (979–984)</td>
<td>Grand Hall C</td>
</tr>
<tr>
<td>652.</td>
<td>Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma (1003–1008)</td>
<td>Seaport Ballroom EFGH</td>
</tr>
<tr>
<td>653.</td>
<td>Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma (1009–1014)</td>
<td>Seaport Ballroom ABCD</td>
</tr>
<tr>
<td>704.</td>
<td>Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas (1021–1026)</td>
<td>Room 6A</td>
</tr>
<tr>
<td>705.</td>
<td>Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence (1027–1032)</td>
<td>Room 6CF</td>
</tr>
<tr>
<td>711.</td>
<td>Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells (1033–1038)</td>
<td>Room 6DE</td>
</tr>
<tr>
<td>801.</td>
<td>Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders (1051–1056)</td>
<td>Hall A</td>
</tr>
<tr>
<td>904.</td>
<td>Outcomes Research – Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease (1057–1062)</td>
<td>Marriott Grand Ballroom 8-9</td>
</tr>
<tr>
<td>905.</td>
<td>Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma (1063–1068)</td>
<td>Marriott Grand Ballroom 2-4</td>
</tr>
</tbody>
</table>
The Hematology ASH Education Program 2023 provides review articles from the Education Program at the 2023 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.

### NEW HEMATOLOGY 2023

**NEW PRINT EDITION — FREE SHIPPING**

<table>
<thead>
<tr>
<th>Membership Category</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member - Active and International</td>
<td>$120</td>
</tr>
<tr>
<td>Member - U.S. &amp; International Associate</td>
<td>$100</td>
</tr>
<tr>
<td>Member - Graduate/Medical Student/Resident</td>
<td>$100</td>
</tr>
<tr>
<td>Non-member</td>
<td>$160</td>
</tr>
</tbody>
</table>

ORDER TODAY AT
- ASH STORE onsite
- Hematology.org/store

*Free shipping ends on 12/31/2023.*
POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the San Diego Convention Center, Halls G-H. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Pacific time) each day, as well as access posters from previous days on the virtual platform.

The Poster Hall hours are as follows:
Saturday, December 09 9:00 a.m. – 7:30 p.m.
Sunday, December 10 9:00 a.m. – 8:00 p.m.
Monday, December 11 9:00 a.m. – 8:00 p.m.
Poster Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
### Saturday-Monday, 09–11 Dec 2023

**POSTER PRESENTATIONS**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I</td>
<td>1600–1616</td>
</tr>
<tr>
<td>621. Lymphomas: Translational – Molecular and Genetic: Poster I</td>
<td>1617–1638</td>
</tr>
<tr>
<td>622. Lymphomas: Translational – Non-Genetic: Poster I</td>
<td>1639–1654</td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I</td>
<td>1655–1668</td>
</tr>
<tr>
<td>626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I</td>
<td>1718–1737</td>
</tr>
<tr>
<td>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I</td>
<td>1777–1794</td>
</tr>
<tr>
<td>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I</td>
<td>1795–1811</td>
</tr>
<tr>
<td>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I</td>
<td>1812–1843</td>
</tr>
<tr>
<td>636. Myelodysplastic Syndromes – Basic and Translational: Poster I</td>
<td>1844–1854</td>
</tr>
<tr>
<td>637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I</td>
<td>1855–1884</td>
</tr>
<tr>
<td>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I</td>
<td>1897–1919</td>
</tr>
<tr>
<td>653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I</td>
<td>2005–2024</td>
</tr>
<tr>
<td>654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I</td>
<td>2025–2040</td>
</tr>
<tr>
<td>701. Experimental Transplantation: Basic and Translational: Poster I</td>
<td>2041–2054</td>
</tr>
<tr>
<td>703. Cellular Immunotherapies: Basic and Translational: Poster I</td>
<td>2055–2089</td>
</tr>
<tr>
<td>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I</td>
<td>2090–2117</td>
</tr>
<tr>
<td>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I</td>
<td>2118–2143</td>
</tr>
<tr>
<td>711. Cell Collection and Processing: Poster I</td>
<td>2144–2148</td>
</tr>
<tr>
<td>722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I</td>
<td>2176–2201</td>
</tr>
<tr>
<td>723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Poster I</td>
<td>2202–2213</td>
</tr>
<tr>
<td>731. Autologous Transplantation: Clinical and Epidemiological: Poster I</td>
<td>2214–2227</td>
</tr>
<tr>
<td>732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I</td>
<td>2228–2247</td>
</tr>
<tr>
<td>802. Chemical Biology and Experimental Therapeutics: Poster I</td>
<td>2259–2267</td>
</tr>
<tr>
<td>803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I</td>
<td>2268–2294</td>
</tr>
<tr>
<td>901. Health Services and Quality Improvement – Non-Malignant Conditions: Poster I</td>
<td>2295–2325</td>
</tr>
<tr>
<td>902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I</td>
<td>2326–2345</td>
</tr>
<tr>
<td>903. Health Services and Quality Improvement – Myeloid Malignancies: Poster I</td>
<td>2346–2358</td>
</tr>
<tr>
<td>904. Outcomes Research – Non-Malignant Conditions: Poster I</td>
<td>2359–2384</td>
</tr>
<tr>
<td>906. Outcomes Research – Myeloid Malignancies: Poster I</td>
<td>2423–2442</td>
</tr>
<tr>
<td>TIP1. TIP – Classical Hematology: Poster I</td>
<td></td>
</tr>
<tr>
<td>TIP2. TIP – Transplant/Immunotherapies: Poster I</td>
<td></td>
</tr>
<tr>
<td>TIP3. TIP – Myeloid Malignancies: Poster I</td>
<td></td>
</tr>
<tr>
<td>TIP4. TIP – Lymphoid Malignancies (Including Myeloma): Poster I</td>
<td></td>
</tr>
</tbody>
</table>

### Sunday, December 10, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. – 8:00 p.m.</td>
<td>Poster Session II – Viewing (Non-CME)</td>
</tr>
<tr>
<td>5:30 p.m. – 8:00 p.m.</td>
<td>Poster Session II – Presentations (Non-CME)</td>
</tr>
</tbody>
</table>

**CME credit is not offered. Poster Presentations**
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2577–2597)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (2598–2607)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II (2608–2628)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2637–2658)
401. Blood Transfusion: Poster II (2659–2668)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Clinical and Translational: Poster II (2669–2687)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster II (2688–2699)
506. Bone Marrow Microenvironment: Poster II (2700–2710)
508. Bone Marrow Failure: Acquired: Poster II (2711–2727)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2728–2738)
602. Myeloid Oncogenesis: Basic: Poster II (2739–2766)
603. Lymphoid Oncogenesis: Basic: Poster II (2767–2781)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2782–2807)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2808–2826)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2827–2839)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2840–2867)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2884–2905)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2906–2925)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2926–2968)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2969–2984)
621. Lymphomas: Translational—Molecular and Genetic: Poster II (2985–3006)
622. Lymphomas: Translational—Non-Genetic: Poster II (3007–3021)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3022–3055)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II (3056–3084)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II (3085–3104)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (3105–3144)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3145–3163)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3164–3180)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3181–3211)
635. Myelodysplastic Syndromes—Basic and Translational: Poster II (3212–3225)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II (3226–3253)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II (3254–3265)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3266–3288)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3289–3323)
652. Multiple Myeloma: Clinical and Epidemiological: Poster II (3324–3376)
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II (3377–3396)
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3397–3416)
701. Experimental Transplantation: Basic and Translational: Poster II (3417–3430)
703. Cellular Immunotherapies: Basic and Translational: Poster II (3431–3464)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II (3465–3493)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II (3494–3519)
711. Cell Collection and Processing: Poster II (3520–3524)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II (3525–3550)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II (3551–3576)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II (3577–3591)
731. Autologous Transplantation: Clinical and Epidemiological: Poster II (3592–3603)
732. Autologous Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3604–3622)
801. Gene Therapies: Poster II (3623–3633)
802. Chemical Biology and Experimental Therapeutics: Poster II (3634–3642)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II (3643–3670)
901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster II (3671–3701)
902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II (3702–3719)
903. Health Services and Quality Improvement – Myeloid Malignancies: Poster II (3720–3733)
904. Outcomes Research—Non-Malignant Conditions: Poster II (3734–3759)
905. Outcomes Research—Lymphoid Malignancies: Poster II (3760–3798)
Monday, December 11, 2023

9:00 a.m. – 8:00 p.m.  Poster Session III – Viewing

5:30 p.m. – 8:00 p.m.  Poster Session III – Presentations

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3817–3835)
102. Iron Homeostasis and Biology: Poster III (3836–3845)
112. Thalassemia and Globin Gene Regulation: Poster III (3846–3852)
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (3853–3870)
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (3871–3905)
201. Granulocytes, Monocytes, and Macrophages: Poster III (3906–3918)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3919–3931)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III (3932–3950)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3951–3970)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3971–3979)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III (3980–4000)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4010–4031)
401. Blood Transfusion: Poster III (4032–4040)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4041–4058)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster III (4059–4070)
506. Bone Marrow Microenvironment: Poster III (4071–4081)
508. Bone Marrow Failure: Acquired: Poster III (4082–4098)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4099–4110)
602. Myeloid Oncogenesis: Basic: Poster III (4111–4137)
603. Lymphoid Oncogenesis: Basic: Poster III (4138–4151)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4198–4209)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4210–4237)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4254–4276)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4296–4339)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4340–4356)
621. Lymphomas: Translational—Molecular and Genetic: Poster III (4357–4378)
622. Lymphomas: Translational—Non-Genetic: Poster III (4379–4393)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4394–4427)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III (4457–4475)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4476–4513)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4514–4533)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4534–4550)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4551–4581)
636. Myelodysplastic Syndromes—Basic and Translational: Poster III (4582–4593)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III (4594–4621)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III (4622–4633)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4634–4657)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4658–4692)
652. Multiple Myeloma: Clinical and Epidemiological: Poster III (4693–4745)
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster III (4746–4765)
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4766–4785)
701. Experimental Transplantation: Basic and Translational: Poster III (4786–4799)

703. Cellular Immunotherapies: Basic and Translational: Poster III (4800–4834)

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4835–4863)

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4864–4889)

711. Cell Collection and Processing: Poster III (4890–4894)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III (4895–4921)

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4922–4947)

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4948–4961)

731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4962–4974)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4975–4993)

801. Gene Therapies: Poster III (4994–5004)

802. Chemical Biology and Experimental Therapeutics: Poster III (5005–5013)

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (5014–5040)

901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster III (5041–5071)

902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster III (5072–5090)

903. Health Services and Quality Improvement - Myeloid Malignancies: Poster III (5091–5105)

904. Outcomes Research—Non-Malignant Conditions: Poster III (5106–5131)

905. Outcomes Research—Lymphoid Malignancies: Poster III (5132–5170)

906. Outcomes Research—Myeloid Malignancies: Poster III (5171–5191)
Select Inclusion Criteria¹,²*

For both cohorts:
- Patients ≥18 years of age with a diagnosis of CML-CP
- No previous accelerated phase or blast crisis
- No T315I mutation at any time prior to study entry

For 2L patient cohort:
- Warning or failure with 1L TKI therapy at the time of screening
  - Warning is defined as:
    - BCR::ABL1 IS >1% to 10% 6 months after treatment initiation
    - BCR::ABL1 IS >0.1% to 1% 12 months after treatment initiation
  - Treatment failure with/resistance to 1L TKI is defined as:
    - BCR::ABL1 IS >10% if 1L treatment duration between 6 and 12 months
    - BCR::ABL1 IS >1% if 1L treatment duration is longer than 12 months
    - Loss of MMR beyond 12 months after treatment initiation²
  - Treatment intolerance of 1L TKI and BCR::ABL1 IS >0.1% at screening²

For 1L patient cohort:
- Patients with newly diagnosed CML-CP (treatment with 1 prior TKI [imatinib, dasatinib, nilotinib, or bosutinib] for ≤4 weeks is allowed)

Study Design²

Primary endpoint: MMR at 12 months in 2L cohort

Safety follow-up

If a new mutation is detected by exploratory NGS assay without treatment failure, the patient may continue on the study at the same dose (unless meeting dose escalation criteria) or discontinue from the study treatment as per the investigator’s decision.

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

References:
FRIDAY MORNING SYMPOSIA
7:00 A.M. – 10:00 A.M.

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice (for in-person participants)

7:00 a.m. – 10:00 a.m.
Room 6CF
San Diego Convention Center

This program is provided by the Cleveland Clinic, The Aplastic Anemia and MDS International Foundation.

Chair:
Sudipto Mukherjee, MD, PhD, MPH, Cleveland Clinic, Cleveland, OH

Speakers:
Uma M. Borate, MBBS, MS, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Austin Kulasekaraj, MD, PhD, MPH, King’s College Hospital, London, United Kingdom
Esther Natalie Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
Kristen Marie Pettit, MD, C.S. Mott Children’s Hospital, Ann Arbor, MI
Abhay Singh, MD, MPH, Cleveland Clinic, Cleveland, OH

Contact: Kristin Bower
Email: bowerk@ccf.org

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

7:00 a.m. – 10:00 a.m.
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

This program is provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC and supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Chair:
Brian T. Hill, MD, PhD, Cleveland Clinic, Cleveland, OH

Speakers:
Danielle M. Brande, MD, Duke Cancer Center, Durham, NC
Deborah M. Stephens, DO, University of Utah, Salt Lake City, UT

Contact: Ishana Fleurant
Email: Ifleurant@clinicaloptions.com
BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)

**7:00 a.m. – 10:00 a.m.**
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck, and Seagen Inc.

**Chair:**
Neil Love, MD, Research To Practice, Key Biscayne, FL

**Speakers:**
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN
Nancy L. Bartlett, MD, Washington University School of Medicine, Saint Louis, MO
Jonathan B. Cohen, MD, MS, Winship Cancer Institute, Emory University, Atlanta, GA
Jonathan W. Friedberg, MD, MMSc, University of Rochester, Rochester, NY
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Medical Crossfire™ Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

**7:00 a.m. – 10:00 a.m.**
Room 6B
San Diego Convention Center

This program is provided by Physicians Education Resources, LLC and supported by Lilly, Merck & Co., Inc., and Pharmacyclics.

**Chair:**
Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

**Speakers:**
Catherine C. Coombs, MD, University of California Irvine, Irvine, CA
Paolo Strati, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Steven P. Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Myelodysplastic Syndromes 2023: What’s New?

**7:00 a.m. – 10:00 a.m.**
San Diego Ballroom AB
Marriott Marquis San Diego Marina

This program is provided and supported by MDS Foundation, Inc.

**Co-Chairs:**
René Buckerstein, MD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

**Speakers:**
Mario Cazzola, MD, University of Pavia, Pavia, Italy
Matteo Giovanni Della Porta, MD, Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

7:00 a.m. – 10:00 a.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

Chair:
Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA

Speaker:
Craig Emmitt Cole, MD, Michigan State University, East Lansing, MI

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

7:00 a.m. – 10:00 a.m.
Pacific Ballroom Salons 15-17
Marriott Marquis San Diego Marina

This program is sponsored by PVI, PeerView Institute for Medical Education and supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.

Chair:
Nikhil C. Munshi, MD, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA

Speakers:
Mohamed Mohty, MD, PhD, Saint-Antoine Hospital, Sorbonne University, Paris, France
Krina K. Patel, MD, Msc, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

FRIDAY EARLY AFTERNOON SYMPOSIA:
11:00 A.M. – 2:00 P.M.

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

11:00 a.m. – 2:00 p.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by educational grants from CTI Biopharma, Geron Corporation, GSK, and Karyopharm Therapeutics.

Speakers:
Jean-Jacques Kiladjian, MD, PhD, Hospital Saint-Louis, Paris, France
Abdulraheem Yacoub, MD, The University of Kansas, Leawood, KS

Contact: Ishana Fleurant
Email: Ifleurant@clinicaloptions.com
An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by an educational grant from AstraZeneca.

Chair:
John P. Leonard, MD, Weill Cornell Medicine, New York, NY

Speakers:
Ann Lacasce, MD, Dana-Farber Cancer Institute, Boston, MA
Matthew A. Lunning, DO, FACP, University of Nebraska, Omaha, NE

Contact: Ishana Fleurant
Email: ifleurant@clinicaloptions.com

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)

11:00 a.m. – 2:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.

Chair:
Neil Love, MD, Research To Practice, Key Biscayne, FL

Speakers:
Michael Dickinson, MBBS, D. Med Sci, FRACP, FRCPA, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
Grzegorz S. Nowakowski, MD, Mayo Clinic, Rochester, MN
Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

11:00 a.m. – 2:00 p.m.
Room 30 A-E
San Diego Convention Center

This program is provided by Answers in CME and supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Speakers:
Sikander Ailawadhi, MD, Mayo Clinic, Jacksonville, FL
Ajay Chari, MD, University of California, San Francisco, San Francisco, CA

Contact: Caitlan Bose
Email: caitlan.bose@answersincme.com

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

11:00 a.m. – 2:00 p.m.
Ballroom 20CD
San Diego Convention Center

This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, AstraZeneca, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Chair:
Prof. John G. Gribben, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, United Kingdom

Speakers:
John N. Allan, MD, Weill Cornell Medicine, New York, NY
Nicole Lamanna, MD, Herbert Irving
Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center, New York, NY
Meghan C. Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

11:00 a.m. – 2:00 p.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC., and supported by Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc., and Curis, Inc.

Chair:
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Courtney D. DiNardo, MD, MSc, University of Texas MD Anderson Cancer Center, Houston, TX
Amir T. Fathi, MD, Massachusetts General Hospital, Boston, MA
Gail J. Roboz, MD, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma

11:00 a.m. – 2:00 p.m.
Room 6DE
San Diego Convention Center

This program is provided by PRIME Education, LLC and supported by Genmab, US Inc. and ADC Therapeutics.

Chair:
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA

Speaker:
Douglas Burgoyne, PharmD, FAMCP, University of Utah, Salt Lake City, UT
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA
Peter A. Riedell, MD, University of Chicago, Chicago, IL

Contact: Jill Friedman
Email: j.friedman@primeinc.org

Medical Crossfire®: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource and supported by American Regent, Inc.

Chair:
George M. Rodgers, MD, PhD, University of Utah Medical Center, Salt Lake City, UT

Speaker:
Sidarth Anand, MD, UCLA Health, Los Angeles, CA
Patricia A. Locanto-Ford, MD, Pennsylvania Hospital, Philadelphia, PA

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 11-13
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource, LLC and supported by Amgen, Inc., Servier Pharmaceuticals, and Takeda Oncology.

Chair:
Elias Jabbour, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Lia Gore, MD, University of Colorado Cancer Center, Aurora, CO
More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 2-4
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by an independent educational grant from Argenx US, Inc., Sanofi, and Novartis Oncology.

Chair:
Spero Cataland, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH

Speakers:
Srikanth Nagalla, MBBS, Miami Cancer Institute, Miami, FL
Marie Scully, MD, University College London, London, England

Contact: Harmony Washington
Email: hwashington@medscapelive.com

Multiple Myeloma: Clinical Challenges for the Community Clinician

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 5-6
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, Janssen, Sanofi, Karyopharm, and Legend.

Chair:
Colin Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Speakers:
Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
Nisha S. Joseph, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Contact: Cathy Zehr
Email: cathy.zehr@catalystmeded.com

Optimizing Myelofibrosis Management With Current and Emerging Therapies

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by AbbVie, Bristol Myers Squibb, GSK, and Karyopharm Therapeutics.

Chair:
Prithviraj Bose, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Stephen T. Oh, MD, PhD, Washington University School of Medicine, Saint Louis, MO
Nikolai A. Podoltsev, MD, PhD, Yale University School of Medicine, New Haven, CT

Contact: Harmony Washington
Email: hwashington@medscapelive.com

Reimaging Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 18-19
Marriott Marquis San Diego Marina

This program is provided by Catalyst Medical Education and supported by Sanofi.

Chair:
Guy Young, MD, Children’s Hospital Los Angeles, Los Angeles, CA

Speakers:
Glaivy Batsuli, MD, Stanford University, Stanford, CA
Cindy A. Leissinger, MD, Tulane University School of Medicine, New Orleans, LA

Contact: Cathy Zehr
Email: cathy.zehr@catalystmeded.com
**Satellite Symposia**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>Room 6B, San Diego Convention Center</td>
<td>This program is provided by Physicians’ Education Resource, LLC and supported by Geron Corporation, Incyte Corporation, Protagonist Therapeutics, and PharmaEssentia USA. Chair: Andrew T. Kuykendall, MD, Moffitt Cancer Center, Tampa, FL. Speakers: Gabriela S. Hobbs, MD, Massachusetts General Hospital, Boston, MA; Barbara Mora, MD, Ospedale ASST Sette Laghi, University of Insubria, Varese, Italy; Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX. Contact: Kelly Donald  Email: <a href="mailto:kdonald@mjhevents.com">kdonald@mjhevents.com</a></td>
</tr>
</tbody>
</table>

### Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m. – 2:00 p.m.</td>
<td>Ballroom 20AB, San Diego Convention Center</td>
<td>This program is provided by Karmanos Cancer Institute and supported by Prothena, Amyloidosis Foundation Amyloidosis Support Group. Chair: Jeffrey A. Zonder, MD, Karmanos Cancer Institute, Detroit, MI. Speakers: Rafat Abounour, MD, Indiana University School of Medicine, Indianapolis, IN; Giada Bianchi, MD, Brigham and Women’s Hospital, Boston, MA; Ela Muchtar, MD, Mayo Clinic, Rochester, MN; Laura Obici, MD, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Contact: Christiane Houde  Email: <a href="mailto:houdec@karmanos.org">houdec@karmanos.org</a></td>
</tr>
</tbody>
</table>

### FRIDAY LATE AFTERNOON SYMPOSIA:

3:00 P.M. – 6:00 P.M.

#### A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m. – 6:00 p.m.</td>
<td>Marriott Grand Ballroom 11-13, Marriott Marquis San Diego Marina</td>
<td>This program is provided by Medscape Oncology and supported by Agios and Novartis Oncology. Chair: Morag Griffin, FRCPA, MRCP, St James’s University Hospital, Leeds, United Kingdom. Speaker: Michael R. DeBaun, MD, MPH, Vanderbilt University Medical Center, Nashville, TN. Contact: Harmony Washington  Email: <a href="mailto:hwashington@medscapelive.com">hwashington@medscapelive.com</a></td>
</tr>
</tbody>
</table>

#### Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m. – 6:00 p.m.</td>
<td>Pacific Ballroom Salons 15-17, Marriott Marquis San Diego Marina</td>
<td>This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax. Chair: Sergio A. Giralt, MD, FACP, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY.</td>
</tr>
</tbody>
</table>
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Satellite Symposia

**Friday, 08 Dec 2023**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

PIANKAL DESAI, MD, MPH, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY

GHAYAS C. ISA, MD, University of Texas MD Anderson Cancer Center, Houston, TX

TAPAN M. KADIA, MD, University of Texas MD Anderson Cancer Center, Houston, TX

SELINA M. LUGER, MD, FRCPC, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

**Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease**

**3:00 p.m. – 6:00 p.m.**
San Diego Ballroom AB
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by Sanofi.*

**Chair:**
CATHERINE BROOME, MD, Georgetown University, Washington, DC

**Speakers:**

DAVID DINGLI, MD, Mayo Clinic, Rochester, MN

DEVA SHARMA, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Ishana Fleurant
Email: ifleurant@clinicaloptions.com

### Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

**3:00 p.m. – 6:00 p.m.**
Room 30 A-E
San Diego Convention Center

*This program is provided by RMEI Medical Education, LLC and supported by an educational grant from Genmab US, Inc. and AbbVie.*

**Chair:**

JOSHUA BRODY, MD, Icahn School of Medicine at Mount Sinai, New York, NY

**Speakers:**

LORENZO FALCHI, MD, Memorial Sloan Kettering Cancer Center, New York, NY

LORI A. LESLIE, MD, Hackensack Meridian School of Medicine, Hackensack, NJ

Contact: Erika Sinofsky
Email: esinofsky@rmei.com

### Advancing cTTP Care Through Integration of the Latest Clinical Evidence

**3:00 p.m. – 6:00 p.m.**
Ballroom 20AB
San Diego Convention Center

*This program is provided by PRIME Education, LLC and supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.*

**Speakers:**

AZRA BOROGOVAC, MD, City of Hope National Medical Center, Irvine, CA

CHRISTINA HAAS, PHARM.D., University of Illinois at Chicago College of Pharmacy, Chicago, IL

LONG ZHENG, MD, PhD, University of Kansas Medical Center, Kansas City, KS

Contact: Eryn Litvinas
Email: e.litvinas@primeinc.org

### AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

**3:00 p.m. – 6:00 p.m.**
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by educational grants from Alexion Pharmaceuticals, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, and Prothena.*

**Chair:**

ANGELA DISPENZIERI, MD, Mayo Clinic, Rochester, MN

**Speaker:**

ASHUTOSH D. WECHALEKAR, MBBS, DM, FRCP, FRCPATH, University College London Hospitals, London, United Kingdom

Contact: Ishana Fleurant
Email: ifleurant@clinicaloptions.com
Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

3:00 p.m. – 6:00 p.m.
Room 6DE
San Diego Convention Center

This program is provided by PRIME Education, LLC and supported by Gilead Sciences, Inc.

Chair:
Amer M. Zeidan, MBBS, MHS, Yale University, New Haven, CT

Speakers:
Douglas Burgoyne, PharmD, FAMCP, University of Utah, Salt Lake City, UT
Rami S. Komrokji, MD, Moffitt Cancer Center, Tampa, FL

Contact: Eryn Litvinas
Email: e.litvinas@primeinc.org

An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

3:00 p.m. – 6:00 p.m.
Pacific Ballroom Salons 18-19
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by educational grants from Genentech, a member of the Roche Group, Genmab, Ipsen Biopharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.

Chair:
Julie M. Vose, MD, MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:
Peter Martin, MD, Weill Cornell Medical College, New York, NY
Sonali M. Smith, University of Chicago, Chicago, IL

Contact: Ishana Fleurant
Email: Ifleurant@clinicaloptions.com

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

3:00 p.m. – 6:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.

Chair:
Neil Love, MD, Research To Practice, Key Biscayne, FL

Speakers:
Farrukh T. Awan, MD, The University of Texas, Dallas, TX
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute, Inc., Boston, MA
Stephen J. Schuster, MD, University of Pennsylvania, Philadelphia, PA
William G. Wiarda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX
Jennifer A. Woyach, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Case Challenges in Myelofibrosis for the Community Clinician

3:00 p.m. – 6:00 p.m.
Marriott Grand Ballroom 5-6
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by CTI Biopharma Corp.

Chair:
Ruben A. Mesa, MD, Atrium Health Levine Cancer Institute, Charlotte, NC

Speakers:
Angela G. Fleischman, MD, PhD, University of California, Irvine, Irvine, CA
Rajajit K. Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Harmony Washington
Email: hwashington@medscapelive.com
**SATELLITE SYMPOSIA**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

**Changing the Path of Myelofibrosis: Exploring How We Can Do More for Our Patients**

*3:00 p.m. – 6:00 p.m.*  
Marriott Grand Ballroom 8-9  
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Morphosys.

**Chair:**  
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

**Speakers:**  
Claire N Harrison, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom  
Ronald Hoffman, MD, Tisch Cancer Institute, New York, NY  
Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Harmony Washington  
Email: hwashington@medscapelive.com

---

**Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans**

*3:00 p.m. – 6:00 p.m.*  
Room 6B  
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Vertex Pharmaceuticals.

**Chair:**  
Biree Andemariam, MD, University of Connecticut Health, Farmington, CT

**Speakers:**  
Lydia H. Pecker, MD, Johns Hopkins University School of Medicine, Baltimore, MD  
Nirmish Shah, MD, Duke University Medical Center, Durham, NC

Contact: Kelly Donald  
Email: kdonald@mjhevents.com

---

**Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH**

*3:00 p.m. – 6:00 p.m.*  
Marriott Grand Ballroom 2-4  
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Alexion Pharmaceuticals, Inc.

**Chair:**  
Ilene C. Weitz, MD, Keck School of Medicine of USC, Los Angeles, CA

**Speakers:**  
Vincent T Ho, MD, Harvard Medical School, Boston, MA  
David J Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA

Contact: Harmony Washington  
Email: hwashington@medscapelive.com

---

**Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings**

*3:00 p.m. – 6:00 p.m.*  
Pacific Ballroom Salons 24-26  
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource, LLC and supported by Novartis Pharmaceuticals Corporation.

**Chair:**  
Jorge Cortes, MD, Augusta University, Augusta, GA

**Speakers:**  
Andreas Hochhaus, MD, Universitätsklinikum Jena, Jena, Germany  
Amanda Rodriguez, PA-C, Moffitt Cancer Center, Tampa, FL

Contact: Kelly Donald  
Email: kdonald@mjhevents.com
Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

3:00 p.m. – 6:00 p.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Jazz Pharmaceuticals, Inc and Servier Pharmaceuticals.

Chair:
RACHEL E. RAU, MD, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX

Speakers:
LAUREN HUANG, DNP, ARNP, PNP-PC, Seattle Children’s Hospital, Seattle, WA
LUKE MAESE, DO, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
ETAN ORGEL, MD, Keck School of Medicine of USC, Los Angeles, CA

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

3:00 p.m. – 6:00 p.m.
Ballroom 20CD
San Diego Convention Center

This program is provided by PVI, PeerView Institute for Medical Education and supported by AstraZeneca LP.

Chair:
SHMUEL SHOHAM, MD, Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:
GHADY HAIDAR, MD, University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA
CAROL ANN HUFF, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

FRIDAY EVENING SYMPOSIA:
7:00 P.M. – 10:00 P.M.

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)

7:00 p.m. – 10:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from Abbvie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi.

Chair:
NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

Speakers:
AMRITA KRISHNAN, MD, City of Hope, Irvine, CA
SAGAR LONIAL, MD, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
ROBERT Z. ORLOWSKI, MD, PHD, University of Texas MD Anderson Cancer Center, Houston, TX
NOOPUR RAJE, MD, Massachusetts General Hospital Cancer Center, Boston, MA
PAUL G. RICHARDSON, MD, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com
Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

7:00 p.m. – 10:00 p.m.
Marriott Grand Ballroom 11-13
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, and Seagen.

Chair:
ALEX F. HERRERA, MD, City of Hope, Duarte, CA

Speakers:
PHILIPPE ARMAND, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
CARLA CASULO, MD, University of Rochester, Rochester, NY

Contact: Harmony Washington
Email: hwashington@medscapelive.com

How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

7:00 p.m. – 10:00 p.m.
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource, LLC and supported by Incyte Corporation, ST Shared Services LLC, a Mallinckrodt company, and Equillium Bio.

Chair:
COREY CUTLER, Dana-Farber Cancer Institute, Boston, MA

Speakers:
HANNAH CHOE, MD, The Ohio State University Wexner Medical Center, Columbus, OH
CARRIE L. KITKO, MD, Vanderbilt University, Nashville, TN
MIGUEL-ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kelly Donald
Email: kdonald@mjhevents.com
PRODUCT THEATERS

Product Theaters as of October 19, 2023.
Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

**Sponsored by Johnson & Johnson**

**Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types**

11:30 a.m. – 12:30 p.m.
Room 3
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
Vipin Khare, MD, Johnson & Johnson

**Sponsored by Bristol Myers Squibb**

**Learn More About a CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)**

11:30 a.m. – 12:30 p.m.
Room 4
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speakers:
Amani Kitali, MBA, MPH, PMP, Bristol Myers Squibb
Josephine Machado, MSN, APN-C, AOCNP, Bristol Myers Squibb

**Sponsored by Blueprint Medicines**

**The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)**

11:30 a.m. – 12:30 p.m.
Room 2
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
Daniel Shaheen, PharmD, Blueprint Medicines
SUNDAY

**Sponsored by Pfizer**

**A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer**

8:00 a.m. – 9:00 a.m.  
Room 2  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Caroline Hoang, PhD, Pfizer

**Sponsored by BioLineRx, Inc.**

**APHEXDA (motixafortide): Learn about this new FDA approved treatment option**

8:00 a.m. – 9:00 a.m.  
Room 3  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
 Ella Sorani, PhD, BioLineRx, Inc.

**Sponsored by Pharming Healthcare Inc.**

**Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician's Perspective and a Patient's Experience**

8:00 a.m. – 9:00 a.m.  
Room 4  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Anurag Relan, MD, Pharming Healthcare Inc.

**Sponsored by AbbVie Oncology**

**Exploring Time Off Treatment with a BCL-2 Inhibitor**

8:00 a.m. – 9:00 a.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speakers:**  
Jalaja Potluri, MD, AbbVie  
Ahmed Kotb, MD, AbbVie

**Sponsored by Genmab and AbbVie**

**Unveiling a Subcutaneous Therapy for 3L+ DLBCL**

8:00 a.m. – 9:00 a.m.  
Room 5A  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Samantha Brodkin, DO, MS, Genmab

**Sponsored by Apellis Pharmaceuticals**

**A Complement Inhibitor for PNH**

11:30 a.m. – 12:30 p.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
This session will include a patient perspective provided by Louis Hernandez.  
**Speakers:**  
Peter Hillmen, MD, Apellis Pharmaceuticals  
Mary Rowan, RN, BSN, Apellis Pharmaceuticals
<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Room</th>
<th>Location</th>
<th>Speakers</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsored by Pfizer</strong></td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>5A</td>
<td>San Diego Convention Center</td>
<td>For in-person participants only.</td>
<td></td>
</tr>
<tr>
<td><strong>A Discussion on a Treatment Option for Sickle Cell Disease</strong></td>
<td></td>
<td></td>
<td></td>
<td>Speaker: <strong>Kim Smith-Whitley, MD, Pfizer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsored by Johnson &amp; Johnson</strong></td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>1B</td>
<td>San Diego Convention Center</td>
<td>For in-person participants only.</td>
<td></td>
</tr>
<tr>
<td><strong>Janssen invites you to learn about a treatment for adult patients</strong></td>
<td></td>
<td></td>
<td></td>
<td>Speaker: <strong>Anthony Vaganos, MBiotech, GSK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>for RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>Sponsored by AstraZeneca</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsored by Eli Lilly and Company</strong></td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>2</td>
<td>San Diego Convention Center</td>
<td>For in-person participants only.</td>
<td></td>
</tr>
<tr>
<td><strong>Learn about an alternative treatment for certain B-cell malignancies.</strong></td>
<td></td>
<td></td>
<td></td>
<td>Speaker: <strong>John Pagel, MD, PhD, Loxo@Lilly</strong></td>
<td><strong>Sponsored by Bristol Myers Squibb</strong></td>
</tr>
<tr>
<td><strong>Sponsored by GSK</strong></td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>4</td>
<td>San Diego Convention Center</td>
<td>For in-person participants only.</td>
<td></td>
</tr>
<tr>
<td><strong>Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)</strong></td>
<td></td>
<td></td>
<td></td>
<td>Speaker: <strong>Vikram Shetty, MD, AstraZeneca</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsored by Bristol Myers Squibb</strong></td>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>3</td>
<td>San Diego Convention Center</td>
<td>For in-person participants only.</td>
<td></td>
</tr>
<tr>
<td><strong>Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL</strong></td>
<td></td>
<td></td>
<td></td>
<td>Speaker: <strong>Pavith Singh, PharmD, RPh, MBA, Bristol Myers Squibb</strong></td>
<td></td>
</tr>
</tbody>
</table>
MONDAY

**Sponsored by Johnson & Johnson**

**A new, first-in-class treatment for RRMM patients**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>5B</td>
<td>Room 5B, San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

Saurabh N. Patel, MD, Johnson & Johnson

---

**Sponsored by Sanofi**

**Achieving Higher Factor VIII Levels in Hemophilia A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>3</td>
<td>Room 3, San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

This session will include a patient perspective provided by David, living with Hemophilia A and Sanofi Peer Ambassador.

**Speakers:**

Peter Chen, PhD, Sanofi
Ekta Seth Chhabra, PhD, Sanofi

---

**Sponsored by Genentech**

**An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>1B</td>
<td>Room 1B, San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

**Speaker:**

Jamie H. Hirata, PharmD, Genentech

---

**Sponsored by Gamida Cell**

**Latest Advancement in Allogeneic Hematopoietic Cell Transplantation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>5A</td>
<td>Room 5A, San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

Ronit Simantov, MD, Gamida Cell

---

**Sponsored by Bristol Myers Squibb**

**An FDA approved treatment option for anemia in LR-MDS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 p.m. – 1:15 p.m.</td>
<td>3</td>
<td>Room 3, San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

Christina Hughes, PhD, Bristol Myers Squibb

---

**Sponsored by Johnson & Johnson and Legend Biotech**

**CARVYKTI® Product Summary for Healthcare Providers**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 p.m. – 1:15 p.m.</td>
<td>1B</td>
<td>Room 1B, San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

Lisa Kallenbach, MD, MPA, Johnson & Johnson
Sponsored by Sanofi

Outcomes and Economic Impact of Treatment with CABLIVI® (caplacizumab-yhdp) (non-CME)

12:15 p.m. – 1:15 p.m.
Room 4
San Diego Convention Center

For in-person participants only.

Speakers:
RAHUL BOHRA, MSc, PhD, Sanofi
ALIX ARNAUD, MSc, Sanofi
INDUSTRY THEATERS

Industry Theaters as of October 19, 2023. Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by AbbVie (Pharmacyclics)

BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape

11:30 a.m. – 12:30 p.m.
Room 5A
San Diego Convention Center

For in-person participants only.

Speaker:
JAMES P. DEAN, MD, PhD, AbbVie

Sponsored by AstraZeneca

COVID-19: Protecting Vulnerable Populations

11:30 a.m. – 12:30 p.m.
Room 5B
San Diego Convention Center

For in-person participants only.

Speaker:
KETUL PATIL, PhD, AstraZeneca

Sponsored by GSK

GSK Oncology: Breaking Barriers for Patients with Multiple Myeloma

11:30 a.m. – 12:30 p.m.
Room 1B
San Diego Convention Center

For in-person participants only.

Speakers:
TANIA SMALL, MD, GSK Collegeville PA
JULIAN PEREZ RONCO, MD, MBH, MPH, GSK

Sponsored by Genentech, A Member of the Roche Group

Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors

11:30 a.m. – 12:30 p.m.
Room 1A
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
JOHN PASI, MD, PhD, Genentech
SUNDAY

**Sponsored by X4 Pharmaceutical**

**Classical Hematology: Looking into the Future**

8:00 a.m. – 9:00 a.m.
Room 1B
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speakers:**
Christophe Arbet-Engels, MD, PhD, X4 Pharmaceutical

**Sponsored by Vertex Pharmaceuticals Inc.**

**The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy**

8:00 a.m. – 9:00 a.m.
Room 1A
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speakers:**
Aric Parnes, MD, Vertex Pharmaceuticals Inc.
Tony Bortan, PhD, Vertex Pharmaceuticals Inc.
Nnenna Ukachi, MD, MPH, Vertex Pharmaceuticals Inc.

MONDAY

**Sponsored by AstraZeneca**

**Emerging AstraZeneca Hematology Pipeline**

12:15 p.m. – 1:15 p.m.
Room 5B
San Diego Convention Center

For in-person participants only.

**Speakers:**
Alan Yong, MD, AstraZeneca
Richard Hermann, MD, AstraZeneca
Vikram Shetty, MD, AstraZeneca

**Sponsored by Gilead and Kite Oncology**

**Gilead and Kite Oncology Pipeline**

12:15 p.m. – 1:15 p.m.
Room 1A
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speakers:**
Carol O’Hear, MD, PhD, Gilead and Kite Oncology
Rolando Enoch, MS, Gilead and Kite Oncology
Frank Neumann, MD, PhD, Gilead and Kite Oncology
Chris McDonald, MBA, Gilead and Kite Oncology

**Sponsored by Agios Pharmaceuticals, Inc.**

**In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease**

12:15 p.m. – 1:15 p.m.
Room 5A
San Diego Convention Center

For in-person participants only.
This session will include a patient perspective provided by Golie Lorenzo Green.

**Speakers:**
Ahmar U Zaidi, MD, Agios Pharmaceuticals
Sarah Gerrens, MD, PhD, Agios Pharmaceuticals
COMPANY SHOWCASES

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies’ services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CME credit is not offered.

SATURDAY

Sponsored by Galapagos

Galapagos’ 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model [non-CME]

1:30 p.m. – 1:45 p.m.
Room 5A
San Diego Convention Center

For in-person participants only.

Speakers:
Ruiz Astigarraga, MSc, Galapagos
Jacqueline Vink-Korndorffer, MSc, Galapagos

Sponsored by GRAIL LLC

Showcase on Galleri®, a Multi-Cancer Early Detection Test [non-CME]

1:30 p.m. – 1:45 p.m.
Room 5B
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
Rita Shklovich, MD, PhD, GRAIL, LLC

Sponsored by Precision NanoSystems

Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies [non-CME]

3:30 p.m. – 3:45 p.m.
Room 5B
San Diego Convention Center

For in-person participants only.

Speaker:
Angela Zhang, PhD, Precision NanoSystems

Sponsored by Syndax Pharmaceuticals

Reimaging Cancer Care at Syndax: Clinical Development of Targeted Therapies [non-CME]

3:30 p.m. – 3:45 p.m.
Room 5A
San Diego Convention Center

For in-person participants only.

Speakers:
Neil Gallagher, MD, PhD, Syndax Pharmaceuticals
Kate Madigan, MD, Syndax Pharmaceuticals
SUNDAY

Sponsored by Halia Therapeutics

Halia Therapeutics- Targeting the Chronic Inflammatory Bone Marrow Microenvironment

4:00 p.m. – 4:15 p.m.
Room 5B
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

Speakers:
DAVID BEARSS, PhD, Halia Therapeutics
ALAN LIST, MD, Halia Therapeutics
<table>
<thead>
<tr>
<th>Exhibitors</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>309</td>
</tr>
<tr>
<td>Acrotech Biopharma</td>
<td>2100</td>
</tr>
<tr>
<td>Actinium Pharmaceuticals</td>
<td>2033</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corporation</td>
<td>2129</td>
</tr>
<tr>
<td>ADC Therapeutics</td>
<td>1325</td>
</tr>
<tr>
<td>Agios Pharmaceuticals</td>
<td>133</td>
</tr>
<tr>
<td>Aixial</td>
<td>2450</td>
</tr>
<tr>
<td>Allogene Therapeutics</td>
<td>3205</td>
</tr>
<tr>
<td>Alpine Immune Sciences</td>
<td>3443</td>
</tr>
<tr>
<td>American Association for Cancer Research</td>
<td>200</td>
</tr>
<tr>
<td>American Society for Transplantation and Cellular Therapy (ASTCT)</td>
<td>2120</td>
</tr>
<tr>
<td>American Society of Gene and Cell Therapy (ASGCT)</td>
<td>11</td>
</tr>
<tr>
<td>American Society of Hematology</td>
<td>1215, Virtual</td>
</tr>
<tr>
<td>American Society of Pediatric Hematology Oncology (ASPHO)</td>
<td>23</td>
</tr>
<tr>
<td>Amgen</td>
<td>833</td>
</tr>
<tr>
<td>Amyloidosis Foundation</td>
<td>2056</td>
</tr>
<tr>
<td>Amyloidosis Support Groups</td>
<td>37</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>615, 714</td>
</tr>
<tr>
<td>Aplastic Anemia and MDS International Foundation, Inc.</td>
<td>2130</td>
</tr>
<tr>
<td>AplusA</td>
<td>1849</td>
</tr>
<tr>
<td>Applied Cells</td>
<td>3447</td>
</tr>
<tr>
<td>Aptitude Health</td>
<td>2257</td>
</tr>
<tr>
<td>Aptose Biosciences Inc.</td>
<td>505</td>
</tr>
<tr>
<td>Arcellx</td>
<td>748</td>
</tr>
<tr>
<td>argenx</td>
<td>3318</td>
</tr>
<tr>
<td>ARUP Laboratories</td>
<td>2453</td>
</tr>
<tr>
<td>Ascentage Pharma</td>
<td>3355</td>
</tr>
<tr>
<td>Association for Value-Based Cancer Care</td>
<td>16</td>
</tr>
<tr>
<td>Association of PAs in Oncology</td>
<td>Virtual</td>
</tr>
<tr>
<td>Association of Public Health Laboratories</td>
<td>29</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>2311</td>
</tr>
<tr>
<td>Astex Pharmaceuticals, Inc.</td>
<td>1549</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1433</td>
</tr>
<tr>
<td>Atara Biotherapeutics, Inc.</td>
<td>1456</td>
</tr>
<tr>
<td>Exhibitors</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>---</td>
</tr>
<tr>
<td>AVM Biotechnology LLC</td>
<td>112</td>
</tr>
<tr>
<td>Bayer</td>
<td>1454</td>
</tr>
<tr>
<td>Beam Therapeutics</td>
<td>3255</td>
</tr>
<tr>
<td>Beckman Coulter Life Sciences</td>
<td>2351</td>
</tr>
<tr>
<td>BeiGene USA</td>
<td>3013</td>
</tr>
<tr>
<td>Binaytara Foundation</td>
<td>26</td>
</tr>
<tr>
<td>Binding Site, Inc.</td>
<td>132</td>
</tr>
<tr>
<td>Bio Products Laboratory USA, Inc.</td>
<td>2022, 2026</td>
</tr>
<tr>
<td>Biognosys</td>
<td>3451</td>
</tr>
<tr>
<td>BioIVT</td>
<td>3409</td>
</tr>
<tr>
<td>BioLineRx, Inc.</td>
<td>3155</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical Inc.</td>
<td>1948</td>
</tr>
<tr>
<td>Biomea Fusion, Inc.</td>
<td>3223</td>
</tr>
<tr>
<td>BioSkryb Genomics</td>
<td>2102</td>
</tr>
<tr>
<td>BioSpyder</td>
<td>3044</td>
</tr>
<tr>
<td>Blood Cancers Today / Mashup Media</td>
<td>3154</td>
</tr>
<tr>
<td>Blue Spark Technologies, Inc.</td>
<td>1256</td>
</tr>
<tr>
<td>bluebird bio</td>
<td>743, 756</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>1749</td>
</tr>
<tr>
<td>BostonGene</td>
<td>2350</td>
</tr>
<tr>
<td>Brazilian Association of Hematology, Hemotherapy And Cell Therapy (AHHH)</td>
<td>40</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>2609, Virtual</td>
</tr>
<tr>
<td>Cardinal Health</td>
<td>3201</td>
</tr>
<tr>
<td>Caribou Biosciences, Inc.</td>
<td>2551</td>
</tr>
<tr>
<td>Cellular Highways Ltd</td>
<td>3444</td>
</tr>
<tr>
<td>Centessa Pharmaceuticals</td>
<td>3401</td>
</tr>
<tr>
<td>Certara</td>
<td>3425</td>
</tr>
<tr>
<td>Children's Hospital of Philadelphia</td>
<td>3348</td>
</tr>
<tr>
<td>CIBMTR (Center for International Blood &amp; Marrow Transplant Research)</td>
<td>2118</td>
</tr>
<tr>
<td>Citius Pharmaceuticals</td>
<td>3354</td>
</tr>
<tr>
<td>City of Hope Comprehensive Cancer Center</td>
<td>2204</td>
</tr>
<tr>
<td>Cleveland Clinic Taussig Cancer Institute</td>
<td>2134</td>
</tr>
<tr>
<td>Clinical Advances in Hematology and Oncology</td>
<td>2801</td>
</tr>
<tr>
<td>CLL Society</td>
<td>7, Virtual</td>
</tr>
<tr>
<td>Cogent Biosciences</td>
<td>2704</td>
</tr>
<tr>
<td>College of American Pathologists</td>
<td>14</td>
</tr>
<tr>
<td>Cooley's Anemia Foundation</td>
<td>Virtual</td>
</tr>
<tr>
<td>CRISPR Therapeutics</td>
<td>3043</td>
</tr>
<tr>
<td>Cryoport Systems</td>
<td>455</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>643</td>
</tr>
<tr>
<td>Curis, Inc.</td>
<td>2107</td>
</tr>
<tr>
<td>Cytiva</td>
<td>2251</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>D2V Clinical, Inc.</td>
<td>3446</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>2819</td>
</tr>
<tr>
<td>Dana-Farber Cancer Institute</td>
<td>2900</td>
</tr>
<tr>
<td>DAVA Oncology</td>
<td>1156, 1157</td>
</tr>
<tr>
<td>Diagenode, Inc.</td>
<td>2132</td>
</tr>
<tr>
<td>Diamond Blackfan Anemia Canada</td>
<td>19</td>
</tr>
<tr>
<td>Diamond Blackfan Anemia Foundation Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Doximity</td>
<td>2355</td>
</tr>
<tr>
<td>Edenbridge Pharmaceuticals, LLC</td>
<td>2016</td>
</tr>
<tr>
<td>Editas Medicine</td>
<td>2152</td>
</tr>
<tr>
<td>Elsevier</td>
<td>2605</td>
</tr>
<tr>
<td>Emmaus Medical, Inc.</td>
<td>3305</td>
</tr>
<tr>
<td>Emmes Company LLC</td>
<td>2356</td>
</tr>
<tr>
<td>Enable Injections</td>
<td>405</td>
</tr>
<tr>
<td>EpiCypher</td>
<td>3442</td>
</tr>
<tr>
<td>Eurasian Hematology Oncology Group</td>
<td>39</td>
</tr>
<tr>
<td>Eurofins Viracor</td>
<td>3405</td>
</tr>
<tr>
<td>European Hematology Association</td>
<td>2449</td>
</tr>
<tr>
<td>Flagship Biosciences</td>
<td>3349</td>
</tr>
<tr>
<td>Flatiron Health</td>
<td>3156</td>
</tr>
<tr>
<td>Florida Cancer Specialists &amp; Research Institute</td>
<td>3145</td>
</tr>
<tr>
<td>Food And Drug Administration - Center for Biologics Evaluation And Research</td>
<td>34</td>
</tr>
<tr>
<td>Foresight Diagnostics</td>
<td>2014</td>
</tr>
<tr>
<td>Fortrea</td>
<td>3242</td>
</tr>
<tr>
<td>Foundation for Sickle Cell Disease Research</td>
<td>5</td>
</tr>
<tr>
<td>Foundation for the Accreditation of Cellular Therapy (FACT)</td>
<td>12</td>
</tr>
<tr>
<td>Foundation for Women &amp; Girls with Blood Disorders</td>
<td>21</td>
</tr>
<tr>
<td>Foundation Medicine</td>
<td>3203</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Center</td>
<td>3337</td>
</tr>
<tr>
<td>Fulcrum Therapeutics</td>
<td>752</td>
</tr>
<tr>
<td>Fulgent Oncology</td>
<td>3345</td>
</tr>
<tr>
<td>Galapagos</td>
<td>3419</td>
</tr>
<tr>
<td>Gamida Cell</td>
<td>2653, 2752</td>
</tr>
<tr>
<td>Genentech</td>
<td>333</td>
</tr>
<tr>
<td>Genmab</td>
<td>3029</td>
</tr>
<tr>
<td>Genmab - Patient Support Services</td>
<td>2945</td>
</tr>
<tr>
<td>Genomic Testing Cooperative</td>
<td>3315</td>
</tr>
<tr>
<td>GenPath</td>
<td>142</td>
</tr>
<tr>
<td>GenScript ProBio USA Inc</td>
<td>2155</td>
</tr>
<tr>
<td>Geron Inc.</td>
<td>1251</td>
</tr>
<tr>
<td>Gilead and Kite Oncology</td>
<td>1415</td>
</tr>
<tr>
<td>Global Pediatric MDS Initiative</td>
<td>31</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>GRAIL</td>
<td>1326</td>
</tr>
<tr>
<td>GSK</td>
<td>1814</td>
</tr>
<tr>
<td>Gundersen Health System</td>
<td>4</td>
</tr>
<tr>
<td>Halia Therapeutics</td>
<td>2254</td>
</tr>
<tr>
<td>Harborside</td>
<td>3253</td>
</tr>
<tr>
<td>Haymarket Oncology</td>
<td>2614</td>
</tr>
<tr>
<td>HCU Network America</td>
<td>Virtual</td>
</tr>
<tr>
<td>Healgen Scientific LLC</td>
<td>754</td>
</tr>
<tr>
<td>HealthTree Foundation</td>
<td>24</td>
</tr>
<tr>
<td>HealthWell Foundation</td>
<td>32</td>
</tr>
<tr>
<td>HEMA Biologics</td>
<td>1853</td>
</tr>
<tr>
<td>Hemophilia Federation of America (HFA)</td>
<td>17</td>
</tr>
<tr>
<td>Horizon Therapeutics</td>
<td>3416</td>
</tr>
<tr>
<td>Hospital Information Services for Jehovah’s Witnesses (USA)</td>
<td>33</td>
</tr>
<tr>
<td>Ichnos Sciences</td>
<td>305</td>
</tr>
<tr>
<td>ICON plc</td>
<td>3249</td>
</tr>
<tr>
<td>Imaging Endpoints II, LLC</td>
<td>104</td>
</tr>
<tr>
<td>Incyte Corporation</td>
<td>1233</td>
</tr>
<tr>
<td>Intermountain Health</td>
<td>3303</td>
</tr>
<tr>
<td>International Myeloma Foundation</td>
<td>3351</td>
</tr>
<tr>
<td>International Myeloma Society</td>
<td>2</td>
</tr>
<tr>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
<td>8</td>
</tr>
<tr>
<td>Intrinsic LifeSciences</td>
<td>2020</td>
</tr>
<tr>
<td>Invivoscribe, Inc.</td>
<td>349</td>
</tr>
<tr>
<td>iProcess Global Research Inc</td>
<td>3438</td>
</tr>
<tr>
<td>Ipsen Biopharmaceuticals</td>
<td>1453</td>
</tr>
<tr>
<td>IQVIA Biotech</td>
<td>2151</td>
</tr>
<tr>
<td>Italian Society of Hematology</td>
<td>1449</td>
</tr>
<tr>
<td>JAMA Network</td>
<td>301</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Innovative Medicine</td>
<td>1033, 1225, 1324</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>2419</td>
</tr>
<tr>
<td>John Theurer Cancer Center</td>
<td>401</td>
</tr>
<tr>
<td>Kaiser Permanente/ The Southeast Permanente Medical Group</td>
<td>3445</td>
</tr>
<tr>
<td>Karyopharm Therapeutics Inc.</td>
<td>733</td>
</tr>
<tr>
<td>Kindstar Globalgene (HK) Limited</td>
<td>3448</td>
</tr>
<tr>
<td>Kura Oncology</td>
<td>2701</td>
</tr>
<tr>
<td>Kyan Technologies PTE LTD</td>
<td>3457</td>
</tr>
<tr>
<td>Kyowa Kirin, Inc.</td>
<td>1949</td>
</tr>
<tr>
<td>Labcorp Oncology</td>
<td>2753</td>
</tr>
<tr>
<td>Larvol</td>
<td>3347</td>
</tr>
<tr>
<td>Legend Biotech</td>
<td>3005</td>
</tr>
<tr>
<td>Leukemia Research Foundation</td>
<td>1</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth Number</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Loxo@Lilly</td>
<td>2729, Virtual</td>
</tr>
<tr>
<td>Lunaphore Technologies</td>
<td>3453</td>
</tr>
<tr>
<td>Machaon Diagnostics, Inc.</td>
<td>3055</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
<td>3412</td>
</tr>
<tr>
<td>Mayo Clinic Laboratories</td>
<td>3415</td>
</tr>
<tr>
<td>Mayo Clinic Referring Provider Office</td>
<td>2041</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
<td>122</td>
</tr>
<tr>
<td>MDOutlook</td>
<td>3219</td>
</tr>
<tr>
<td>Mechatronics Instruments B.V.</td>
<td>1057</td>
</tr>
<tr>
<td>Med Learning Group</td>
<td>755, 2545</td>
</tr>
<tr>
<td>Medexus Pharma</td>
<td>2502</td>
</tr>
<tr>
<td>Medidata, a Dassault Systèmes company</td>
<td>2142</td>
</tr>
<tr>
<td>Medpace Inc.</td>
<td>136</td>
</tr>
<tr>
<td>Medscape Oncology &amp; Hematology</td>
<td>2340</td>
</tr>
<tr>
<td>Melinta Therapeutics</td>
<td>3257</td>
</tr>
<tr>
<td>Menarini Silicon Biosystems</td>
<td>555</td>
</tr>
<tr>
<td>Menarini Stemline</td>
<td>1047</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>2111</td>
</tr>
<tr>
<td>Miltenyi Biotec</td>
<td>3329</td>
</tr>
<tr>
<td>Mission Bio</td>
<td>2015</td>
</tr>
<tr>
<td>MJH Life Sciences</td>
<td>2019</td>
</tr>
<tr>
<td>MLM Medical Labs</td>
<td>604</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>655</td>
</tr>
<tr>
<td>MorphoSys</td>
<td>2405</td>
</tr>
<tr>
<td>Multiple Myeloma Research Foundation</td>
<td>22</td>
</tr>
<tr>
<td>National Comprehensive Cancer Network (NCCN)</td>
<td>13</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>2401</td>
</tr>
<tr>
<td>NeoGenomics Laboratories</td>
<td>851</td>
</tr>
<tr>
<td>NMDP</td>
<td>2112</td>
</tr>
<tr>
<td>Northside Hospital</td>
<td>2105</td>
</tr>
<tr>
<td>Northwell Health</td>
<td>2029</td>
</tr>
<tr>
<td>Notable Labs</td>
<td>2454</td>
</tr>
<tr>
<td>Novartis</td>
<td>2429</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>619</td>
</tr>
<tr>
<td>NURIX</td>
<td>821</td>
</tr>
<tr>
<td>Omeros Corporation</td>
<td>2305</td>
</tr>
<tr>
<td>ONO PHARMA</td>
<td>243</td>
</tr>
<tr>
<td>OPTOLANE Technologies, Inc.</td>
<td>2027</td>
</tr>
<tr>
<td>Ossium Health, Inc.</td>
<td>300</td>
</tr>
<tr>
<td>OxyDial Inc</td>
<td>2501</td>
</tr>
<tr>
<td>Parexel</td>
<td>449</td>
</tr>
<tr>
<td>Pfizer</td>
<td>1832</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>Booth</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>PharmaEssentia Corporation</td>
<td>2915</td>
</tr>
<tr>
<td>Pharming Healthcare, Inc.</td>
<td>2250</td>
</tr>
<tr>
<td>Platelet Disorder Support Association</td>
<td>10</td>
</tr>
<tr>
<td>PlatformQ Health</td>
<td>116</td>
</tr>
<tr>
<td>Precision for Medicine</td>
<td>649</td>
</tr>
<tr>
<td>Precision NanoSystems</td>
<td>2255</td>
</tr>
<tr>
<td>Premier Research</td>
<td>2148</td>
</tr>
<tr>
<td>ProPharma Group</td>
<td>3343</td>
</tr>
<tr>
<td>Protagonist Therapeutics, Inc.</td>
<td>2122</td>
</tr>
<tr>
<td>PROTEINA Co., LTD.</td>
<td>3455</td>
</tr>
<tr>
<td>Proteintech</td>
<td>2852</td>
</tr>
<tr>
<td>Prothena</td>
<td>400</td>
</tr>
<tr>
<td>PSI CRO</td>
<td>3352</td>
</tr>
<tr>
<td>Q2 Solutions</td>
<td>2548</td>
</tr>
<tr>
<td>Rapid Novor Inc.</td>
<td>1548</td>
</tr>
<tr>
<td>Rare Disease Therapeutics, Inc.</td>
<td>1355</td>
</tr>
<tr>
<td>Recordati Rare Diseases</td>
<td>2500</td>
</tr>
<tr>
<td>Recordati Rare Diseases – Medical</td>
<td>3001</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>633</td>
</tr>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>2805</td>
</tr>
<tr>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>3411</td>
</tr>
<tr>
<td>Rutgers Cancer Institute of New Jersey/RWJBarnabas Health</td>
<td>3150</td>
</tr>
<tr>
<td>Sanofi</td>
<td>915</td>
</tr>
<tr>
<td>Sanofi</td>
<td>3429</td>
</tr>
<tr>
<td>Sarah Cannon Research Institute</td>
<td>2104</td>
</tr>
<tr>
<td>Seagen</td>
<td>117, 355</td>
</tr>
<tr>
<td>Sebia</td>
<td>2455</td>
</tr>
<tr>
<td>Secura Bio Inc.</td>
<td>3321</td>
</tr>
<tr>
<td>SeQure Dx</td>
<td>3449</td>
</tr>
<tr>
<td>Servier Pharmaceuticals</td>
<td>1347</td>
</tr>
<tr>
<td>Shanghai Model Organisms Center</td>
<td>2550</td>
</tr>
<tr>
<td>Shield Therapeutics</td>
<td>2745</td>
</tr>
<tr>
<td>Shwachman-Diamond Syndrome Foundation</td>
<td>27</td>
</tr>
<tr>
<td>Sight Diagnostics</td>
<td>1357</td>
</tr>
<tr>
<td>Silence Therapeutics</td>
<td>3057</td>
</tr>
<tr>
<td>Sobi, Inc.</td>
<td>105, 2028</td>
</tr>
<tr>
<td>Society for Immunotherapy of Cancer (SITC)</td>
<td>18</td>
</tr>
<tr>
<td>Society of Hematologic Oncology</td>
<td>2552</td>
</tr>
<tr>
<td>Spark Therapeutics, Inc.</td>
<td>549</td>
</tr>
<tr>
<td>Stanford Cancer Institute</td>
<td>3436</td>
</tr>
<tr>
<td>Star Therapeutics</td>
<td>2157</td>
</tr>
<tr>
<td>STEMCELL Technologies</td>
<td>118</td>
</tr>
</tbody>
</table>
Sumitomo Pharma Oncology 143
Sutro Biopharma 302
Sutter Health – Bay Area 3244
Syndax Pharmaceuticals, Inc. 2400
Syneos Health 1555
Syros 2804
Taiho 827, 2141
Takeda Hematology 2321
Takeda Oncology 2229
Team Telomere 30
Telo Genomics 404
Tempus Labs, Inc. 3051
The Japanese Society of Hematology 9
The Leukemia & Lymphoma Society 2705
The MDS Foundation, Inc. 3
TheraDex Oncology 815
ThermoFisher 727
ThinkCyte, Inc. 140
Trinity Biotech 3000
Turkish Society of Hematology 6
TwinStrand Biosciences 3143
U.S. Department of State Bureau of Medical Services 38
UC San Diego Hemophilia and Thrombosis Treatment Center 25
UCI Health 28
University of Chicago – Data for the Common Good 41
Vaniam Group 3149
Vertex Pharmaceuticals Inc. 715, 841
Viracta Therapeutics 504
wAIHA Warriors 36
Waldenstrom’s Macroglobulinemia Foundation 15
Wolters Kluwer 2301
Worldwide Clinical Trials 3313
X4 Pharmaceuticals 501, 1957
Xcene Research 2515
66th ASH® Annual Meeting and Exposition

SAVE THE DATE
December 7-10, 2024 • San Diego, CA
CD47-Blocking Agents:

Emerging Checkpoint Inhibitor Approach in Hematologic Malignancies

CD47 signaling has been shown to inhibit phagocytosis and promotes tumor cell immune evasion

• CD47, or integrin-associated protein, is a cell-surface ligand expressed at low levels by nearly all cells of the body
• CD47 is overexpressed in various hematologic malignancies and expressed by cells within the tumor microenvironment
• Its interaction with signal regulatory protein (SIRP)α on phagocytic cells sends an inhibitory “Don’t eat me” signal that is known to prevent phagocytosis of the tumor cell
• Overexpression of CD47 is thus often associated with poor clinical outcomes

CD47 blockade may enhance phagocytosis and may promote antitumor activity

• CD47-blocking agents can bind to CD47 on tumor cells and prevent it from delivering its inhibitory signal to phagocytic cells
• Some CD47-blocking agents in development include an Fc region from human IgG, which may potentially generate a prophagocytic signal

CD47 blockade may promote both innate and adaptive immunity

• Upon engulfment, the antigen-presenting cell (APC) presents antigens from the engulfed tumor cells, potentially leading to T-cell activation and tumor cell lysis

VISIT US AT BOOTH #1832 TO LEARN MORE

CD, cluster of differentiation; Fc, fragment crystallizable; FcγR, Fc gamma receptor; IgG, immunoglobulin G.
DISCOVER THE CURRENT OF CALQUENCE

Follow the current to the latest long-term efficacy and safety data, now with up to ~6 years of median follow-up*1

Visit Booth #1433 at the 2023 ASH Annual Meeting

*At median 74.5-month follow-up (range: 0.0-89.0 months).1